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For a large number of compounds in clinical use we know that membrane transporter proteins 
modulate their pharmacokinetic properties. The family of organic anion transporting 
polypeptides (OATP) facilitates the cellular entry of such compounds. In my thesis I will focus 
on two members of this phylogenetically conserved protein family, namely OATP2B1 and 
OATP1A2. While OATP2B1 is relatively unique in its ubiquitous expression throughout the 
body, particularly in key organs contributing to drug absorption, metabolism and elimination, 
the tissue localization of OATP1A2 is more restricted to few organs such as the brain. 
Currently, various exogenous substrates of OATP2B1 and OATP1A2 have been identified, 
many of which are shared among other members of the OATP family. Important tools to better 
understand the physiological and pharmacological functions of each OATP are the use of 
transporter-specific substrates. Consequently, experimental approaches for fast and easy 
transporter substrate identification are desired. The competitive counterflow technique is one 
such method enabling the screening of compounds with reasonable throughput and cost. In this 
work, I demonstrated that the method could be successfully applied to identify substrates of 
OATP2B1 and OATP1A2. Competitive counterflow experiments were performed with both 
transporters to test centrally active drugs belonging to the class of dopamine receptor agonists 
and antagonists. Bromocriptine, cabergoline, and domperidone were identified as novel 
substrates of OATP2B1 while OATP1A2 was additionally identified to transport 
metoclopramide. Confirmation of the transporter expression in cellular structures of the brain 
suggests their involvement in the uptake of the drugs from the blood-stream into the central 
nervous system. Beside synthetic drugs, there are also herbal remedies with therapeutic 
indications to manage diseases of the central nervous system. In this regard, constituents of 
Passiflora incarnata and Valeriana officinalis were investigated for interaction with OATP2B1 
and OATP1A2. Whereas no transporter interactions were shown for constituents of Valeriana 
officinalis, the flavonoids orientin and vitexin present in Passiflora incarnata were identified 
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as substrates of OATP2B1. Vitexin was also identified as a substrate of OATP1A2 as well as 
the aglycon apigenin. Mass spectrometric analysis of Passiflora incarnata formulations 
identified vitexin and orientin, but not apigenin. Consequently, these two constituents could be 
involved in possible interactions between the formulations and the transporters. Importantly, 
there is still limited knowledge about systemic availability of flavonoids and to what extent 
they reach the central nervous system. However, OATP2B1 is widely considered to be 
important in intestinal drug absorption, and it follows that constituents of herbal remedies may 
interact with co-administered oral drugs which are OATP2B1 substrates. Another herbal 
constituent that we found to interact with OATP2B1 is the St. John’s wort constituent 
hyperforin. It is a potent inhibitor of OATP2B1 function with an IC50 of 0.32 μM and indeed, 
competitive counterflow experiments identified it as an OATP2B1 substrate. This 
phloroglucinol is known for drug-herb interactions involving induction of enzymes which 
mediate drug metabolism. Our finding of OATP2B1 playing a role in cellular uptake of 
hyperforin suggests that the transporter is a determinant influencing the intracellular effect of 
the herbal constituent. Furthermore, the identification of hyperforin as an OATP2B1 substrate 
would imply by extension the plant’s interaction potential with OATP2B1 substrates. 
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Introduction 
Progress in medicine would be unimaginable without the continued development of 
therapeutics. Starting with mixtures of herbal and animal origin, the chemical understanding 
and finally the possibility to synthesize drugs, the treatment of diseases has rapidly evolved in 
the last 100 years. Today, synthetic molecules dominate the drug market; however, herbal 
compounds remain popular in the society. Altogether, there are approximately 15 000 
molecules that have been approved by the US Food and Drug Administration (FDA) that are 
widely and often used. According to the definition provided by the FDA, a drug is a compound 
used to diagnose, treat, cure, mitigate, or prevent disease or other abnormal conditions1. As 
reported in the 2017 World Drug Report, around a quarter of a billion people across the world 
used drugs at least once in the year 2015, which represents around 5 percent of the global adult 
population2. Although medications have been optimized for their indication through studies 
involving populations of patients, there is a need to consider the phenomenon of interindividual 
differences in the response to the xenobiotic when prescribing for individuals. Among the 
reasons for these differences is the variable handling and processing of the substance by the 
organism, which is termed pharmacokinetics. The parameters that are used to characterize drug 
disposition are the magnitude of achieved plasma concentrations and their duration over time. 
With this assessment, it may be possible to infer the most important mechanisms influencing 
the plasma concentration. Here, one usually refers to the different processes of drug disposition 
with the acronym ADME. This means, compounds have to be Absorbed to enter the system 
after administration, they have to be Distributed in order to exert their pharmacological effect 
and they have to be Metabolized and Excreted from the organism in order to avoid toxicity. 
One molecular mechanism which influences each ADME process and which determines 
interindividual differences in drug response is the transmembrane transfer.   
1 https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms, last access on February 18, 2021 
2 https://www.unodc.org/wdr2017/field/Booklet_1_EXSUM.pdf; last access on February 18, 2021 
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Each cell is surrounded by a highly dynamic, semipermeable lipid bilayer consisting of 
phospholipids whose tails form a hydrophobic core. This is covered by a hydrophilic layer 
consisting of the hydrophilic head groups. It is widely accepted that the plasma membrane, due 
to its composition and function, impacts the crossing of a substance depending on its 
physicochemical properties. Permeation of biological membranes can occur either passively, 
actively, or via vesicle transport. Passive transport occurs without the need of energy and can 
be further divided into simple diffusion, facilitated diffusion, and osmosis. Osmosis describes 
the movement of water, whereas simple diffusion is defined as the random movement of a solute 
along a concentration gradient. The rates of solute movement from regions of high to a low 
concentration occur without reaching a saturation limit. In the process of facilitated diffusion, 
solute permeation requires membrane proteins that are located within the lipid bilayer. In 
general, these processes are saturable, compound selective and sometimes stereo-specific. 
Finally, there is active transport defined by the need of direct energy in the form of adenosine 
triphosphate (ATP) which allows the transport of the substrate against a concentration gradient 
via an integral membrane protein. It is widely accepted that both proteins enabling facilitated 
diffusion or active transport are key determinants of ADME and hence the overall 
pharmacokinetics of a molecule.  
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Efflux transporters 
One important and highly studied group of active membrane transporters comprise the efflux 
transporters of the ATP-binding cassette (ABC) superfamily. ABCB1 (Permeability 
glycoprotein (P-gp), multidrug resistance protein 1(MDR1)) was first identified in 1976 by Ling 
et al. as a mechanism contributing to the multidrug resistance in cancer cells. Since then the 
field has enormously evolved [1]. Today we know that ABCB1 is not only expressed in cancer 
cells, but also contributes to intestinal, hepatic and renal excretion of its substrate drugs. 
Furthermore, ABCB1 is of major relevance in tissue barriers to drugs such as the brain (blood-
brain barrier, BBB) and the placenta [2]. Importantly, it is not only the understanding of 
function and relevance of ABCB1 that has evolved; it is also the number of other efflux 
transporters that have become known to contribute to the handling of drugs in the human 
organism. Indeed, today we know that the phylogenetically conserved family of ABC-
transporters consists of 48 members, of which several have been shown to be involved in the 
handling of drugs in the human organism [3]. I want to highlight the members of the ABCC-
subfamily, namely ABCC2 and ABCC3 and the transporter ABCG2 (breast cancer resistance 
protein, BCRP), which have been intensively investigated for their role in pharmacokinetics. 
Briefly, ABCC2 and ABCC3 are highly expressed in the liver, where they are assumed to 
transport products of the Phase II-drug metabolism, namely sulfated and glucuronidated 
metabolites produced through the actions of sulfotransferases (SULTs) and UDP-
glucuronosyltransferases (UGTs). Importantly, while ABCC2 is expressed in the canalicular 
membrane of hepatocytes, extruding its substrates into bile [4], ABCC3 is expressed in the 
sinusoidal membrane transporting molecules from hepatocytes back into the systemic 
circulation [5]. Although highly expressed in the liver, both transporters have also been 
observed in other tissues including intestine, kidney, and placenta [5-8]. For ABCG2 it should 
be mentioned that it has a similar tissue distribution as ABCB1, and this transporter is known 
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to be of relevance for the limitation of intestinal absorption, dia-placental transfer and brain 
entry of drugs as well as for the promotion of renal and hepatic drug elimination [9].  
In summary, members of the ABC-family are efflux transporters that actively extrude 
compounds, thereby reducing the intracellular amount of their substrates. These ABC 
transporters have broad substrate specificity that contributes to limiting drug exposure in the 
tissues and promoting drug elimination, which in a broader sense, act with a xenoprotection 
function to the human organism. However, when considering the mechanisms of directed 
transport or transcellular transfer, it seems evident that if there is a mechanism mediating 
extrusion there should also be a mechanism facilitating cellular entry or uptake.  
Uptake transporters 
One example of membrane proteins facilitating the cellular uptake of their substrates is the 
superfamily of solute carriers (SLC). They form the second largest family of membrane proteins 
and consist of 52 gene families. The SLCO (former SLC21) or organic anion transporting 
polypeptides (OATP) represent one type of SLC transporters, which are divided into 6 families 
with 13 subfamilies. An overview of the OATP transporters is shown in Figure 1.  
In general, OATPs are assumed to be integral membrane proteins of 652-848 amino acids in 
length with 12 transmembrane domains, where both the N- and C-terminus are located in the 
cytosol. Among the OATPs, there are members showing a wide distribution in human tissues, 
while others appear to be only expressed in specific organs. Although the exact mechanism of 
transport remains to be fully elucidated, the OATPs are generally involved in the sodium-
independent transport of a broad range of rather large (>350 Da) amphipathic organic anions 
[10], including compounds of endogenous and exogenous origin. However, there are also 
neutral or even positively charged substrates of OATPs. Generally, the transport via an OATP 
is considered to facilitate cellular uptake in exchange for intracellular anions such as reduced 
glutathione [11, 12], or bicarbonate [13, 14].  
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Figure 1. Phylogenetic tree of the families and subfamilies of OATP transporters. With more than 40% amino 
acid sequence identity, transporters are categorized in the same family (OATP1-OATP6). The sub-families are 
defined by a sequence identity with more than 60% (OATP1A-OATP1D). Human OATPs are written with capital 
letters, animal with small letters. b, bovine; c, chicken; m, mouse; r, rat; s, skate; red circles indicate the transporters 
of interest in this work. Adapted from Hagenbuch [15]. 
Since their first identification in 1995, the rapidly growing family of OATPs have become 
increasingly relevant, especially concerning their contribution to the handling of drugs in the 
organism. In terms of pharmacokinetics, the liver specific OATP1B1 and OATP1B3 are best 
investigated for their role in hepatic handling of their substrate drugs. Briefly, both OATP1B 
transporters are highly expressed in the sinusoidal membrane of hepatocytes, and are shown to 
recognize a broad range of substrates [16-18]. With the identification of naturally occurring 
genetic variants of OATP1B1 with altered expression and/or transport activity, there were 
additional implications of this particular transporter in the variable pharmacokinetics of drugs 
[19]. Beside the impacts of pharmacogenetics, OATP1B transporters are considered important 
determinants of drug-drug interactions (summarized by Shitara [20]). Today, it is recommended 
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that new molecular entities be tested for interaction with the OATP1B transporters during drug 
discovery and development by the FDA and the European Medicines Agency.3 Importantly, a 
great overlap in substrates and/ or inhibitors has been recognized among other OATPs such as 
OATP2B1 and OATP1A2. Their relevance in the organism has not been clarified so far and 
will be addressed, investigated and discussed in the present work. 
Current understanding of OATP1A2/SLCO1A2 
OATP1A2 (also known as OATP, OATP1 or OATP-A) belongs to the OATP1 family and was 
the first human OATP studied [21]. In this first report, OATP1A2 was cloned from the human 
liver and its transport function was assessed. Moreover, expression was shown in liver, brain, 
lung, kidney, and testis [21]. Since then, expression of OATP1A2 has been studied by multiple 
groups, suggesting the highest expression of OATP1A2 in endothelial cells of the blood-brain 
barrier [22, 23] and in the neuronal membrane [24], as indicated in Figure 2. Here, OATP1A2 
is assumed to participate in the brain entry and in neuronal processes, respectively. In liver, 
OATP1A2 has been reported to be located within cholangiocytes [25], where it is thought to be 
involved in maintaining the homeostasis of bile acids [21]. The transport protein was also 
reported to be expressed in the distal tubule of the nephron, where it may play a role in the 
tubular reabsorption [25, 26]. Furthermore, OATP1A2 expression was found in different cell 
types of the placenta including villous cytotrophoblasts, syncytiotrophoblasts, and extravillous 
trophoblasts [27]. In the syncytiotrophoblasts expression was found in the apical membrane 
suggesting that the transporter is involved in the transfer from the mother to the fetus [28]. 
Notably, an early report by Glaeser et al. revealed OATP1A2 in the intestine [29]. However, 
recent findings of studies testing the abundance of transporters by LC-MS/MS analytics were 
3 US Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, implications 
for dosing, and labeling recommendations. 2012; European Medicines Agency. Guideline on the Investigation of Drug 
Interactions, 2012; last access on February 18, 2021 
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not able to confirm the presence of the transporter in this particular tissue [30]. In accordance, 
the intestinal presence and function of OATP1A2 is no longer considered by many.  
Taken together, OATP1A2 has been reported to be expressed in multiple organs of the human 
organism, however its role and relevance in the handling of molecules is still poorly understood. 
Clinical studies to investigate a transporter’s function can be either drug-drug interaction 
studies, with concomitant administration of drugs functioning as victim and perpetrator or they 
can be pharmacogenetic studies where genetic variants are granting a loss of function. The 
design of either type of study includes the selection of a substrate. Here, OATP1A2 has been 
reported to transport molecules of exogenous and endogenous origin. The latter include the 
common OATP substrate estrone-3 sulfate (E1S), but also dehydroepiandrosterone sulfate 
(DHEAS) [31], and thyroid hormones [32]. In terms of xenobiotics, OATP1A2 substrates are 
within the class of antihistamines (e.g., fexofenadine [33]), beta-blockers (e.g., nadolol [34]), 
statins (e.g., rosuvastatin [35]), central active drugs such as serotonin-receptor agonists (e.g., 
triptanes [36, 37]), or δ-opioid peptides (e.g., deltorphin II [22]) and anti-cancer drugs (e.g., 
imatinib [38]). Additionally, OATP1A2 is assumed to interact with food constituents as 
reported for naringin, a constituent of grapefruit juice, or honey flavonoids and catechins of 
green tea [39-41].  
Some of the above mentioned substrates have been used in clinical studies, where the 
investigators intended to study the role of OATP1A2 in pharmacokinetics. Briefly, 
pharmacokinetic parameters were determined in patients receiving a known OATP1A2 
substrate and a competitor, which was previously shown to inhibit the transporter’s function. 
Naringin, often found in fruit juices, or catechins which are constituents of green tea are 
examples of the studied OATP1A2 competitors. In this regard, patients received fexofenadine 
or nadolol as known OATP1A2 substrates [34, 42] co-administered with fruit juices or green 
tea which contained the inhibiting constituents (an overview of the study designs and their 
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outcomes can be found in the Appendix, Table 1). Interestingly, a decrease of the AUC and 
Cmax were observed in most studies. Since OATP1A2 was previously assumed to be localized 
in the apical membrane of enterocytes, the phenomenon was attributed to a change in intestinal 
absorption via OATP1A2. Today, we venture to contend that this might not be the case and 
observations must be ascribed to mechanisms aside from OATP1A2 inhibition. Similarly, there 
are studies trying to elucidate the relevance of OATP1A2 in brain drug entry. In this context, 
Li et al. investigated the BBB penetration of the small-molecule AZD1775 (adavosertib), a 
WEE1 kinase inhibitor under investigation for the treatment of glioblastoma. Briefly, with a 
combination of in vivo, in vitro and physiologically based pharmacokinetic (PBPK) modeling 
the authors provide evidence that the penetration of this molecule into the tumor tissue is most 
likely mediated by OATP1A2. The authors base this assumption on the acidic tumor 
environment which decreases the efflux of AZD1775 via ABCB1 and ABCG2, while 
OATP1A2 is not affected [43]. Consequently, OATP1A2 is assumed to facilitate the brain entry 
of AZD1775, at least under pathological conditions as shown for glioblastoma.  
In addition to drug-drug interaction studies, there are examples, where genetic variants were of 
great value for the investigation of a transporter's function in the human organisms [44]. As 
summarized in the Appendix, Table 2, there are various genetic variants for OATP1A2 reported 
of which rs11568563 (c.516A>C, p.172E>D) was shown to exhibit reduced capacity for uptake 
of E1S, the delta-opioid receptor agonists deltorphin II, [D-penicillamine(2,5)]-enkephalin 
(DPDPE), and methotrexate in in vitro experiments [25, 26]. On the contrary, rs10841795 
(c.38T>C, p.13I>T) was shown to induce uptake of E1S and methotrexate [26]. Beside in vitro 
investigations there are also clinical studies investigating the impact of genetic variations on 
the pharmacokinetics of substrate drugs. Briefly, the rs3764043 (intronic c.−423G>A aka c.-
361G>A) was investigated for its influence on imatinib clearance in patients with chronic 
myeloid leukemia. Individuals homozygous for the reference G allele had a significantly lower 
clearance than carriers of the GA or AA genotype, however, no influence on clinical response 
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was observed [45]. For darunavir, the change of T to C in position 38 (rs10841795 (c.38T>C, 
p.13I>T)) was linked to a slightly higher cerebrospinal fluid concentration compared to that
observed in individuals carrying the reference variant [46]. Finally, the variants rs4762699 and 
rs2857468 were shown to be highly associated with the risk of life-threatening febrile 
neutropenia in breast cancer patients treated with docetaxel and doxorubicin [47]. The 
neuromuscular blocker rocuronium which is mainly eliminated by excretion into the bile was 
identified as OATP1A2 substrate and the genotypes -A or AA for SLCO1A2 -189_-188InsA 
showed a reduced total clearance assuming involvement of the transporter in the elimination 
pathway of this drug [48]. 
In summary, with the hitherto available data on OATP1A2, it is reasonable to conclude that this 
transporter has an impact on the handling of its substrate drugs. Although OATP1A2 may not 
be involved in the absorption of compounds in the intestine, there is clinical data suggesting a 
role in elimination and brain entry of selected compounds. Whether this is of clinical relevance, 
warrants further studies. Notably, OATP1A2 transports E1S and DHEAS and is highly 
expressed at the blood brain barrier, where it may be involved in neurosteroid homeostasis [31]. 
Clearly, there is a need to further investigate the transporter’s role in the handling of molecules. 
However, an important prerequisite to future studies is the identification of more specific 
substrates and innovative experimental approaches which could better expose the physiological 
and pharmacological roles of OATP1A2.  
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Current understanding of OATP2B1/SLCO2B1 
In 2000 Tamai et al. were the first to report on OATP2B1 (also known as OATP-B) as an uptake 
transporter and its broad expression profile in human tissues [49]. Hitherto, expression was 
confirmed in various tissues including the coronary artery [50], heart [51], lung [52], mammary 
gland [53], pancreas [54], placenta [55], platelets [56], skeletal muscle [57], and skin [58] 
(compare Figure 2). Moreover, OATP2B1 was shown to be expressed in endothelial cells of 
the blood-brain barrier [24]. Importantly, OATP2B1 expression was found in tissue 
contributing to the absorption, metabolism and elimination of drugs, namely the intestine, the 
liver, and the kidney. In the liver, OATP2B1 was shown to be located within the sinusoidal 
membrane of hepatocytes, where the transporter is assumed to facilitate the hepatocellular entry 
of its substrates [59]. In the kidney, OATP2B1 was found in the apical membrane of proximal 
tubular cells. However, in distal tubules the transporter sorts to the basal membrane [60]. For 
the localization in enterocytes, there are contradictory findings. 
Specifically, Kobayashi et al. detected the transporter on the luminal surface of enterocytes 
performing immunohistochemical analysis of human intestinal tissue slices [61]. In a more 
recent publication, Keiser et al. argued against these findings, proposing a basolateral 
localization of OATP2B1 [62]. Here, the authors enriched the basal and apical membrane 
fraction of enterocytes prior to mass spectrometric analysis revealing the protein in the 
basolateral fraction. Notably however, the authors rated their immunofluorescent staining as 
ambiguous. Their proteomic finding was supported by in vitro studies testing the vectorial 
transport of known OATP2B1 substrates using the Ussing Chamber with human jejunal mucosa 
as well as the Caco2-Transwell system. They found a dominating flux of known OATP2B1 
from the basolateral to the apical compartment and concluded that this disqualifies the 
transporter’s involvement in intestinal drug absorption [62].  
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Despite the debate on its localization in the intestine, various groups have conducted clinical 
studies in order to elucidate the relevance of OATP2B1 in pharmacokinetics of its substrates. 
In these studies, the following compounds aliskiren [63], celiprolol [64], fexofenadine [65], 
glibenclamide [66], montelukast [67], rosuvastatin [66, 68, 69], sulfasalazine [66], sumatriptan 
[66], and voriconazole [70] were used. Most of the studies were designed to test for the 
influence of coadministered substrates and/or genetic variants on the oral absorption of the test 
compound. The potential relevance of OATP2B1 on drug disposition was determined by 
comparing systemic exposure (AUC), level of the maximal plasma concentration (Cmax) and 
time to Cmax (tmax). One example is voriconazole where systemic exposure of patients carrying 
the genetic variant rs3781727 (c.*396T>C) was compared to carriers of the reference allele. 
Notably, the carriers of the genetic variant exhibited a lower systemic exposure (AUC0-4), and 
a reduced Cmax of voriconazole than carriers of the wild type variant [70]. Furthermore, 
pronounced reduction in systemic exposure was observed, when selected OATP2B1 substrates 
were coadministered with fruit juices [63-66]. Importantly, there is in vitro data showing 
inhibition of OATP2B1 with constituents of fruit juices including nobiletin, naringin or 
hesperidin [71, 72]. Nobiletin is a polymethoxy-flavone and naringin and hesperidin are 
flavanone glycosides belonging to the class of flavonoids, a large group of polyphenolic 
secondary metabolites which are often found in plants. Accordingly, in the clinical studies 
which observed reduced exposure of selected substrates is currently interpreted as reduced 
intestinal absorption due to inhibition of OATP2B1 [63, 65, 67]. The assumption that intestinal 
OATP2B1 is prone to drug-food interaction is further supported by findings in Slco2b1-/- mice. 
Here, the authors not only observed reduced fexofenadine maximal plasma concentrations and 
AUC after oral application compared to wildtype (wt) mice, they also found that grapefruit 
juice reduced the Cmax and AUC in wt mice. No such effect was observed in animals lacking 
the transporter [73]. Although fruit juices and their constituents including naringin or hesperidin 
are most extensively studied for their influence on OATP2B1 and oral drug absorption, there 
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are several other flavonoids reported to interact with the transporter. In this regard, Mandery et 
al. identified apigenin, kaempferol, and quercetin to inhibit the transporter-mediated cellular 
uptake of atorvastatin and fexofenadine [74]. They conclude that co-administration of a drug 
and a herbal remedy might result in drug-herb interactions because of competition for cellular 
entry via OATP2B1. Whether these findings are of clinical relevance warrants further testing.  
Beside drugs, OATP2B1 is also shown to transport endogenous compounds including the 
thyroid hormones thyroxine (T4) and triiodothyronine (T3) and coproporphyrin (CP) III [75, 
76]. The isomers CPI and CPIII are byproducts of the heme biosynthesis and due to their 
interaction with hepatic OATPs, they are currently under investigation as biomarkers to monitor 
the function of hepatic OATP-transporters [77, 78]. Moreover, OATP2B1 was shown to 
transport the steroid hormones DHEAS, E1S and pregnenolone-sulfate (PregS) [79]. In addition 
to DHEAS, E1S is a highly abundant steroid hormone in the human organism that exhibits poor 
binding activity to the estrogen receptor. Indeed, its physiological function is rather the 
provision of a precursor reservoir that intracellular steroid sulfatases convert to unconjugated, 
active estrone and estradiol when needed. Due to the hydrophilic sulfate moiety, sulfated 
steroids depend on a transporter-mediated mechanism for the transmembrane transfer. It is 
generally assumed that OATPs are involved in the handling of conjugated steroids. OATP2B1 
is presumed to play a role due to its ubiquitous expression and abundance in organs targeted by 
steroid hormones such as the placenta, the mammary gland or the gonads. One organ, where 
OATP2B1 may be of relevance for the transmembrane transfer of sulfated steroids is the brain. 
Here, the transporter is assumed to be localized in the luminal membrane of endothelial cells of 
the blood brain barrier (BBB). In this regard, there is particular interest in DHEAS and PregS 
since there are reports showing these endogenous compounds affect neuronal excitability  and 
have been considered in the treatment of brain disorders [80-83]. Both DHEAS and PregS can 
either be synthesized directly in the brain or they are taken up from the bloodstream [82, 83]. It 
remains to be tested whether OATP2B1 is of relevance in this process.  
16
To summarize, OATP2B1 has a broad expression pattern including high abundance in organs 
of pharmacokinetic relevance, and possesses an affinity towards many endogenous and 
exogenous compounds. Further studies are warranted to better understand its apical and 
basolateral sorting, especially in the intestine since there continues the debate whether 
OATP2B1 is involved in the intestinal absorption of its substrate drugs. Nevertheless, the 
available data demonstrate beyond doubt that OATP2B1 is involved in cellular substrate entry. 
However, due to the significant and complicating substrate overlap between OATP2B1 and 
other OATPs, the pharmacological understanding of OATP2B1 is still in its infancy. 
Consequently, the identification of a specific OATP2B1 substrate would provide a necessary 
chemical tool to investigate specific physiological functions and to test clinical hypotheses. 
Figure 2. Summary of tissue expression and membrane sorting of (A) OATP1A2 and (B) OATP2B1. Green 
circles, OATP1A2; blue circles, OATP2B1; Color-coding of the semi-circles: red, blood; grey, brain; yellow, 
urine; green, bile; white, intestinal lumen, ochre, cells of the respective tissue, question mark indicates that there 
is inconsistent data. Adapted from the Human Protein Atlas (https://www.proteinatlas.org/; last access on February 
18, 2021) and Hagenbuch and Stieger [84].  
Competitive Counterflow 
The pharmacokinetics of a drug highly depend on its permeability or in other word its ability to 
cross cellular membranes. It is assumed that various molecules due to their favorable 
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physicochemical properties readily diffuse across lipid bilayers. Important physicochemical 
properties to promote diffusion of a drug include good lipophilicity (often defined as the 
partition coefficient between octanol and water), smaller molecular size, low numbers of 
hydrogen bond acceptors and donors and neutral charge state. Conversely, molecules that do 
not conform to these physicochemical properties have limited transmembrane transfer by 
passive diffusion. Consequently, the permeability of molecules that are hydrophilic and charged 
is assumed to rely on facilitating mechanisms such as uptake transporters. As an essential 
property conveying a drug’s pharmacokinetics, it is a prerequisite to understand how a drug is 
penetrating through membranes. New molecular entities are commonly tested for their 
permeability. The Caco-2 transwell system is an in vitro intestinal transport model where the 
vectorial transport of drugs is measured by their fluxes across cell monolayers in the apical to 
basolateral direction and vice versa. The observation of asymmetric drug fluxes across the 
transwell system indicates that there are active components involved in the transcellular 
transport. However, one limitation is that Caco-2 cells vary in their transporter expression 
across and within laboratories making it difficult to reliably identify interaction with specific 
transporters. In order to test for interaction with selected drug transporters, there are 
experimental recommendations by the International Transporter Consortium [85]. Hitherto, 
every approach is based on cell models in which the transporter of interest can either be 
transiently or stably overexpressed. These cell models are used to quantify the transported 
amount of the test compound. There are different approaches to make the compound 
“measurable” of which the labeling with a radioactive isotope is one possibility. Additionally, 
in case the test compound is fluorescent it can be quantified by detection of its spectral emission 
at a certain excitation. Commonly, the highly sensitive liquid chromatography-mass 
spectrometry approach is used to quantify the intracellular amount of the test compound [85]. 
In the case where a 2-fold or higher intracellular increase of the test compound is measured 
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compared to control cells, the compound is considered a substrate according to the guidance4. 
The above described methods provide the opportunity to calculate the kinetic parameters 
conforming to the Michaelis-Menten equation (Figure 3) based on the observations. The 
Michaelis-Menten equation is originally based on the description of an enzymatic reaction - the 
existence of an enzyme and its substrate, the forming of a complex, and the resulting product 
leading to the preserved enzyme. Translating this concept to an uptake transporter and its 
substrate in a simple way would mean the binding of the substrate to the transporter on the 
cellular surface, its transport through the membrane and its intracellular release. As shown in 
Figure 3 Michaelis-Menten kinetics are described by two parameters: the maximal velocity or 
maximal transport rate of substrate (Vmax) and the Michaelis constant km. Vmax describes the 
maximal amount of substrate that can be transported in the system in a certain time. Reaching 
Vmax means that the transporting system reaches the maximal capacity and increasing the 
amount of substrate (concentration) would not change the turnover rate. The Michaelis constant 
km describes the affinity of the substrate to the transporter and it corresponds to the 
concentration at half-maximal velocity (½ Vmax). A small value for km indicates a high affinity 
of the substrate to the transporter. Certainly, the meaning of these parameters obtained in in 
vitro experiments is challenging to extrapolate to a complex system such as the human 
organism. However, advancements in mathematical modeling provide somewhat reliable in 
vitro to in vivo prediction of drug-drug interaction potential in the case of coadministration of 
two substrates.  
The above-mentioned methods provide important information on the interaction of a molecule 
with a transporter, however, they are expensive in both time and costs. Interestingly, in 1956 
Rosenberg and Wilbrandt introduced a method called competitive counterflow based on their 
observation for glucose transport in human red blood cells [86]. In detail, Rosenberg and 
4 US Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, 
implications for dosing, and labeling recommendations. 2012; last access on February 18, 2021 
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Wilbrandt treated human red blood cells with glucose until a steady state was reached. 
Subsequently, they found that addition of substrates, but not of inhibitors of the glucose 
transporter significantly changed this equilibrium [86]. Later, the method was described by 
William Stein who defined it as a phenomenon of competitive exchange in a system where a 
transport mechanism is at or close to saturation on both sides of the membrane [87]. 
Importantly, this implies bidirectional transport of the system which controls the substrate 
equilibrium. As soon as a second substrate is added, the net-flux of the primary substrate 
becomes unidirectional – in our case an outward direction. This results in a decreased 
intracellular amount of the primary substrate. However, if the test compound is an inhibitor it 
will block transport turnover, the first substrate is “caught” inside the cell and the equilibrium 
remains unaffected. Since it is only possible to measure the changed accumulation of the 
primary substrate, competitive counterflow is defined as an indirect method. So far, it was 
successfully applied to identify substrates of the organic cation transporter 2 and the organic 
anion transporters 2 and 3 [88, 89]. Currently, it is unknown whether this method can be applied 
to identify substrates of OATPs.  
Figure 3. Michaelis-Menten equation and Michaelis-Menten saturation curve. V, velocity; Vmax, maximal 




The use of St. John’s wort (Hypericum perforatum) as medication enjoys a long history. The 
first description of the plant and its use to heal burns dates back to the year 50 AD. In the Middle 
Ages it was recognized as psychotherapeutic agent to treat melancholy [90]. Finally, since 1985, 
the plant has been used to treat mild to moderate depressive symptoms and is still an important 
medication in this field. Its activity has been confirmed in several clinical studies [91-93]. 
Numerous compounds belonging to various substance classes have been identified in extracts 
of St John’s wort [94]. The major classes of compounds are naphthodianthrones (e.g. 
hypericin), phloroglucinol derivatives (e.g. hyperforin), and flavonoids (e.g. quercetin, 
hyperoside, rutoside). The amounts of the respective constituent in the extracts strongly depend 
on the method applied for extraction. This is in particular the case for hyperforin. With the 
extraction method originally used, hyperforin, which is chemically unstable, was degraded 
rapidly. However, around 1990 a new extraction method was developed resulting in higher 
hyperforin contents. This was seen as an improvement since hyperforin was thought to be one 
of the determinants of the extract’s pharmacological activity [95]. Today we know that the 
antidepressant effect cannot be reduced to one single constituent but is the result of a synergistic 
effect of multiple components, and is potentially independent of the hyperforin content. 
Importantly, there are formulations on the market containing a very little amount of hyperforin 
for which an antidepressant effect was clinically confirmed, when compared to synthetic 
antidepressants [91, 93]. The exact mechanism of action is indeed still not fully understood. 
There are studies reporting an interaction with monoamine-receptors, neurotransmitter reuptake 
or catechol-o-methyltransferase which could contribute to the observed antidepressant effect 
[96]. Recently, the effect of St. John’s wort was also linked to a modulation of the membrane 
fluidity [97].  Beside its antidepressant effect, St. John’s wort has also been the subject of 
negative headlines due to severe adverse events observed after coadministration with drugs. 
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These mainly occurred after the extraction method had been changed resulting in a higher 
content of hyperforin. There were in particular reports showing reduced exposure of the 
protease inhibitor indinavir  and heart transplant rejection because of an elevated metabolism 
of the immunosuppressant cyclosporine [98, 99]. Enhancements of first pass-metabolism and 
clearance of the co-administered drugs are responsible for the observed events. Moreover, it 
was demonstrated that hyperforin binds and activates the nuclear receptor Pregnane X Receptor 
(PXR) thereby upregulating the expression and activity of its target genes. Target genes of PXR 
include the important metabolising enzyme CYP3A4 and the efflux transporters ABCB1, and 
ABCC3 [100-102]. Indinavir and cyclosporin are substrates of both CYP3A4 and ABCB1, 
thereby explaining the reduction in exposure due to limited bioavailability and enhanced 
clearance. The elevated expression of PXR target genes was shown in enterocytes and 
hepatocytes thereby suggesting cellular entry of hyperforin. It is currently unknown whether 
there are transporters involved in facilitating the transmembrane transport of hyperforin. 
Passiflora incarnata 
The extract of Passiflora incarnata has been medicinally used since the 16th century [103]. P. 
incarnata is one of about 500 different species, which belong to the genus of Passiflora. Often 
used in combination with other plants such as Petasites hybridus or Valeriana officinalis, 
Passiflora is believed to exert an anxiolytic and sedative effect. This indication is supported by 
findings in rodents, where Passiflora treatment affected the outcomes of behavioral tests 
including the elevated plus maze test, the water maze test or the light/dark box choice situation 
test [104-106]. Furthermore, in a double blind randomized trial of patients with generalized 
anxiety disorder that received either a Passiflora incarnata extract or oxazepam no significant 
difference in efficacy between interventions was observed. Moreover, in the group treated with 
the Passiflora extract, lower incidences of impairment of job performance were reported [107]. 
The observed anxiolytic effect might be mediated by interaction of the extract with the gamma-
aminobutyric acid (GABA)A/ benzodiazepine receptor and the GABAB receptor as shown in in 
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vitro experiments [104, 108]. However, the identification of specific constituents that are major 
active ingredients have not yet been determined. Nevertheless, flavonoids are known to be a 
major group of constituents, and include vitexin, isovitexin, orientin, isoorientin, and apigenin 
[109]. In comparative analysis of 34 Passiflora species, the C-glycosylflavones orientin and 
vitexin were reported to be the most abundant flavonoids [109]. Data from in vitro experiments 
suggest that orientin exerts a neuroprotective effect possibly mediated by activation of the 
phosphatidyl-inositol-3 kinase (PI3K)/AKT signaling pathway [110]. As to vitexin, Abbasi et 
al. showed an anticonvulsant effect in the rat brain after intracerebroventricular administration 
of the compound [111]. In addition, Gozalo et al. compared the per os treatment with a 
Passiflora extract and apigenin alone, thereby observing a comparable sedative response in 
mice for both treatments. After pretreatment with the benzodiazepine antagonist flumazenil, the 
effect of apigenin was no longer observed suggesting the binding of the compound to the 
GABAA receptor [112]. In contrast, Zanoli et al. compared intraperitoneally administered 
apigenin and chrysin, another flavonoid found in Passiflora extracts showing an anxiolytic 
effect after treatment with chrysin. This effect could not be observed after treatment with 
apigenin. Notably, the anxiolytic effect of chrysin was blocked by flumazenil, indicating its 
binding to the GABAA receptor [113]. 
Although there are indicators suggesting that constituents of Passiflora have to enter the brain 
in order to exert their pharmacological effects, it is currently unknown whether and to what 
extent the flavonoids are systemically available after oral administration. Indeed, flavonoids are 
known to be extensively metabolized by the gut microbiome [114, 115]. However, the catechin 
epigallocatechin gallate, a tea polyphenol, was radioactively labeled and a broad tissue 
distribution of the radionuclide was observed in mice [116]. For major flavonoids of Passiflora 
species, such experiments have not been conducted so far nor are there any studies investigating 
their interaction with OATPs which may influence their pharmacokinetics.  
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Aims of the thesis 
1. To test the applicability and validity of the competitive counterflow approach for the
identification of OATP2B1 or OATP1A2 substrates
2. To test the applicability of the competitive counterflow method for the investigation of
the influence of herbal extracts on the transporters function
3. To further investigate the role of OATP2B1 in the handling of the identified substrate
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Establishment and Validation of Competitive Counterflow as a
Method To Detect Substrates of the Organic Anion Transporting
Polypeptide 2B1
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ABSTRACT: The organic anion transporting polypeptide (OATP) 2B1 is ubiquitously expressed and known to facilitate
cellular entry. It is widely accepted that transport proteins play a pivotal role in pharmacokinetics. Consequently, testing for
interaction with drug transporters became an important part in the assessment of new molecular entities in order to predict and
prevent drug-drug interactions. Recently, competitive counterflow (CCF), an indirect method allowing the identification of
substrates, was successfully applied to the organic cation transporter 2. It was the aim of this study to test whether CCF can be
used to identify substrates of OATP2B1. A protocol for CCF experiments using estrone 3-sulfate (E1S) as the driven compound
in expression-verified MDCKII-OATP2B1 cells was established. The protocol was tested using a substance library, which was
prior screened for inhibition of OATP2B1-mediated transport accounting for both E1S-binding sites. In CCF experiments, all
previously reported OATP2B1 substrates significantly reduced the amount of E1S in equilibrium, classifying them as substrates.
In addition, we identified and verified novel substrates of OATP2B1, namely, astemizole and domperidone. Results of the CCF
were complemented with cytotoxicity assays or cell-based reporter gene assays to validate the finding of etoposide and
teniposide or hyperforin being substrates of OATP2B1, respectively. Our study indicates that the method of CCF can be used
to identify substrates of OATP2B1, irrespective, whether interacting with binding site A or A and B, but is limited by solubility
issues or the amount of transporter that is expressed in the used cellular system.
KEYWORDS: drug transporter, organic anion transport, OATP2B1, competitive counterflow, substrate identification
■ INTRODUCTION
Membrane proteins facilitating cellular entry or efflux play a
pivotal role in pharmacokinetics. In terms of cellular uptake,
the family of solute carrier transporter (SLC) summarizes a
variety of members, where the contribution to drug transport
has been shown.1 One subfamily of this huge phylogenetically
conserved protein family is the family of organic anion
transporting polypeptides (OATPs).
In this study, we focused on organic anion transporting
polypeptide 2B1 (OATP2B1). This transporter is an integral
membrane protein consisting of 12 transmembrane domains
and exhibiting ubiquitous expression with shown presence in
the heart, placenta, brain, skin, platelets, lung, mammary gland,
and skeletal muscle.2−9 Importantly, OATP2B1 is highly
expressed in organs with prominent function in drug
absorption and elimination. Indeed, Kullak-Ublick et al.10
reported the transporter to be highly expressed in the
sinusoidal membrane of hepatocytes. However, conflicting
data exist on the localization of OATP2B1 in enterocytes. Even
if several groups demonstrated localization and function in the
apical membrane of enterocytes,11,12 Keiser et al. recently
reported the transporter to be localized at the basolateral
pole.13 However, various functional studies support the idea of
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OATP2B1 contributing to the apical uptake in enterocytes
and, therefore, intestinal drug absorption. One compound
assessed in this perspective is fexofenadine. Several groups
reported in vitro findings on fexofenadine being a substrate of
OATP2B1,14,15 even if others were not able to show an
interaction with this transporter.16 Utilizing the inhibition of
the OATP2B1 function by grapefruit juice (GFJ),17 Dresser et
al. were able to show that concomitant ingestion of GFJ
significantly reduces the AUC and Cmax of the antihistaminic in
healthy volunteers, measured over an 8 h period, whereby
suggesting reduction of fexofenadine bioavailability by
inhibition of transporter-mediated uptake.18 This is further
supported by recent findings showing that GFJ interacts with
intestinal absorption of the OATP2B1-substrates rosuvastatin,
glibenclamide, celiprolol, and sumatriptan.19 Multiple con-
stituents of GFJ are assumed to inhibit OATP2B1, including
the flavonoid naringin.20,21 However, it seems noteworthy, that
OATP2B1 has been shown to exhibit two distinct substrate
binding sites, and naringin only inhibits one of them. The
binding site interacting with naringin (site A) was shown to
bind the known OATP2B1 substrate estrone 3-sulfate (E1S)
8
at low concentrations, while binding site B mostly drives E1S
uptake at higher concentrations. Additionally, site B interacts
with testosterone, which is assumed to be a specific substrate of
this binding site of OATP2B1.22 Notably, the presence of
multiple binding sites and the variable experimental set up of in
vitro studies may be reasons for controversial findings on
substrates and inhibitors as described above for fexofenadine.
The International Transporter Consortium recommended
different approaches to test the interaction of new molecular
entities (NME) with transport proteins.23 In detail, they
suggest the use of transient or stable cellular models
overexpressing the transporter of interest and various methods
to quantify substrate accumulation. The recommended
techniques to detect the NME are radiolabeled or fluorescent
tracers or the employment of highly sensitive liquid
chromatography−mass spectrometry.23 These detection meth-
ods imply direct uptake studies of the compound of interest,
which will provide a reliable result, but can be extremely
consuming either in time, money, or both. Interestingly, in
1956, Rosenberg and Wilbrandt introduced the method of
competitive counterflow (CCF) and applied it to verify
transporter-mediated handling of glucose in human red
blood cells. Performing experiments after reaching the steady
state, they were able to show that addition of a substrate, but
not of an inhibitor, of the transporter significantly changed the
observed equilibrium of the test compound.24 Recently this
method was used to successfully identify substrates of the
organic cation transporter 2 (OCT2).25
It was the aim of this study to test whether CCF experiments
can also be applied to identify substrates of the organic anion
transporting polypeptide OATP2B1.
■ EXPERIMENTAL SECTION
Substances. Radiolabeled compounds [3H]-estrone 3-
sulfate (E1S) and [
3H]-domperidone were purchased from
Hartmann Analytic (Braunschweig, Germany), while [3H]-
astemizole was commercially obtained from PerkinElmer
(Waltham, USA). Compounds applied in this study, except
for fexofenadine (Lubio Science, Luzern, Switzerland),
ketoconazole and troglitazone (TOCRIS, Bio-Techne AG,
Zug, Switzerland), and paclitaxel (Lucerna-Chem AG, Luzern,
Switzerland), were from Sigma-Aldrich (Buchs, Switzerland).
Cell Culture. The cell lines MDCKII (ATCC No. CRL-
2936), HeLa (ATCC No. CCL-2), and HepG2 (ATCC No.
HB-8065) were originally obtained from the American Type
Culture Collection (ATCC, Wesel, Germany) and were
cultured in Dulbecco’s modified Eagle medium (DMEM,
Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS,
Sigma-Aldrich) and 1% stable glutamine (BioConcept, Basel,
Switzerland). MDCKII-OATP2B1 cells have previously been
established2 and were kept under continuous selection by
addition of 0.75 mg/mL hygromycin B (Carl Roth, Karlsruhe,
Germany). Cells were maintained at 37 °C in a humidified
atmosphere with 5% CO2.
Western Blot Analysis. MDCKII-OATP2B1 and
MDCKII cells were seeded at a density of 1.8 × 106 cells/10
cm cell culture dish (Eppendorf, Hamburg, Germany). One
day after seeding, cells were treated with sodium butyrate (2
mM) for 24 h and then harvested in 5 mM-Tris HCl (pH 7.4)
supplemented with the protease inhibitor cocktail (Sigma-
Aldrich). After three cycles of freezing and thawing, the cell
homogenate was centrifuged for 45 min at 100 000g and 4 °C
for membrane fraction enrichment. The resulting pellet was
suspended in 5 mM-Tris HCl, and the amount of protein was
quantified by BCA assay (Thermo Fisher Scientific, Reinach,
Switzerland). HeLa cells were seeded to the same amount, and
24 h later they were infected with the recombinant attenuated
vaccinia virus vTF-7 (ATCC No. VR-2153; 100 pfu/well).26
After 30 min of incubation with the virus, jetPRIME (2 μL/ μg
DNA) (Polyplus distributed by Chemie Brunschwig, Basel,
Switzerland) was used to transfect 800 ng/well of OATP2B1-
pEF6 or pEF6-control (pEF6-V5/HIS, Thermo Fisher
Scientific). After 24 h of incubation, the cells were harvested
as described above. For the adenoviral expression system,
HeLa cells were infected with 200 pfu/cell Ad-OATP2B19 or
Ad-LacZ as the control 1 day after seeding. Adenoviral titer
was determined using the Adeno-X Rapid Titer Kit (Clontech,
Saint-Germain-en-Laye, France). Cells were harvested 48 h
after infection. Proteins were separated by 10% SDS-PAGE
using the Mini-PROTEAN System, followed by transfer onto a
nitrocellulose membrane using the Mini Trans-blot Cell (Bio-
Rad Laboratories AG, Cressier, Switzerland). After protein
transfer, the membranes were incubated in blocking buffer (5%
FCS- Tris-buffered saline with 0.04% Tween 20 (TBST)) for 1
h, followed by incubation with the primary antibody at 4 °C
overnight. For the detection of OATP2B1, the previously
reported antiserum was used (diluted 1:5000).27 The Na+/K+-
ATPase served as a loading control (ab76020, abcam, Lucerna
Chem AG). Immobilization of the primary antibody was
detected with HRP-labeled secondary antibodies and the ECL
Western blotting substrate (Pierce distributed by Thermo
Fisher Scientific). Chemiluminescence was visualized and
digitalized using the Chemidoc XRS system (Bio-Rad
Laboratories AG). Finally, the Image Lab 4.1 software (Bio-
Rad Laboratories AG) was used for densitometrical analysis of
the protein content normalizing the observed amount of
OATP2B1 to that of Na+/K+-ATPase in the same sample.
Immunofluorescent Staining. For immunofluorescent
staining, cells were seeded on coverslips at a density of 75 000
cells/well in 12-well plates (Eppendorf). One day after seeding,
MDCKII-OATP2B1 or HeLa cells were treated as described in
detail above. Cells were fixed with ice-cold methanol:acetone
(1:2) for 15 min, permeabilized with 0.2% Tween 20
phosphate buffer saline (PBS), and then incubated with 5%-
FCS-1% bovine serum albumin (BSA)-PBS before exposure to
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the anti-OATP2B1-anti-serum (1:100).27 The anti-rabbit
Alexa Fluor 488 antibody was used as the secondary antibody
(Life Technologies distributed by Thermo Fisher Scientific).
After mounting the cells with Roti-Mount FluorCare
containing 4′,6-diamidino-2-phenylindole (DAPI) for nuclei
staining, expression and localization was detected using the
Leica DMi8Microscope and the LASX software (Leica
Microsystems, Heerbrugg, Switzerland).
LC−MS/MS Sample Preparation. Cells infected or
transfected as described above were the basis for the mass
spectrometric analysis. In detail, cells were harvested and
homogenized in 10 mM Tris-0.5 mM MgCl2 (pH 7.5) using
the Potter S homogenizer (Sartorius, Göttingen, Germany).
Then the cell homogenate was centrifuged for 5 min at 600g
followed by a 5 min centrifugation of the supernatant at
15 000g and 4 °C. Finally, the resulting supernatant was
centrifuged for 1 h at 100 000g and 4 °C. The resulting pellet
was dissolved in 100 μL 2% sodium-deoxycholate in 100 mM
ammonium bicarbonate. After the addition of 10 mM tris(2-
carboxyethyl)phosphine (TCEP, Sigma-Aldrich) and ultra-
sonication with a vial Tweeter Ultrasonicater (Hielscher,
Teltow, Germany), samples were heated at 95 °C and 300 rpm
(Micro Centrifuge Tube Thermomixer; Eppendorf) for 10 min
before protein concentration was determined with the
Microplate BCA Protein Assay Kit (Thermo Fisher Scientific).
Then, 15 mM chloroacetamide (Sigma-Aldrich) was added for
carbamidomethylation of cysteins at 37 °C and 500 rpm for 30
min. Of each sample, a total of 50 μg was digested for 12 h at
37 °C with porcine trypsin (Promega, Madison, USA) at a final
enzyme/protein-ratio of 1:50. The reaction was stopped with
50 μL of 5% trifluoroacetic acid (TFA) in water. Peptides were
desalted by solid phase extraction using iST cartridges
(PreOmics, Planegg/Martinsried, Germany) and dried using
an acid resistant CentriVap concentrator (Labcono, Kansas
City, USA). Before MS analysis, dried peptides were
resuspended in 0.15% formic acid (Sigma-Aldrich) and 2%
acetonitrile (Thermo Fisher Scientific).
Mass Spectrometry. Mass spectrometric analysis of
peptide samples was performed on a Q-Exactive HF mass
spectrometer equipped with a nanoelectrospray ion source
(both Thermo Fisher Scientific). Data were acquired in the
data dependent acquisition (DDA) mode. The μRPLC-MS
system was set up as described previously.28 The chromato-
graphic separation of peptides was performed by an EASY
nano-LC 1000 system (Thermo Fisher Scientific) equipped
with a heated RP-HPLC column (75 μm × 37 cm) packed in-
house with 1.9 μm C18 resin (Reprosil-AQ Pur, Dr. Maisch).
Peptides were separated using a linear gradient ranging from
95% solvent A (0.1% formic acid) and 5% solvent B (80%
acetonitrile, 20% water, 0.1% formic acid) to 45% solvent B
over 60 min at a flow rate of 200 nL/min. For DDA
acquisition, each MS1 scan was followed by high-collision-
dissociation (HCD) of the 20 most abundant precursor ions
with an active dynamic exclusion setting of 30 s. The total
cycle time was approximately 1 s. For MS1, 3 × 106 ions were
accumulated in the Orbitrap cell over a maximum time of 100
ms and scanned at a resolution of 120 000 fwhm (at 200 m/z).
MS2 scans were acquired at a target setting of 1 × 105 ions, an
accumulation time of 50 ms, and a resolution of 15 000 fwhm
(at 200 m/z). Singly charged ions and ions with an unassigned
charge state were excluded from the triggering of MS2 events.
The normalized collision energy was set to 28%, the mass
isolation window was set to 1.4 m/z.
Mass Spectrometry Data Analysis. The acquired DDA-
based raw-files were converted to a MASCOT generic file
format using the msconvert tool (part of ProteoWizard, version
3.0.4624 (2013-6-3)). Converted files were searched using a
target decoy strategy by MASCOT (Matrix Sciences) against
the UniProt databases of Homo sapiens (May 2016, Hela cell
data) and Canis familiariz (Feb 2018, MDCK cell data)
containing commonly observed contaminant proteins. Addi-
tionally, the human OATP2B1 (UniProt ID O94956) was
added to the Canis familiariz database. The precursor ion
tolerance was set to 10 ppm, and fragment ion tolerance was
set to 0.02 Da. For database search, strict trypsin specificity
allowing for three missed cleavages was used. Carbamidome-
thylation of cysteins (+57 Da) was set as a fixed modification,
and oxidation of methionine (+16 Da) or protein N-terminal
acetylation (+42 Da) was set as a variable peptide
modification. Scaffold (version 4.8.4 Proteome Software Inc.)
was used to validate MS/MS-based peptide and protein
identifications. The protein false discovery rate (FDR) was set
to 1%, and protein identifications were accepted if they
contained at least 2 identified peptides. Protein probabilities
were assigned by the Protein Prophet algorithm.29 Proteins
that contained similar peptides and could not be differentiated
based on MS/MS analysis alone were grouped to satisfy the
principles of parsimony. The normalized spectral abundance
factor (NSAF) method was used to calculate OATP2B1
protein intensity.
OATP2B1 Transport Inhibition Study. For transport
experiments, MDCKII-OATP2B1 or MDCKII cells were
seeded at a density of 50 000 cells/well in 24-well plates.
One day after seeding, the cells were treated with 2 mM
sodium butyrate for another day. After preincubation with
Hank’s balanced salt solution (HANKs) (Sigma-Aldrich), the
cells were exposed to HANKs containing [3H]-E1S (100 000
dpm/well, 6 nM) and the respective test compound. After 5
min of incubation, cells were washed twice with ice-cold PBS
and lysed in 200 μL of lysis buffer (10% SDS-5 mM EDTA,
pH 7.4). Protein quantification was determined using the
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) and
the microplate reader Infinite M200 Pro (Tecan, Man̈nedorf,
Switzerland). The residual of the cell homogenate was used to
measure the amount of radiolabeled substrate using 2 mL of
scintillation fluid (Rotiszint eco Plus, Carl Roth) and the liquid
scintillation counter Tri-Carb 2900TR (TopLab, Basel,
Switzerland).
CCF Experiments. MDCKII-OATP2B1 or MDCKII cells
were seeded and stimulated as described above. On the day of
experiment, cells were preincubated with HANKs buffer
containing 100 000 dpm/well (6 nM) [3H]-E1S for 30 min
to reach steady state. Then, the supernatant was removed, and
HANKs buffer (pH 5.5 or pH 7.4) was added containing
100 000 dpm/well (6 nM) [3H]-E1S and the respective test
compounds. The cells were exposed for 90 s to reach the
equilibrium of the CCF. The concentration of the test
compounds was 10× the estimated IC50; this concentration
had been recommended to be applied in CCF experiments.25
Protein quantification and intracellular radioactivity were
measured as described above. Data were analyzed relating
[3H]-E1S uptake in the presence of the tested compound to the
percent of the respective solvent control.
Determination of OATP2B1-Mediated Uptake of
Astemizole and Domperidone. MDCKII as a control and
MDCKII-OATP2B1, seeded and stimulated as described
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above, were exposed to 0.1 μM astemizole or 0.1 μM
domperidone supplemented with 50 000 dpm/well of the
respective radiolabeled tracer [3H]-astemizole (2 nM) or [3H]-
domperidone (4.3 nM) for 5 min. Cellular accumulation of the
radiolabel was quantified as described above. For inhibition
studies, MDCKII-OATP2B1 cells were treated with the same
amount of astemizole or domperidone plus 100 μM BSP. Data
were analyzed as fmol/μg of protein/min and compared to the
solvent control.
Cell-Based Reporter Gene Assay. MDCKII-OATP2B1
cells were seeded at a density of 40 000 cells/well in 24-well
plates. One day after seeding, the cells were transfected with
hPXR-pEF6 or pEF6-control (250 ng/well). The previously
reported CYP3A4-XREM-pGL3basic30 (250 ng/well) was
used as the reporter gene construct, while pRL-TK (25 ng/
well) encoding for Renilla luciferase served as the transfection
control. One day after transfection with jetPRIME using 2 μL/
μg of DNA, the cells were exposed to hyperforin (0.1 μM)
and/or bromosulfophthalein (BSP, 10 μM) or solvent control
for 24 h. Luciferase activity was determined using the Dual-
Luciferase Assay System (Promega, Dübendorf, Switzerland)
and the plate reader Infinite M200 Pro as recommended by the
manufacturer. The luminescence detected for the Firef ly
luciferase was normalized to that observed for the Renilla in
each sample. Data are presented as the fold of solvent control.
Determination of Cellular Viability. MDCKII and
MDCKII-OATP2B1 cells were seeded at a density of 10 000
cells/well in 96-well plates (Eppendorf) and stimulated as
described above. After 6 h of incubation with etoposide or
teniposide, the medium was changed. The treatment with
Figure 1. OATP2B1 protein expression comparing different methods of cellular delivery. Expression and localization of the transporter were
assessed by immunofluorescent staining (A). In detail, MDCKII-OATP2B1 and HeLa cells either infected with vTF-7 and transfected with
OATP2B1-pEF6 or infected with Ad-OATP2B1 were fixed and then stained. Antibody binding and nucleic counterstaining with DAPI was
visualized by fluorescence microscopy. Amount of OATP2B1 was determined by Western blot analysis of the enriched membrane fraction. Na+/
K+-ATPase served as the control (B). Amount of OATP2B1 was determined by LC−MS/MS in each cellular expression system. Data are shown as
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paclitaxel was performed for 24 h. Cell viability was assessed 24
h after the treatment started using the Resazurin Fluorometric
Cell Viability Kit (PromoCell GmbH, Heidelberg, Germany)
according to the manufacturers’ instruction. Fluorescence was
detected using the Infinite M200 Pro plate reader (Ex = 530
nm, Em = 590 nm). Viability was calculated as the percent of
solvent control after subtracting the fluorescence of the








Statistical Analysis. Analysis of data was performed using
the GraphPad Prism software 6.0 (GraphPad Software) and
Table 1. Influence of Compounds on the OATP2B1-Mediated Uptake Accounting for the Previously Reported Binding Site A
(Low Concentration of E1S) or Binding Site B (High Concentration of E1S)
a,b














astemizole 20.71 13.98−30.66 170.20 104.30−277.60 n.r. 38 n.d.
atorvastatin 0.26 0.18−0.37 4.32 3.29−5.66 0.7 2 0.2 2
2.84 38
BSP 1.91 0.93−3.92 23.76 14.18−39.81 2.0 67 0.7 10
cerivastatin 5.40 2.17−13.43 43.41 22.03−85.56 66.2 2 n.r. 32
cyclosporin A 61.14 29.35−127.4 0.07 36 n.d.
37 38
20 42
domperidone 6.31 3.27−12.17 70.57 36.40−136.80 n.d. n.d.
dronedarone 96.36 55.00−168.80 342.60 203.20−577.70 n.d. n.d.
enalapril n.i. 38 n.d.
erythromycin >1100 39 n.d.
etoposide 71.23 54.93−92.37 n.i. 38 n.d.
fenofibrate 118.20 47.70−292.90 42.88 18.70−98.29 n.i. 38 n.d.
fexofenadine 524.50 418.3−657.50 n.d. 0.14 17
fluoxetine n.i. 38 n.d.
FTC n.d. n.d.
gemfibrozil 388.30 264.0−571.1 8.0 36 n.d.
glibenclamide 0.57 0.26−1.27 2.0 68 6.3 34
hyperforin 0.55 0.29−1.06 12.89 4.73−35.10 n.d. n.d.
indomethacin 22.14 11.06−44.30 239.30 73.31−781.20 n.i. 38 n.d.
irbesartan 6.92 3.70−12.93 445.40 172.3−1151 n.d. n.d.
itraconazole 79.49 30.97−204.0 174.40 73.88−411.90 n.r. 38 n.d.
ketoconazole 5.25 3.36−8.23 23.61 8.26−67.55 n.i. 38 n.d.
lorglumide 0.89 0.36−2.23 n.d. n.d.
loxiglumide 7.33 4.89−10.97 n.d. n.d.
metoprolol n.d. n.d.
naringin 12.62 7.70−20.66 36.4 20 n.d.
4.63 21
paclitaxel 25 42 n.s. 42
n.i. 38




sunitinib 88.34 49.01−159.20 88 40 n.d.
talinolol 407.40 297.0−558.8 n.r. 22 629 33
teniposide 14.24 9.68−20.94 n.r. 37
tolbutamide n.i. 38
T4 7.68 3.83−15.38 41.67 13.27−130.90 2.43 41 0.77 35
T3 2.10 1.35−3.12 19.65 8.77−44.02 0.51 41




verapamil n.i. 38 n.d.
aInhibitory potency was estimated calculating the respective IC50 using data obtained in transport experiments using MDCKII-OATP2B1 cells. In
addition, previously reported IC50 and km (Michaelis Menten constant) values are listed.
bn = 3−5 experiments; BSP, bromosulfophthalein; FTC,
fumitremorgin C; T4, thyroxine; T3, triiodothyronine; n.r., not reported; n.d., not determined; n.i., no inhibition; and n.s., no substrate.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.8b00631
Mol. Pharmaceutics 2018, 15, 5501−5513
5505
35
Microsoft Excel (Microsoft, Redmond, USA). In the context of
data presentation, the respective statistical test is indicated. A
p-value below 0.05 was considered statistically significant.
■ RESULTS
Comparison of Cellular OATP2B1 Content in Differ-
ent Heterologous Expression Systems. OATP2B1 ex-
pression was assessed after applying three methods for the
delivery of the information encoding for the transporter. These
systems were stably transfected MDCKII-OATP2B1 cells, a
vTF-7-based expression system (HeLa OATP2B1-pEF6), and
an adenoviral expression system (HeLa Ad-OATP2B1). At
first, expression and localization of OATP2B1 was compared
by immunofluorescent staining. As shown in Figure 1A, all
cellular expression systems resulted in a positive fluorescent
signal. Especially in MDCKII-OATP2B1, we observed a well-
defined signal at the basolateral membrane of these polarized
cells. In HeLa cells either transfected with OATP2B1-pEF6 or
infected with Ad-OATP2B1, we observed some membrane
enrichment even if the fluorescent signal was much less
defined. No staining was observed in MDCKII, HeLa pEF6, or
HeLa Ad-LacZ cells, which served as controls. As shown in
Figure 1B by a representative image, Western blot analysis
detecting the uptake transporter in the enriched membrane
fraction revealed the highest level of the transporter in the
stable expression system, while the lowest amount was found
after adenoviral delivery (mean OATP2B1 expression
normalized to Na+/K+-ATPase ± SD; MDCKII-OATP2B1
vs HeLa OATP2B1-pEF6 vs HeLa Ad-OATP2B1; 1.67 ± 0.32
vs 0.73 ± 0.75 (p > 0.05) vs 0.07 ± 0.01 (p < 0.05), n = 3, one-
way ANOVA corrected for multiple comparisons). Verification
of OATP2B1 protein expression was successfully performed by
mass spectrometry in the MDCKII-based and in the HeLa-
based expression systems. Similar to the results above, we
observed a significantly higher amount of OATP2B1 in
transiently transfected HeLa OATP2B1-pEF6 vs HeLa Ad-
OATP2B1 cells and a robust expression of OATP2B1 in the
MDCKII-OATP2B1 cell line by quantitative mass spectrom-
etry (Figure 1C).
Screening of a Compound Library for Interaction
with OATP2B1. A list of 40 compounds was prepared,
summarizing known substrates,2,10,14,17,31−35 known inhibi-
tors,18,21,22,36−41 and substances without impact on
OATP2B1.37,38,42 In addition, 11 molecules were added to
the library where interaction with OATP2B1 was unknown. All
compounds were tested for inhibition of OATP2B1-mediated
uptake of E1S in MDCKII-OATP2B1 cells. In order to account
for the previously reported binding sites,22 we tested inhibition
of OATP2B1 using a low (0.005 μM) and a high (50 μM)
concentration of E1S referred to as binding site A and B,
respectively. Three concentrations of each compound were
used for an estimation of inhibitory potency (IC50). Selection
of the concentrations applied in the inhibition study was either
based on IC50 values reported in the literature (compare Table
1) or, if no IC50 was available, the experiment was performed
with 1, 10, 100 μM of the respective test compound. As
summarized in Table 1, inhibition of both binding sites was
observed for the previously reported substrates atorvastatin,
bromosulfophthalein, cerivastatin, and thyroxine (T4), while
fexofenadine, glibenclamide, and talinolol were binding site A
inhibitors. Furthermore, the previously reported inhibitors
astemizole, itraconazole, and triiodothyronine (T3) were
verified. Cyclosporine A, gemfibrozil, naringin, sunitinib, and
teniposide were specifically inhibiting binding site A. However,
even if no interaction with OATP2B1 was shown by
others,37,38,40 we observed potent inhibition by etoposide,
fenofibrate, indomethacin, and ketoconazole. For the com-
pounds where interaction with OATP2B1 was unknown, we
observed potent inhibition of binding site A in the presence of
lorglumide and loxiglumide and for both binding sites in the
presence of domperidone, dronedarone, hyperforin, irbesartan,
and troglitazone. Finally, no inhibition was observed for
enalapril, erythromycin, fluoxetine, fumitremorgin C (FTC),
metoprolol, paclitaxel, penicillin G, probenecid, proglumide,
tolbutamid, valproate, valsartan, venlafaxine, and verapamil.
CCF Experiments. CCF experiments are conducted after
reaching the steady state, whereby defining the time of
preincubation in the experimental set up. Accordingly, this
time of preincubation was determined performing time-
dependent uptake studies using tritium-labeled E1S at a
concentration of 6 nM. Independent of the cellular expression
system, the steady state was reached after at least 30 min
(Figure S1). This time of preincubation was the basis for the
following experiments, where the time of reaching equilibra-
tion in the CCF was assessed, exchanging the supernatant used
for preincubation with transport buffer containing the same
amount of E1S (6 nM) and a very high amount (50 μM) of
E1S. In MDCKII-OATP2B1 cells and in the vTF-7-based
expression system, the equilibrium was reached after 90 s of
incubation. However, we were not able to determine the
equilibrium in the adenoviral system (Figure S1). We
interpreted this by the much lower transport rate, which
might be explained by the much lower amount of OATP2B1
detected in these cells (Figure 1). The time of reaching
equilibration in the CCF was validated in MDCKII-OATP2B1
cells using the known substrates BSP and atorvastatin, both
applied at a concentration of 50 μM (Figure S2).
Application of CCF with a Compound Library.
Subsequently, we applied the established CCF protocol to
our compound library using MDCKII-OATP2B1 cells. As
recommended by Harper et al.,25 concentrations used in the
CCF experiment were 10-fold higher than the estimated IC50
value (Table 1), if applicable. In the case of solubility issues, we
used a concentration of 250 μM of the respective compound.
As shown in Figure 2 and summarized in Table S1, we
observed a significantly reduced amount of E1S in the CCF for
all previously validated substrates of OATP2B1 (atorvastatin,
BSP, cerivastatin, fexofenadine, glibenclamide, talinolol, and
thyroxine (T4), compared to Table 1). All but fexofenadine,
glibenclamide, and talinolol were identified above as inhibitors
of both binding sites. Furthermore, among the compounds we
observed to inhibit binding site A and B, we identified
astemizole, domperidone, hyperforin, irbesartan, itraconazole,
ketoconazole, and triiodothyronine (T3) as substrates of
OATP2B1, while troglitazone, indomethacin, fenofibrate, and
dronedarone did not significantly influence the steady state of
E1S. However, for fenofibrate and dronedarone, we did not
reach the recommended 10-fold of IC50.
Among the compounds, which we observed to only inhibit
binding site A, cyclosporine A, etoposide, lorglumide,
loxiglumide, naringin, sunitinib, and teniposide significantly
reduced the amount of E1S, suggesting that these compounds
are substrates of the transporter. For cyclosporine A,
gemfibrozil, and sunitinib, the used concentration (250 μM)
did not reach the recommended 10-fold of IC50. Accordingly,
the lack of interaction observed for gemfibrozil does not
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necessarily mean that this compound is not a substrate of
OATP2B1. The same applies to the above-mentioned
dronedarone and fenofibrate.
Analyzing the amount of E1S in MDCKII-OATP2B1 cells
revealed no significant reduction in the presence of molecules
identified to be noninhibitors of OATP2B1 (enalapril,
erythromycin, fluoxetine, fumitremorgin C, metoprolol,
paclitaxel, penicillin G, probenecid, proglumide, valproate,
valsartan, venlafaxine, and verapamil). Interestingly, for
enalapril, fluoxetine, and fumitremorgin C, we even observed
significantly increased amounts compared to the solvent
control. In order to determine whether these compounds
influence the cellular amount of E1S in native MDCKII cells
direct inhibition or CCF, experiments were conducted. As
shown in Figure S4A, none of the tested compounds
influenced cellular E1S accumulation at 5 min of exposure or
the steady-state equilibrium (Figure S4B) (p > 0.05, one-way
ANOVA with Dunnett’s test). The molecules tested were
identified inhibitors and substrates (astemizole, atorvastatin,
and hyperforin), compounds that did not interact with
OATP2B1 in CCF experiments but were identified as
inhibitors (dronedarone, fenofibrate, gemfibrozil, indometha-
cin, and troglitazone), or the above-mentioned fluoxetine and
fumitremorgin C, where we observed significantly increased
E1S accumulation in the steady state equilibrium but no direct
interaction with OATP2B1-mediated transport.
Validation of Identified Substrates of OATP2B1.
Applying CCF, we identified the epipodophyllotoxins, etopo-
side, and teniposide, but not the taxane paclitaxel, as substrates
of OATP2B1. In order to verify this observation, we tested the
influence of OATP2B1 expression on the cytotoxic effect of
these molecules. In detail, in the presence of OATP2B1,
etoposide exhibited a significantly enhanced cytotoxicity, as
determined by estimating the inhibitory potency (IC50;
MDCKII vs MDCKII-OATP2B1; 1559 μM, CI 63.46 to
38323 μM vs 101.3 μM, CI 73.30 to 140.1 μM; Figure 3A).
Similar results were obtained for teniposide (362.8 μM, CI
224.1 to 587.3 μM vs 7.848 μM, CI 5.141 to 11.98 μM; Figure
3B) but not for paclitaxel (234.9 μM, CI 119.5 to 461.7 μM vs
385.3 μM, CI 148.1 to 1003 μM; Figure 3C). These results
supported the notion that etoposide and teniposide are
substrates of the uptake transporter.
Another compound herein identified as a substrate was
hyperforin. This constituent of St John’s wort is a known
activating ligand of the pregnane X receptor (PXR), whereby
enhancing expression of CYP3A4.43 Assuming that cellular
accumulation and thereby the cellular activity of hyperforin is
influenced by the function of OATP2B1, we tested whether
concomitant administration of BSP, a known competitive
inhibitor of OATP2B1, influences hyperforin-induced trans-
activation of CYP3A4 in cell-based reporter gene assays. As
shown in Figure 3D we observed significantly reduced
transactivation when exposing the cells to hyperforin (0.1
μM) and BSP (10 μM) compared to hyperforin alone, no such
effect was observed in MDCKII cells. Importantly BSP does
not function as a ligand of PXR.
Finally, the CCF experiments suggested that the antihist-
amine astemizole and the dopamine D2 receptor antagonist
domperidone are substrates of OATP2B1. In order to validate
those findings, direct uptake experiments were performed
using [3H]-astemizole and [3H]-domperidone. As shown in
Figure 4, MDCKII-OATP2B1 exhibited significant [3H]-
astemizole uptake (mean uptake ± SEM 2.3 ± 0.31 pmol/μg
of protein/min, Figure 4A) and [3H]-domperidone uptake
(mean uptake ± SEM 2.2 ± 0.2 pmol/μg of protein/min,
Figure 4B) compared to MDCKII. Testing the influence of
concomitant administration of BSP on the cellular accumu-
lation revealed significantly reduced uptake of [3H]-astemizole
(Figure 4C) or [3H]-domperidone (Figure 4D) compared to
the solvent control.
Influence of the pH on CCF Experiments with
OATP2B1. It has been reported that OATP2B1 function is
sensitive to pH, especially for E1S. Nozawa et al. reported
increased uptake with decreasing pH.14 In accordance with
their findings, we observed an almost 2-fold increase in cellular
accumulation in the presence of pH 5.5 compared to
experiments conducted at physiological pH assessing the
time-dependent uptake of E1S (Figure 5A). To test, whether
pH affects the results from CCF, we performed the experiment
at pH 5.5 (Figure 5B) using a selection of the tested
compounds, namely, atorvastatin, BSP, and naringin, which we
identified as substrates in the CCF conducted at physiological
pH (Figure 5C). Penicillin G was chosen as a negative control
Figure 2. CCF experiments in MDCKII-OATP2B1 cells testing a
compound library. CCF experiments were conducted in MDCKII
cells expressing OATP2B1. The amount of E1S was determined 90 s
after exchanging the supernatant in the steady state. The experiment
was conducted using each inhibitor at 10-fold IC50. For some
inhibitors, this concentration was not reached due to solubility issues
(indicated in gray). These and all noninhibitors were tested at 250
μM. Data are shown as mean ± SD, n = 3 independent experiments
each performed in biological triplicates. *p ≤ 0.05, one-way ANOVA
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Figure 3. Verification of newly identified substrates of OATP2B1 by indirect methods. MDCKII or MDCKII-OATP2B1 cells were treated with
increasing concentrations of etoposide (A), teniposide (B), or paclitaxel (C), followed by determination of cell viability. The dose response curves
were fitted to estimate the IC50 value in the presence or absence of OATP2B1. Data are presented as mean ± SD, n = 3 experiments, *p ≤ 0.05, and
two-way ANOVA with Sidak’s multiple comparisons test. MDCKII-OATP2B1 cells were transfected with the synthetic CYP3A4-XREM-pGL3-
basic reporter construct and tested for PXR-mediated transactivation by hyperforin in the presence or absence of the OATP2B1-inhibitor BSP (D).
Data are presented as mean ± SD, n = 3 independent experiments each conducted in biological triplicates. *p ≤ 0.05, one-way ANOVA with
Dunnett’s multiple comparisons test.
Figure 4. Transport of astemizole and domperidone by OATP2B1.
Cellular uptake of astemizole (A) and domperidone (B) was assessed
in MDCKII and MDCKII-OATP2B1 cells. Inhibition studies were
conducted in MDCKII-OATP2B1 cells comparing uptake of
astemizole (C) and domperidone (D) in the presence of 100 μM
BSP compared to the solvent control. Data are presented as mean ±
SD, n = 3 independent experiments each conducted in biological
triplicates. *p ≤ 0.05, Student’s t-test.
Figure 5. Influence of pH on CCF experiments with OATP2B1.
Time-dependent uptake of E1S at pH 5.5 and pH 7.4 was determined
in MDCKII-OATP2B1 cells (A). Data are presented as mean ± SD, n
= 3 in biological triplicates, *p ≤ 0.05, two-way ANOVA with Sidak’s
multiple comparisons test. CCF experiments were conducted at pH
5.5 (B) and pH 7.4 (C). Data are presented as mean ± SD of n = 3
independent experiments performed in biological triplicates. *p ≤
0.05, one-way ANOVA with Dunnett’s multiple comparisons test.
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since it did not influence the equilibrium, and as it was
previously reported to not be substrate of OATP2B1.42 For
atorvastatin, BSP, and naringin, we observed significantly
decreased cellular E1S accumulation at pH 5.5, while penicillin
G did not affect the equilibrium.
■ DISCUSSION
In this article we report, that the method of CCF is applicable
for OATP2B1 substrate identification. According to the FDA
guidelines, an attempt to identify potential drug transporter
interactions has to be made if available clinical data suggest
that renal, biliary, or gut secretion contributes significantly to
drug elimination observed in available clinical data.44 With the
CCF, the portfolio of approaches to screen for transporter
interaction is broadened by an additional method. Kim
Brouwer and colleagues, on behalf of the International
Transporter Consortium, summarized the procedures that
could be used to test transport of new molecular entities.45 All
of the methods described apply direct quantification of the
compound of interest using cellular systems overexpressing the
transporter of interest. Most of the approaches described by
Brouwer et al. are based on the quantification of unidirectional
flow, which would be, in the case of a transporter facilitating
uptake, the determination of the cellular accumulation. In
contrast, the CCF finds its basis in considerations on net fluxes
in a cellular system, where the facilitating mechanism would
certainly contribute. Another method considering fluxes, which
is often applied in the preclinical assessment of new molecular
entities, are transcellular flux experiments. Most common are
transwell studies with Caco-2 cells, where the transcellular net
flux in the apical to basal (A→ B) and basal to apical (B → A)
direction is applied to determine whether there is an active
uptake component and to predict oral bioavailability of a
compound.46 As previously and excellently summarized by the
Nobel prize winner William Stein,47 the CCF is based on an
early observation made for the accumulation of glucose in
erythrocytes by Rosenberg and Wilbrandt.24 According to
Stein, the phenomenon of competitive exchange will be found
in any situation where a facilitated diffusion system is at or
close to saturation at both faces of the membrane and a second
substrate sharing the same facilitating system is added. In this
situation, the original low net flux, which is observed in the
steady state, will be converted into a high unidirectional
transport, as the second substrate is competing for substrate
binding.47 Inhibitors not being substrates of the facilitating
system do not significantly influence the amount of the driven
substrate (in our case E1S). According to Harper et al., who
provided the first evidence that CCF could be applied to
differentiate inhibitors and competing substrates of the drug
transporter organic cation transporter 2 (OCT2, SLC22A2), a
ligand or substrate competes with the driven substrate for
recognition but allows transporter turnover, whereby con-
tributing to the observed reduction in cellular accumulation. In
contrast, an inhibitor would block the turnover of the
transporter, whereby reducing the so-called “up-hill” transport,
the equilibrium stays unchanged. This allows for the
differentiation between inhibitors and substrates.25 With the
herein reported method, we extend the application to organic
anions.
We think the observation that the presence of a competing
substrate reduces the cellular amount of the driven substrate
(in our case E1S) does not necessarily have to be translated
into an equimolar bidirectional function of the investigated
transporter. Especially, considering that endogenously ex-
pressed ABC-transporters significantly contribute to the steady
state equilibrium, and that these efflux transporters are sharing
multiple substrates with uptake transporters. This may not be
as important for the previously reported CCF application on
OCTs as there is less overlap between ABC-transporters and
OCTs. The driven substrate in our experiments was E1S. It has
previously been reported that E1S is a substrate of human
ABCG2.48 When we determined the amount of E1S in the
presence of fumitremorgin C, a potent and specific ABCG2
inhibitor,49 we observed significantly enhanced cellular
amounts of E1S, whereby supporting the idea that ABCG2 at
least participates at the steady state. Furthermore, enalapril has
been reported as a substrate of the efflux transporter ABCC2,50
and fluoxetine has been reported as an inhibitor of P-
glycoprotein (ABCB1);51 both compounds significantly
enhanced the cellular amount in our experimental set up,
even if not interacting with the investigated transporter.
Consequently, it may be speculated that if a molecule is a
potent inhibitor of efflux transporters, it may not be identified
as a substrate of OATP2B1 when applying CCF experiments.
However, some of the herein identified substrates are known to
interact with ABC-transporters, including atorvastatin,52
bromosulfophthalein,53 etoposide,54 fexofenadine,55 and hy-
perforin,56 suggesting that this limitation does not necessarily
apply. Importantly, when we tested a selection of compounds
for their influence on cellular accumulation in native MDCKII
cells, we observed no impact on the cellular amount neither
after short-term exposure nor in the steady state equilibrium,
suggesting that the efflux component can only be seen, when
the cellular amount is increased by an uptake mechanism.
We tested multiple compounds for interaction with
OATP2B1 and were able to differentiate inhibitors and
substrates of OATP2B1. However, some of the herein
identified inhibitors have previously been qualified as non-
inhibitors of OATP2B1. Indeed, Karlgren et al. tested a library
of 225 substances for interaction with the hepatically expressed
OATPs, namely, OATP1B1, OATP1B3, and OATP2B1. In
their analysis, a compound was considered an inhibitor when
reducing cellular accumulation of E1S by at least 50% in the
presence of 20 μM of the test compound. Applying these
identifiers, they qualified several inhibitors of our library as
noninhibitors.38 However, testing a wider range of concen-
trations, we observed statistically significant concentration-
dependent inhibition of binding site A of OATP2B1 for
etoposide (IC50 71 μM) and gemfibrozil (IC50 388 μM).
Indomethacin (IC50 A, 22 μM; B, 44 μM), fenofibrate (IC50 A,
118 μM; B, 43 μM), and ketoconazole (IC50 A, 5 μM; B, 23
μM), which are also reported to be noninhibitors, interacted
with both sites, binding site A and binding site B. Considering
the observed inhibitory potency in our study, the classification
as noninhibitor or inhibitor was similar. Our findings on
paclitaxel not being an inhibitor and finally not a substrate of
OATP2B1 are in accordance with those by Karlgren et al.,
while others observed an IC50 of 25 μM.
42
Applying the CCF, none of the noninhibitors as determined
in our inhibition study significantly reduced the amount of E1S
in equilibrium. Importantly, all known OATP2B1 substrates
were identified. Furthermore, we were able to report novel
substrates of OATP2B1. One of these is the antihistaminic
astemizole, where transport was validated by direct uptake
studies. Known for its QT interval prolongation,57 astemizole
was withdrawn from the market in most countries. Never-
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theless, it has been tested as a novel approach in breast cancer
therapy.58 Consequently, it seems to still be a medication
where knowledge about the uptake mechanism is of interest.
Another antihistamine drug, which we identified applying CCF
as a substrate of OATP2B1, is fexofenadine. Although this
compound has been reported as being a substrate of
OATP1A2,16 our findings are in accordance with those by
Shirasaka et al.17 Furthermore, there are multiple lines of
evidence supporting a role of OATP2B1 in fexofenadine
pharmacokinetics, as recently summarized by Akamine and
Miura, including the influence of genetic variants of OATP2B1
and the shown influence of fruit juices on fexofenadine
disposition (AUC and Cmax) in vivo.
59 Multiple components of
fruit juices efficiently inhibit OATP2B1 function.21 One major
constituent of GFJ is naringin, which we also identified as a
substrate of OATP2B1 when performing CCF experiments.
There are various approaches to verify transporter mediated
uptake of a compound. One possibility is to test the influence
of a transporter on the pharmacological effect if this is
depending on cellular accumulation. In this study, we applied
cell-based reporter gene assays and cytotoxicity assays to verify
interaction with OATP2B1. Using MDCKII and MDCKII-
OATP2B1 cells, we were able to show that the cytotoxic effect
of teniposide is significantly enhanced by OATP2B1, whereby
supporting the idea that teniposide is a substrate of OATP2B1,
as we have previously shown by overexpressing OATP2B1 in
human coronary artery smooth muscle cells.37 Etoposide is
another topoisomerase II inhibitor used as a chemotherapeutic
medication. Even if this compound does not interact with
OATP2B1 at low concentrations,37,38 we were able to show
inhibition and to identify it as a substrate. The notion of
etoposide being a substrate of OATP2B1 was validated by
comparing its cytotoxic effect in OATP2B1-expressing and
wild-type cells. Etoposide was significantly more efficient in
cells overexpressing OATP2B1. Interestingly, Reif et al. were
able to show significantly reduced oral bioavailability of
etoposide when drinking GFJ before intake of the
medication.60 Considering the above-mentioned beverage-
drug interactions, these data support our finding of etoposide
being a substrate of the uptake transporter. The chemo-
therapeutic paclitaxel served as the control in our indirect
validation experiment, as it was not identified as a substrate of
OATP2B1.
Finally, we validated hyperforin as a substrate of OATP2B1.
This constituent of St. John’s wort is not only assumed to be of
pharmacological relevance in terms of antidepressant activity,61
but it is also a key component for the drug-drug interaction
potential of this commonly used herbal extract.62 Indeed,
hyperforin is a ligand and potent activator of PXR, which after
activation induces the transcription of multiple genes involved
in drug metabolism.63 The enhanced transcription and
expression of drug metabolizing enzymes (e.g., CYP3A4) and
drug transporters (e.g., P-glycoprotein/ABCB1) is the basis of
current considerations on drug interactions.64 Our findings,
showing that inhibition of OATP2B1 by BSP influences
transactivation by hyperforin, not only support that hyperforin
is indeed a substrate of OATP2B1 but also broadened the
spectrum of possibilities one has to consider when evaluating
the consequences of concomitant drug use. However, it is
beyond the scope of this study to speculate on the
consequences of the concomitant use of OATP2B1 inhibitors
and hyperforin.
When establishing CCF conditions, three different
OATP2B1 overexpressing cellular systems were examined.
Interestingly, when comparing the amount of OATP2B1
expression, Western blot analysis reflected functional data,
while the LC−MS/MS data did not. Notably, our LC−MS/
MS data suggest that membrane enrichment is influenced by
the cellular background, which is in agreement with previous
findings by Wegler et al.65 who compared LC−MS/MS data
from different laboratories by applying different methods of
cellular fractionation. Even if we used HeLa cells for both viral
driven expression systems, the difference in the viruses
(adenovirus and vaccinia virus) may certainly have influenced
the enrichment of the cellular fractions, especially considering
that the vTF-7 virus is lytic in HeLa cells.66
Taken together, the herein established experimental set up
for CCF experiments can be implemented to identify
substrates of OATP2B1. Performance is independent whether
substrates are interacting with binding site A and B or only
with binding site A. Factors limiting the applicability of the
experimental procedure are the inhibitory potency (as
solubility might become an issue) and the amount of
transporter expressed in the cellular system.
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serum; FDA, Food and Drug Administration; GFJ, grapefruit
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OATP1A2 and OATP2B1 Are Interacting with Dopamine-Receptor
Agonists and Antagonists
Anima M. Schaf̈er, Henriette E. Meyer zu Schwabedissen, Sandra Bien-Möller, Andrea Hubeny,
Silke Vogelgesang, Stefan Oswald, and Markus Grube*
ABSTRACT: Interaction with the dopaminergic system in the
central nervous system is either therapeutically intended or it is a
side effect. In both cases, dopamine-receptor agonists (DRA) like
the ergoline derivative bromocriptine and dopamine-receptor
antagonists (DRAn) like metoclopramide have to cross the
blood−brain barrier (BBB). The organic anion transporting
polypeptides (OATP) 1A2 and 2B1 are cellular uptake carriers
for a variety of endogenous and xenobiotic compounds. As both
transporters are expressed in endothelial cells of the BBB, the aim
of the present study was to determine whether the DRA
bromocriptine, cabergoline, and pergolide and the DRAn
metoclopramide and domperidone are interacting with
OATP1A2 and 2B1 and could therefore be candidate genes
modifying wanted and unwanted effects of these drugs. Localization of both transporters in the brain was confirmed using LC−MS/
MS and immunofluorescence stainings. For the functional studies, MDCKII cells stably expressing OATP1A2 or 2B1 were used.
Initial interaction studies with the well-characterized transporter substrate estrone 3-sulfate revealed that all tested compounds
except pergolide inhibit the transport function of both proteins with the most potent effect for bromocriptine (IC50 = 2.2 μM
(OATP1A2) and IC50 = 2.5 μM (OATP2B1)). Further studies using the indirect competitive counterflow method identified
bromocriptine, cabergoline, and domperidone as substrates of both transporters, whereas metoclopramide was only transported by
OATP1A2. These findings were verified for domperidone by direct measurements using its tritium-labeled form as a tracer.
Moreover, the transporter-mediated uptake of this compound was sensitive to the OATP1A2 and OATP2B1 inhibitor naringin. In
conclusion, this study suggests that OATP1A2 and 2B1 may play a role in the uptake of DR agonists and antagonists into the brain.
KEYWORDS: dopamine receptor, OATP1A2, OATP2B1, bromocriptine, domperidone, substrate, competitive counterflow
■ INTRODUCTION
The dopaminergic system is an important pharmacological
target structure. For example, dopamine-receptor agonists
(DRA) like ergoline derivatives are very successfully used in
the treatment of Parkinson’s disease (PD) and are important
therapeutic options in the treatment of acromegaly and
suppression of prolactin secretion by activating dopamine D2
receptors in the anterior pituitary gland.1−3 In addition,
important indications for dopamine-receptor antagonists
(DRAn) are the therapy of depression and the treatment of
nausea and vomiting.4 Regardless of their indication, both
DRA and DRAn have in common that for most of their
pharmacological effects (and side effects), they have to cross
the blood−brain barrier (BBB).
The BBB is a dynamic barrier of cerebral microvessels
located in the brain parenchyma, which is essential to protect
the brain from toxins circulating in the blood. As summarized
by Abbott et al., there are different transport pathways across
the brain endothelial cells.5 One pathway is the active transport
mediated by transport proteins involved in uptake and efflux
mechanisms. The centrally active group of DRA includes
ergolines such as bromocriptine, pergolide, cabergoline, or
lisuride and nonergolines including pramipexole, ropinirole, or
piripedil. Some members of the DRA (bromocriptine,
cabergoline, pergolide, and pramipexole) have been shown to
interact with P-glycoprotein (P-gp, ABCB1, MDR1), an efflux
pump localized at the luminal membrane of capillary
endothelial cells at the BBB.6−9 DRAn like domperidone and
metoclopramide are acting on dopamine receptors localized in
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the central and peripheral nervous system. Compared to
metoclopramide, the CNS penetration of domperidone across
the BBB is poor, which could be explained by its high affinity
to P-gp shown by Schinkel et al.10 However, both
domperidone as well as metoclopramide showed increased
pituitary prolactin secretion.11 Of note, the anterior pituitary
gland is localized outside the brain with respect to the BBB.
To maintain the integrity of the BBB efflux transporters
including P-gp are of particular importance, however, besides
passive diffusion, the selective uptake of substances across the
membrane via transport mechanisms is needed. Potential
candidates are members of the organic anion transporting
polypeptide family (OATP);12,13 particularly, OATP1A2 and
OATP2B1 were described to be localized in the brain.14
Initially, OATP1A2 was found in human brain microvessels
and capillaries,15,16 but the transporter is also localized in the
neuronal membranes.14 OATP1A2 is discussed to play a
crucial role in the neuroactive steroid transport across the
BBB,17 and indeed, a cellular uptake of sulfated steroids
including dehydroepiandrosterone sulfate has been demon-
strated for this transporter.17 Furthermore, OATP1A2 is
involved in the uptake of several central active drugs like
serotonin receptor agonists (triptans),18,19 and Gao et al.
identified δ-opioid peptides, which have to cross the BBB to
fulfill their therapeutic action, including deltorphin II as
OATP1A2 substrates.15 Besides the brain, the transporter is
expressed in the other cell types like the cholangiocytes of the
liver, the cells of the distal convoluted tubule of the nephron,
or the retinal pigment epithelium.14,20,21
OATP2B1 is ubiquitously expressed in the human body.
Localization was confirmed in the heart, intestine, kidney, lung,
mammary gland, pancreas, placenta, platelets, skeletal muscle,
and skin.22−32 Importantly, the transporter was also shown to
be expressed in the BBB.14,16 In contrast to OATP1A2, its
localization seems to be limited to endothelial cells of brain
capillaries, assuming a preferential function in substance
penetration across the BBB rather than in maintaining
neurosteroid homeostasis.14 OATP2B1 is involved in the
uptake of endogenous substances including sulfated steroids17
and thyroid hormones33 as well as of exogenous compounds
including statins,22 antihistamines,34,35 or antidiabetics.36
In summary, little is known about the impact of uptake
transporters for the transmembrane transport of dopamine-
receptor agonists and antagonists into the brain. Since
OATP1A2 and OATP2B1 are interesting candidates in this
context, the aim of the present study was to evaluate whether
DRA and DRAn are transported by OATP1A2 and OATP2B1.
Therefore, we verified the expression and localization of the
transporters in the brain and performed interaction studies
between the transporters and clinical important DRA and
DRAn. In addition, we established the competitive counterflow
method (CCF), which was recently applied by us to
OATP2B1,35 for identification of OATP1A2 transporter
substrates.
■ EXPERIMENTAL SECTION
Materials. Tritium-labeled tracer compounds [3H]-estrone
3-sulfate (E1S, specific activity 50 Ci/mmol) and [
3H]-
domperidone (specific activity 34 Ci/mmol) were obtained
from Hartmann Analytic (Braunschweig, Germany). All other
substances were obtained from Sigma-Aldrich (St. Louis, MO,
USA) if not otherwise stated. Brain tissue specimens for
immunofluorescence staining and protein measurements using
LC−MS/MS were provided by the Department of Pathology
from routine autopsies after the local ethics committee
approval (registration number BB 92/13). Human pituitary
paraffin sections were obtained from Zyagen (San Diego,
California, USA).
Cell Culture. MDCKII cells (ATCC no. CRL-2936) stably
transfected with human OATP1A2 or OATP2B1, respectively,
were grown in 75 cm2 cell culture flasks in Dulbecco’s modified
Eagle’s medium (DMEM, Sigma-Aldrich, Buchs, Switzerland)
supplemented with 2 mmol/L L-glutamine (BioConcept, Basel,
Switzerland) and 10% fetal calf serum (FCS, Sigma-Aldrich),
at 37 °C in a humidified atmosphere containing 5% CO2.
Except for the experiments, the transfected cell lines were
maintained in a medium containing 500 μg/mL Geneticin
(OATP1A2; Carl Roth, Karlsruhe, Germany) or 350 μg/mL
hygromycin B (OATP2B1; Carl Roth). MDCKII-OATP1A2
and MDCKII-OATP2B1 cells were generated as described
before.37
Immunofluorescent Staining. Localization of OATP
transporters in transfected MDCKII cells was performed on
ethanol fixed cells. Primary antibodies were detected using
Alexa-Fluor-488-labeled secondary antibodies (Life Technolo-
gies, Darmstadt, Germany). For nuclear costaining, fluores-
cence mounting medium was supplemented with DAPI (Life
Technologies, Darmstadt, Germany). Localization of
OATP1A2 and OATP2B1 as well as P-gp and glial fibrillary
acidic protein (GFAP) in human brain was characterized by
immunofluorescence staining using paraffin-embedded tissue
slides. After deparaffinization and rehydratization, sections
were boiled in target retrieval solution using citrate buffer (pH
6.0) for OATP2B1 and P-gp staining or the DAKO target
retrieval buffer pH 9.0 (Dako, Hamburg, Germany) for
OATP1A2 and GFAP. After blocking with 5% FCS in
phosphate buffered saline (PBS), samples were probed with
the respective antibodies (OATP1A2: ab105124, Abcam,
Cambridge, UK, 1:50; OATP2B1:22 1:100; P-gp: C219,
Calbiochem/Merck Millipore, Billerica, MA, USA, 1:20;
GFAP: Cell Signaling Technology, Boston, MA, USA, 1:100)
overnight at 4 °C. After additional washing steps using PBS,
samples were incubated with antirabbit Alexa-Fluor-488- or
antimouse Alexa-Fluor-568-labeled secondary antibodies (Life
Technologies, Darmstadt, Germany) at room temperature for
1 h. After removal of unbound secondary antibodies by further
washing steps (PBS, 3×), the samples were embedded using
fluorescence mounting medium supplemented with DAPI
(Life Technologies) for nuclear costaining. Immunofluor-
escence microscopy analysis was performed using the laser
scanning confocal microscopy system LSM780 (Carl Zeiss
MicroImaging, Jena, Germany).
Protein Quantification by LC−MS/MS. Protein quanti-
fication of P-gp, OATP1A2, and OATP2B1 was done by mass-
spectrometry-based targeted proteomics on a 5500 QTRAP
triple quadrupole mass spectrometer (AB Sciex, Darmstadt,
Germany) coupled to an Agilent Technologies 1260 Infinity
system (Agilent Technologies) using a validated LC−MS/MS
method as recently described.38 The following proteospecific
peptides were used for quantification: P-gp, AGAVAEEVLA-
AIR; OATP1A2, EGLETNADIIK; and OATP2B1, SSPAV-
EQQLLVSGPGK while IATEAIENFR (P-gp), YIYLG-
LPAALR (OATP1A2), and YYNNDLLR (OATP2B1) were
used as qualifier peptides. In each case, three mass transitions
were analyzed, and corresponding stable-isotope-labeled
peptides were used as internal standards (ThermoFisher
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Scientific). Sample preparation of human brain tissue was done
using the ProteoExtract Native Membrane Protein Extraction
Kit (Merck, Darmstadt, Germany) as described elsewhere.39
Accuracy (error) and precision (CV) of the assay during
sample analysis were below ±15%. Final protein expression
data (pmol/mg) were calculated by normalization to total
protein content of the isolated membrane fraction as
determined by the BCA method (Thermo Scientific, Waltham,
MA, USA).
Inhibition Assays. For transport studies, cells were seeded
on 24-well plates. The next day, cells were incubated with 2.5
mmol/L sodium butyrate for an additional 24 h to stimulate
transporter expression. For transport experiments, the cell
culture medium was removed, cells were washed once with
PBS (37 °C) and incubated with transport buffer (142 mmol/
L NaCl, 5 mmol/L KCl, 1 mmol/L KH2PO4, 1.5 mmol/L
CaCl2, 5 mmol/L glucose, 1.2 mmol/L MgSO4, and 12.5
mmol/L HEPES; pH 7.3) containing the OATP1A2/
OATP2B1 substrate [3H]-estrone 3-sulfate (E1S, 0.25 μCi/
ml, 1 μmol/L). After 5 min of incubation at 37 °C, substrate
uptake was stopped by aspiration of transport buffer and twice
washing with ice-cold PBS. Subsequently, cells were lyzed in
0.2% SDS containing 5 mmol/L EDTA. An aliquot of 200 μL
was dissolved in a 2 mL scintillation cocktail (Rotiszint eco
plus, Carl Roth, Karlsruhe, Germany), and the radioactivity
was measured using a scintillation β-counter (LKB-Wallac/
PerkinElmer, Freiburg, Germany). For normalization, protein
concentration of the whole cell lysate was determined using the
bicinchoninic acid (BCA) assay (Thermo Fisher Scientific).
Competitive Counterflow. For competitive counterflow
(CCF) experiments, MDCKII-control and MDCKII-
OATP1A2 cells were seeded and stimulated as described
above. On the day of experiment, cells were washed once with
prewarmed PBS and incubated with Hanks’ balanced salt
solution (Hanks’) buffer for 10 min. Since CCF experiments
are conducted in the steady state, this time point was
determined by treating MDCKII-control and MDCKII-
OATP1A2 cells with [3H]-E1S (0.25 μCi/ml) for 2.5, 5, 10,
20, 30, 40, 50, and 60 min. The time point of reaching the
steady state was the starting point for the next step. In a new
experiment, MDCKII-control and MDCKII-OATP1A2 cells
were treated until the steady state was reached before the
supernatant was exchanged to [3H]-E1S (0.25 μCi/ml) either
alone (control) or supplemented with 50 μM or 30 μM E1S or
bromosulfophthalein (BSP), respectively. Both E1S and BSP
are known substrates of OATP1A2, resulting in a decrease of
intracellular [3H]-E1S due to the change in equilibration state.
In order to determine the new equilibrium, MDCKII-control
and MDCKII-OATP1A2 were treated for 0.5, 1, 1.5, 2, 5, 10,
15, and 20 min. After treatment for the respective time, cells
were washed twice with ice-cold PBS and lysed before protein
content and intracellular radioactivity were determined as
described above. CCF experiments with DRA and DRAn were
performed using a concentration of 10 × IC50 as described by
Harper and Wright.40 Due to solubility issues, the highest
concentration was 250 μM. CCF experiments with MDCKII-
OATP2B1 cells were conducted as previously established by
our group.35
Domperidone Uptake Assays. Cells were seeded as
described above. For the domperidone uptake assay, cells were
washed once with PBS (37 °C) and incubated with Hanks’
balanced salt solution (Sigma-Aldrich) for 10 min. Cells were
preincubated with 0.1 μmol/L domperidone for 30 s before
the supernatant was replaced by 0.1 μmol/L domperidone
supplemented with [3H]-domperidone (0.15 μCi/ml). For
inhibition of the uptake, 100 μM naringin was added. Substrate
uptake was stopped after 5 min by aspiration of transport
buffer and washing with ice-cold PBS before lysing as
described above. An aliquot of 200 μL was dissolved in a 2
mL scintillation cocktail, and the radioactivity and protein
concentration were measured as described above.
Statistical Method. All data are presented as arithmetic
means and standard deviations (SDs). Effects were tested for
statistical significance as indicated in the respective figure
legends. A p-value below 0.05 was considered as statistically
significant. The half-maximal inhibitory concentration (IC50)
was determined by nonlinear regression analysis using
GraphPad Prism (GraphPad, SanDiego, USA) with a bottom
constrained to be >0 and a top constant equal to 100. Curve
fitting of time-dependent uptake studies was accomplished
using Savitzky−Golay smoothing.
■ RESULTS
Expression of OATP1A2 and OATP2B1 in Human
Brain and Anterior Pituitary Gland. The expression of
OATP2B1 and OATP1A2 in human brain was determined by
immunofluorescence and LC−MS/MS-based targeted proteo-
mics detection. We confirmed the expression of OATP2B1 in
the vascular endothelium of the BBB as shown by
colocalization with P-gp. In contrast, OATP1A2 was detected
in endothelial cells and, additionally, in glia cells as shown by
colocalization with the glial fibrillary acidic protein (GFAP).
Furthermore, OATP1A2 was present in the anterior pituitary
gland, most likely in vascular structures. Protein abundance in
general was studied in whole human brain homogenates by
LC−MS/MS demonstrating OATP1A2 as the most abundant
transporter compared to OATP2B1 and P-gp (OATP1A2 ≫
P-gp and OATP2B1) (Figure 1).
Interaction Study of DRA and DRAn in MDCKII-
OATP1A2 and MDCKII-OATP2B1 Cells. To study the
interaction of the DRA bromocriptine, cabergoline, and
pergolide as well as the DRAn domperidone and metoclopra-
mide (Figure 2) with OATPs, transporter-overexpressing
MDCKII cells were used. Immunofluorescence staining
indicated a strong OATP2B1 signal in the basolateral
membrane, while OATP1A2 was strongly expressed in the
apical membrane (Figure 3, left panel). As shown in Figure 3,
functional activity of the respective cells was verified by testing
the uptake of the well-established transporter substrate E1S
20,27
in transporter-overexpressing cells compared to wild type cells.
The interaction between the substrate uptake and the above-
mentioned DRA and DRAn (100 μmol/L each) was tested for
both transporters. The DRA cabergoline and especially
bromocriptine strongly inhibited both OATPs (p < 0.05).
For pergolide, no significant inhibition was observed. The
DRAn domperidone inhibited the OATP1A2- and OATP2B1-
mediated E1S uptake (p < 0.05), whereas metoclopramide only
inhibited OATP1A2 function. Subsequently, the half-maximal
inhibitory concentrations (IC50 values) were determined. As
shown in Figure 4 and summarized in Table 1, bromocriptine
and domperidone were potent inhibitors of OATP1A2 and
OATP2B1. On the contrary, cabergoline and metoclopramide
inhibited OATP1A2-mediated transport but only moderately
affected OATP2B1-mediated E1S accumulation.
Competitive Counterflow Experiments with DRA and
DRAn. Besides the interaction between DRA/DRAn and
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OATP1A2/OATP2B1, it was an aim of the study to establish a
CCF method for OATP1A2 using MDCKII-OATP1A2 cells
and its known substrate E1S. Since CCF experiments are
conducted under steady state conditions, the respective
experimental settings were determined for the MDCKII-
OATP1A2 cells (Figure 5A). For this cell line, a steady state of
E1S (1 μM) uptake was reached after 30 min. In the following
CCF experiments, [3H]-E1S (0.3 μCi/ml) was replaced by new
[3H]-E1S (0.3 μCi/ml) supplemented with the respective test
compounds. As seen in Figure 5B,C, a new equilibrium was
reached 7 min after the OATP1A2 substrates BSP and E1S
were added, respectively. The same experiments were
conducted in MDCKII-control cells, revealing no differences
between control and BSP or E1S treated cells. Subsequently,
the DRA and DRAn were tested in CCF experiments for
OATP1A2 and the previously established method for
OATP2B135 with the recommended concentration of 10 ×
IC50
40 for the test compounds. As shown in Figure 6A,B,
bromocriptine and cabergoline significantly reduced the
intracellular E1S amount (p ≤ 0.05). Therefore, we assume
that they are not only inhibitors but also substrates of
OATP1A2 and OATP2B1. In addition, domperidone was
identified as a possible substrate of OATP1A2 and OATP2B1,
since it is competing with the transporter-mediated E1S uptake
(p ≤ 0.05), while metoclopramide was found to be a substrate
only of OATP1A2.
Verification of CCF Experiments by Direct Uptake
Studies. In order to validate the CCF results, cellular
accumulation of domperidone was directly measured using
tritium-labeled domperidone as tracer. In OATP1A2- and
OATP2B1-transfected cells, significantly higher amounts of
domperidone accumulated compared to MDCKII-control
cells. Furthermore, this OATP-specific accumulation was
sensitive to the known OATP1A2/OATP2B1 inhibitor
naringin41,42 (Figure 7A,B).
■ DISCUSSION
In this study, we showed an interaction of frequently
administered DRA and DRAn with OATP1A2 and
OATP2B1. By the use of indirect and direct uptake
experiments, we identified bromocriptine, cabergoline, and
domperidone as substrates of both OATP1A2 and 2B1,
whereas metoclopramide was a substrate only of OATP1A2. In
addition, we verified the expression of both transporters in the
Figure 1. (A) Immunofluorescent staining of OATP2B1 (upper
panel) and OATP1A2 (middle and lower panel, both green
fluorescence) in human brain (upper and middle panel) as well as
anterior pituitary gland sections (lower panel). Costaining was
performed using P-gp (upper panel) or glial fibrillary acidic protein
(GFAP, middle panel, both red fluorescence) specific antibodies and
the DAPI nuclei dye (bars: 20 μm (brain sections) and 50 μm
(pituitary gland sections)). (B) LC−MS/MS-based protein detection
of OATP1A2, OATP2B1, and P-gp in human brain (mean ± SD).
Figure 2. Molecular structure of the dopamine-receptor agonists
bromocriptine (A), cabergoline (B), and pergolide (C) as well as the
dopamine-receptor antagonists domperidone (D) and metoclopra-
mide (E).
Figure 3. Left: Characterization of transporter expression in
OATP1A2 and OATP2B1 transfected MDCKII cells (bars: 20 μm).
Right: Interaction between dopamine-receptor agonists (bright gray)
and antagonists (dark gray) and OATP-mediated transport. E1S
uptake (1 μmol/L, 5 min) was studied in OATP1A2- and OATP2B1-
overexpressing cells in the presence and absence of the respective
compound (100 μmol/L). White bars present MDCKII- and solvent
control. Data are represented in relation to the solvent control (*p <
0.05, one-way ANOVA, followed by Bonferroni’s multiple compar-
isons test, n = 3 independent experiments presented as mean ± SD).
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blood−brain barrier and demonstrated the localization of
OATP1A2 in the pituitary gland.
To study an interaction between DRA/DRAn (bromocrip-
tine, cabergoline, pergolide, domperidone, and metoclopra-
mide) and both transporters, stably OATP-overexpressing
MDCKII cells were used. Initially, an influence of these drugs
on the transporter-mediated intracellular accumulation of the
OATP1A2/OATP2B1 probe substrate E1S was tested.
Figure 4. Determination of half-maximal inhibitory concentrations
(IC50 values) for the dopamine-receptor agonists bromocriptine and
cabergoline (bright gray) and the antagonists domperidone and
metoclopramide (dark gray) using OATP-overexpressing MDCKII
cells. IC50 values for OATP1A2 and OATP2B1 were determined for
E1S uptake (1 μmol/L, 5 min). Single data points are given as mean ±
SD from at least three independent experiments.
Table 1. Influence of DRA and DRAn on the OATP1A2 and
OATP2B1-Mediated Uptake of E1S
a
OATP1A2 OATP2B1
IC50 [μmol/L] (CI) IC50 [μmol/L] (CI)
bromocriptine 2.2 (1.8 to 2.8) 2.5 (2.1 to 3.1)
cabergoline 10.5 (4.0 to 32.8) >100
domperidone 0.5 (0.4 to 0.7) 7.8 (5.2 to 10.6)
metoclopramide 1.5 (1.0 to 2.4) >100
aTransport experiments performed in MDCKII-OATP1A2 and
-OATP2B1 cells were used to estimate the inhibitory potency and
calculate the respective IC50 value.
Figure 5. Establishment of CCF experiments to identify substrates of
OATP1A2. In a time-dependent experiment, MDCKII-control and
MDCKII-OATP1A2 cells were treated with radiolabeled estrone 3-
sulfate (0.25 μCi/ml) to determine the steady state (A). In (B,C), the
MDCKII-control and MDCKII-OATP1A2 cells were treated with
[3H]-E1S (0.25 μCi/ml) for 30 min (steady state) before the
supernatant was exchanged with new radiolabeled E1S supplemented
with the known OATP1A2 substrates BSP (30 μM, B) or E1S (50
μM, C) to determine the equilibrium of competitive counterflow.
Data are presented as mean ± SD of n = 3 independent experiments
(*p < 0.05, one-way ANOVA, followed by Bonferroni’s multiple
comparisons test. For (B,C), * indicates statistical significance
between the two OATP1A2 curves).
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Bromocriptine was found to be an inhibitor of both OATP1A2
and OATP2B1 (IC50 values for OATP1A2 and OATP2B1 are
2.2 and 2.5 μM, respectively), whereas cabergoline was only a
poor inhibitor of OATP2B1 compared to its influence on
OATP1A2 (IC50 values: >100 vs 10.5 μM). Finally, no
interaction with the transporters was observed for pergolide.
All three compounds belong to the group of the ergolines.
Interestingly, their interaction potential with the herein tested
OATPs is different. While bromocriptine and cabergoline
showed an interaction, pergolide did not. When comparing
their chemical structures as shown in Figure 2, it is noticeable
that the greatest difference lies in the modification at position
8. Bromocriptine and cabergoline exhibit a bulky modification
containing amides, whereas pergolide has a methylthiomethyl
group at this particular position.
A transporter-specific interaction potential was also observed
for the DRAn. While metoclopramide only inhibited
OATP1A2 but not OATP2B1 function (IC50 values: >100 vs
1.5 μM), domperidone was a potent inhibitor of both OATPs
(IC50 values: 0.5 μM (OATP1A2); 7.8 μM (OATP2B1)).
To test whether DRA/DRAn inhibiting OATP2B1 and
OATP1A2 are also substrates of these transporters, the CCF
method was applied. Harper and Wright established this
method to distinguish between transported and nontrans-
ported compounds of the organic cation transporter 2
(OCT2).40 Furthermore, the method was applied to organic
anion transporters (OATs), as shown by a recent study
identifying dantrolene as a substrate of OAT2 and OAT3.43
We recently established CCF for OATP2B1, demonstrating
that this method is also applicable to the OATP transporter
family.35 In the present study, the method was adapted for
OATP1A2, for the first time. The time to reach steady state
conditions between uptake and efflux of the high affinity
OATP1A2/OATP2B1 substrate E1S was determined to be 30
min for both transporters. The time to reach an equilibrium
after the test compound was added was 4.6 times longer for
OATP1A2 (7 min) compared to OATP2B1 (90 s).35 To test
the method, the known substrate BSP was identified as the
OATP1A2 and OATP2B1 substrate by CCF, which is in line
with literature results35,44 and indicates the validity of the
method for both transporters.
The following CCF experiments identified bromocriptine,
cabergoline, and domperidone as new OATP1A2/OATP2B1
substrates, while metoclopramide was transported only by
OATP1A2. Domperidone results were verified by direct uptake
measurement using the tritium-labeled compound as a tracer,
thereby confirming our recent findings for OATP2B1.35
Moreover, the transporter-mediated domperidone uptake was
sensitive to the OATP1A2/OATP2B1 inhibitor naringin.42
The CCF method is a screening method to identify transporter
substrates without the need of direct measurement. However, a
limitation of the method is that it cannot be used to determine
kinetic parameters of the transport.
Figure 6. Competitive counterflow experiments with dopamine-
receptor agonists (DRA) and dopamine-receptor antagonists
(DRAn). MDCKII-OATP1A2 (A) and MDCKII-OATP2B1 (B)
cells were treated with radiolabeled E1S (0.25 μCi/ml) until steady
state. Then, the supernatant was replaced by new [3H]-E1S
supplemented with the DRA (bright gray) and DRAn (dark gray)
with a concentration of 10 × IC50. After 7 min, an intracellular
amount of radioactivity was determined using liquid scintillation
counting. DMSO was the solvent control; E1S (white) served as a
system control. Data are given as the mean ± SD of n = 3
independent experiments. *p ≤ 0.05, one-way ANOVA corrected for
multiple comparisons (Dunnett’s test).
Figure 7. Direct uptake studies with domperidone in MDCKII-
OATP1A2 (A) and -OATP2B1 (B) cells. Transporter-overexpressing
as well as MDCKII-control cells were incubated with 0.1 μmol/L
domperidone supplemented with its tritium-labeled form for 5 min.
Domperidone concentrations were normalized to the respective
protein concentration. Intracellular radioactivity of domperidone was
measured by scintillation counting. Data are given as mean ± SD of n
= 3 independent experiments. *p ≤ 0.05, one-way ANOVA followed
by Dunnett’s multiple comparisons test.
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The identification of bromocriptine as a new substrate of
OATP1A2 and OATP2B1 was in line with a previous study
demonstrating bromocriptine to be transported by
OATP1B1.45 While OATP1B1 shows a liver-specific ex-
pression profile and is therefore a candidate gene for systemic
drug−drug interactions, OATP1A2 and OATP2B1 are ex-
pressed in different tissues including the BBB,14 indicating a
possible function in drug uptake to the brain. The brain
expression of both transporters was supported by our LC−
MS/MS results and immunofluorescence stainings. Interest-
ingly, the abundance of OATP1A2 protein in whole brain
tissue lysate was higher compared to OATP2B1 and P-gp.
While our LC−MS/MS data only point to the general
expression of both transporters in the brain, the results of
the confocal microscopy confirmed the localization of
OATP2B1 and OATP1A2 in endothelial cells, whereas
OATP1A2 was also found to be expressed in glia cells. This
finding corroborates the data of Gao et al. showing OATP1A2
expression in neurons of the human cortex, cerebellum, and
hippocampus, while OATP2B1 was only detected in
endothelial cells of brain capillaries.14
Bromocriptine acts as an agonist on cerebral dopamine
receptors and is used in the treatment of various diseases
including Parkinson’s disease and hyperprolactinemia. Interest-
ingly, animal studies using rat and monkey indicate a very poor
distribution of this ergot derivative into the brain, while high
concentrations were detected in the liver.46 Due to the
differences in tissue distribution, one may assume direct
transport to be involved. Indeed, hepatic accumulation may be
explained by the expression of the respective homologues of
OATP1B1 (e.g., Oatp1b2) in hepatocytes, facilitating hep-
atocellular accumulation. In contrast, the low concentrations in
the brain indicate a poor blood-to-brain penetration. In this
context, it seems noteworthy that Vautier et al. found
bromocriptine to be a P-gp substrate in in vivo experiments.7
This efflux transporter is highly expressed at the luminal
membrane of endothelial cells in brain capillaries and may
explain the poor CNS entry of bromocriptine. Our observation
of an OATP1A2/OATP2B1-mediated uptake of bromocrip-
tine into the endothelial cells would counteract the P-gp
function. Consequently, a compound’s transfer into the brain
highly depends on both uptake (e.g., by an OATP) and efflux
(e.g., P-gp) processes.
This is further illustrated by our findings regarding the
dopamine-receptor antagonists domperidone and metoclopra-
mide. Both substances were identified as OATP1A2 substrates,
and domperidone was also shown to be transported by
OATP2B1, but they exhibit a different ability to cross the BBB.
While domperidone has almost no central effects, metoclopra-
mide is likely to have such effects.47 The best explanation for
this different behavior is the interaction with P-gp. While
domperidone is a substrate of the efflux transporter and is
therefore directly expelled back to the bloodstream,
metoclopramide is not or only weakly transported by P-
gp48.49 Taken together, OATP1A2-mediated transport might
be more important for metoclopramide uptake into the brain
compared to domperidone. It is conceivable that OATP1A2
inhibition, for example, by other substrates,50 or genetic loss of
function variants of the transporter20 might reduce extrapyr-
amidal side effects of metoclopramide; however, so far, such
studies are not available.
In addition, inhibition of OATP1A2 (and OATP2B1) by
bromocriptine, domperidone, metoclopramide, or other drugs
may alter the uptake of endogenous compounds like the
neurosteroid DHEAS.17
Interestingly, we detected OATP1A2 not only in the BBB
and glia cells but also in the anterior pituitary gland. The
dopamine receptors play an important role in the pituitary
gland, as they are for example involved in controlling prolactin
secretion.51,52 Therefore, DRA like bromocriptine are used in
the treatment of hyperprolactinemia.1−3 The anterior pituitary
gland is closely connected to the brain but is not part of it.
Here, OATP1A2 was shown to be localized most likely in
blood vessels. Although the capillaries of this gland are lined by
a fenestrated endothelium, endothelial OATP1A2 expression
might be relevant for local uptake of its substrates such as
bromocriptine.
In conclusion, we applied the competitive counterflow
method to OATP1A2 and OATP2B1 and identified the
DRA(n) bromocriptine, cabergoline, and domperidone as
substrates for these transporters. In addition, OATP1A2 but
not OATP2B1 was interacting with metoclopramide. Both
transporters are expressed in the blood−brain barrier and
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ABSTRACT
Herbal medication used in the treatment of sleep disorders
and anxiety often contain extracts of Valeriana officinalis or
Passiflora incarnata. Valerenic acid in V. officinalis and apigen-
in, orientin, and vitexin in P. incarnata are thought to contrib-
ute to their therapeutic effect. It was the aim of this study to
test whether these constituents of herbal extracts are inter-
acting with the uptake of estrone 3-sulfate, pregnenolone sul-
fate, and dehydroepiandrosterone sulfate mediated by the
uptake transporters organic anion transporting polypeptide
2B1 (OATP2B1) or organic anion transporting polypeptide
1A2 (OATP1A2). Madin-Darby canine kidney cells overex-
pressing OATP2B1 or OATP1A2 were used to determine the in-
fluence of the constituents on the cellular accumulation of
the sulfated steroids. Subsequently, competitive counterflow
experiments were applied to test whether identified inhibitors
are also substrates of the transporters. Valerenic acid only in-
teracted with OATP2B1, whereas apigenin, orientin, and vitex-
in interacted with OATP2B1 and OATP1A2. Competitive coun-
terflow revealed that orientin is a substrate of both trans-
porters, while apigenin was transported by OATP1A2 and vi-
texin by OATP2B1. In a next step, commercially available P. in-
carnata preparations were assessed for their influence on the
transporters, revealing inhibition of transporter-mediated es-
trone 3-sulfate uptake. HPLC‑UV‑MS analysis confirmed the
presence of orientin and vitexin in these preparations, thereby
suggesting that these constituents are involved in the interac-
tion. Our data indicate that constituents of P. incarnata may
alter the function of OATP2B1 and OATP1A2, which could af-
fect the uptake of other compounds relying on uptake medi-
ated by the transporters.
Constituents of Passiflora incarnata, but Not of Valeriana officinalis,




The family of OATPs is assumed to play an important role in the
absorption, elimination, and distribution of exogenous and en-
dogenous compounds in the human body, as they facilitate cellu-
lar entry. OATP2B1 is ubiquitously expressed with validated
expression in the intestines, kidneys, and liver where it is assumed
to contribute to drug absorption and elimination [1–3].
Numerous endogenous substrates have been identified including
E1S, DHEAS, and thyroid hormones [4,5]. Its exogenous substrateSchäfer AM et al. Constituents of Passiflora… Planta Med | © 2021. Thieme. All rights reserved.ugs belong to different classes and include HMG‑CoA reductase
ibitors (e.g., atorvastatin), dopamine receptor antagonists
.g., domperidone), antihistamines (e.g., fexofenadine), and
tidiabetics (e.g., glibenclamide) [6–9]. The transporter is also
own to be expressed in organs that are known to exhibit barrier
nction such as the placenta or the blood-brain barrier. In the
centa, OATP2B1 is expressed at the fetal side of the syncytio-
phoblasts, and is assumed to be involved in the transfer of its
bstrates from the fetus to the mother [10]. At the blood-brain












HBSS Hankʼs balanced salt solution
MDCK cells Madin-Darby canine kidney cells
OATP organic anion transporting polypeptide
PregS pregnenolone sulfate
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60cells, suggesting that it is involved in the penetration of its sub-
strates into the brain [11].
OATP1A2 is another member of the OATP family. This trans-
porter is expressed in villous syncytiotrophoblasts, cytotropho-
blasts, and in extravillous trophoblasts of the placenta and was
previously reported to be involved in the transfer from the mother
to the fetus [12]. However, this transporter exhibits its highest ex-
pression in the brain. In contrast to OATP2B1, the transporter is
not only expressed in endothelial cells of the blood-brain barrier
[13], but also in other cells of the CNS, namely, glial cells and neu-
rons [11,14]. Exogenous substrates of OATP1A2 are the opioid
peptide deltorphin II and the HMG‑CoA reductase inhibitor rosu-
vastatin [15,16]. It has also been shown to transport sulfated ste-
roids [17,18]. Besides synthetic compounds, there are also herba
constituents that interact with OATP1A2 or OATP2B1. The flava-
none naringin, for example, a constituent in grapefruit juice, was
shown to be an inhibitor of both transporters [19,20]. Further-
more, OATP2B1 and OATP1A2 are inhibited by honey flavonoids
and catechins found in green tea [21,22]. Finally, the most re-
searched constituents of St. Johnʼs wort, hyperforin and hypericin
were recently identified as interacting with OATP2B1 [23]. Ex-
tracts of St. Johnʼs wort are assumed to exert their pharmacolog-
ical effect in the CNS and are used to treat mild depressive symp-
toms. Passionflower is another herbal remedy that is assumed to
act on the CNS, as passionflower extracts were shown to be anxio-
lytic [24]. The observed effect is possibly mediated by the GABA
system, as extracts of Passiflora actinia and Passiflora incarnata
have been reported to interact with the GABAA receptor and the
benzodiazepine-binding site in vitro [25,26]. However, Appel et al
confirmed an interaction with the GABAA receptor, and reported
an interaction with the GABA binding site, but not with the benzo-
diazepine binding site [27]. The flavonoids orientin, apigenin, and
its glycosylated form vitexin seem to play a role in the antidepres-
sant, anxiolytic, and sedative effects of the plant [28,29]. Notably
apigenin has previously been reported to inhibit OATP2B1- and
OATP1A2-mediated uptake of the dye bromosulfophthalein
(BSP), atorvastatin, and fexofenadine in transporter overexpress-
ing cells [30].
Valeriana officinalis is a plant assumed to also act on the
GABAergic system and is used in the treatment of sleep disorders
[31]. In addition, the herbal extract was identified to have an
anxiolytic effect, as shown in rats [32]. It is assumed that valerenicScacid is the driving force acting on the GABA system, allosterically
modulating the GABAA binding site [33].
Since OATP2B1 and OATP1A2 are both known to transport en-
dogenous sulfated steroid hormones, which are assumed to play a
role in neurosteroid homeostasis [17], we wanted to test whether
flavonoids found in P. incarnata and V. officinalis interact with this
function. The impact of flavonoids on the OATP2B1- or OATP1A2-
mediated transport of E1S, PregS, and DHEAS was assessed, fol-
lowed by competitive counterflow (CCF) experiments. This indi-
rect method provides a fast and cost saving way to test whether
a compound is a substrate of OATPs, and is independent of issues
associated with the direct measurement of transported sub-
stances such as availability of radioactive tracers or isolation of in-
tracellular accumulated molecules. The applicability of this meth-
od to identify substrates of OATP2B1 and OATP1A2 was recently
verified by our laboratory [7,14]. Finally, the commercially avail-
able formulations of P. incarnata were tested for their interaction
with OATP2B1 and OATP1A2 in transport experiments and for the
presence of the flavonoids (apigenin, vitexin, and orientin) by
HPLC‑UV‑MS analysis.Results
At first, we validated the OATP1A2- or OATP2B1-mediated trans-
port of the conjugated steroids DHEAS, E1S, and PregS in MDCKII
cells overexpressing the respective transport protein. As shown in
▶ Fig. 1a, we observed an enhanced cellular amount of DHEAS in
cells overexpressing OATP2B1 or OATP1A2, respectively, com-
pared to wild-type cells (p ≤ 0.05). Similar results were obtained
measuring the cellular amount of E1S (p ≤ 0.05) (▶ Fig. 1b). PregS
was confirmed as a substrate of OATP2B1 and was identified as a
substrate of OATP1A2 (▶ Fig. 1c). Testing the time-dependent
uptake of PregS in MDCKII‑OATP1A2 cells revealed a steady state
after around 30min (▶ Fig. 1d). Determination of the kinetic pa-
rameters of PregS revealed an affinity (km) and a maximum trans-
port velocity (Vmax) of 10.98 µM (CI 4.21 to 27.6 µM) and
0.48 pmol/µg protein/min (CI 0.39 to 0.61 µM), respectively
(▶ Fig. 1e).
In order to determine whether there is an interaction between
apigenin, orientin, and vitexin (found in P. incarnata) and valerenic
acid and valeric acid (found in V. officinalis) with the membrane
transporters, MDCKII cells stably overexpressing OATP2B1 or
OATP1A2 were tested for DHEAS, E1S, and PregS accumulation in
the presence of the constituents. In ▶ Fig. 2a, c,e, the influence
of P. incarnata or V. officinalis constituents on the OATP2B1-medi-
ated cellular accumulation of DHEAS, E1S, or PregS is shown. The
P. incarnata constituent apigenin reduced accumulation of the
three sulfated steroids in OATP2B1 overexpressing cells. Orientin
decreased the cellular amount of DHEAS and PregS, but did not
influence that of E1S. However, vitexin decreased the amount of
E1S and PregS, but not that of DHEAS in OATP2B1 expressing cells.
Finally, valerenic acid only inhibited PregS accumulation, and no
interaction was found for valeric acid.
Testing the interaction of the constituents with OATP1A2
(▶ Fig. 2b,d, f) we identified apigenin as an inhibitor of the accu-
mulation of all three conjugated steroid hormones. No interaction
with the transporter was observed for orientin. Vitexin only influ-häfer AM et al. Constituents of Passiflora… Planta Med | © 2021. Thieme. All rights reserved.












































































































































































































▶ Fig. 1 Accumulation of sulfated steroids in OATP2B1 or OATP1A2 overexpressing cells. The cellular amount of dehydroepiandrosterone sulfate
(DHEAS) (a), estrone-3 sulfate (E1S) (b), and pregnenolone sulfate (PregS) (c) was quantified after 5min exposure in MDCKII cells stably expressing
OATP2B1 or OATP1A2. The intracellular amount was normalized to protein content and time and compared to MDCKII wild type. Data were ana-
lyzed applying a one-way ANOVA corrected for multiple comparisons (Dunnettʼs test, *p ≤ 0.05) of n = 3 experiments, each conducted in biological
triplicate. Time-dependent uptake of PregS in MDCKII‑OATP1A2 was compared to wild-type cells (d), and kinetics (Vmax) as well as affinity (km) was
calculated based on a concentration-dependent PregS uptake (e) (n = 3 in biological triplicate, data are presented as mean ± SD).
Sch
61 th OATP1A2 was observed for valeric acid and valerenic acid in
is experimental setup. Atorvastatin was used as a positive con-
l as it is a known inhibitor of both transporters.
CCF experiments have recently been successfully applied to
ntify substrates of OATP2B1 and OATP1A2 [7,14]. A drawing
borating the difference between transport inhibition assays
d CCF experiments is provided in ▶ Fig. 3. CCF experiments
re performed in the steady state of the known substrate E1S
d at a concentration of 10 times the observed inhibitory con-
ntration (IC50) of the test compound [34]. The inhibitory po-
ncy was determined for the constituents, which were identified
inhibitors of the OATP-mediated accumulation of E1S. As shown
▶ Fig. 4a, c the observed IC50 of apigenin was 6.0 µM (CI 2.6 to
.1 µM) and 1.41 µM (CI 0.31 to 6.48 µM) for OATP2B1 and
TP1A2, respectively. The IC50 of vitexin tested in
DCKII‑OATP2B1 cells was estimated to be 242 µM (CI 182 to
4 µM) (▶ Fig. 4b). Additionally, because it will be used in CCF
periments as a positive control [35] and it has not been de-
ribed so far, the inhibitory potency of atorvastatin for
TP1A2-mediated E1S transport was determined (32.3 µM, CI
.2 to 57 µM) (▶ Fig. 4d).äfer AM et al. Constituents of Passiflora… Planta Med | © 2021. Thieme. All rights reserved.e constituents are substrates of the transporters. However, due
solubility issues, the highest concentration we used was
0 µM. As shown in ▶ Fig. 5a,b, the presence of orientin signifi-
ntly decreased the steady state concentration of E1S testing
lls expressing either OATP1A2 or OATP2B1, suggesting that ori-
tin is not only an inhibitor but also a substrate of both trans-
rters. For vitexin, this effect was only seen for OATP2B1, while
igenin only reduced the steady state concentration in OATP1A2
pressing cells. This implies that vitexin is an inhibitor and sub-
ate of OATP2B1, while apigenin is a substrate and inhibitor of
TP1A2. Valerenic acid and valeric acid did not affect the steady
te of E1S in the CCF, implying that they are no substrates of
TP1A2. However, valerenic acid seems to induce the accumula-
n of intracellular E1S, as it is statistically significantly higher
mpared to the control. Atorvastatin being a substrate of both
TPs [6,35] was confirmed in the CCF experiments as it signifi-
ntly decreased the steady state.
In a following step, two over-the-counter formulations [Arko-
ps “Passionsblume” (German for passionflower) and Valverde
eruhigung” (German for sedation)] containing P. incarnata were
sted for interactions with the transporters. The formulations









































































































































































































































































▶ Fig. 2 Inhibition of herbal constituents on OATP-mediated steroid hormone transport. Intracellular accumulation of DHEAS (a, b), E1S (c, d), or
PregS (e, f) was assessed in MDCKII-OATP2B1 (a, c, e) or MDCKII-OATP1A2 (b, d, f) cells and normalized to the solvent control. Apigenin, orientin,
and vitexin (light grey) are constituents found in P. incarnata, and valerenic acid and valeric acid (dark grey) are present in V. officinalis. Atorvastatin
(black) served as a positive control. Data are presented as mean ± SD of three independent experiments, each performed in biological triplicate.
For statistical analysis, a one-way ANOVA with Dunnettʼs correction for multiple comparisons was applied; *p ≤ 0.05.
Original Papers
62 As shown in ▶ Fig. 6, Valverde tablets had an influence on every
steroid hormone transport of both transporters (p ≤ 0.05)
(▶ Fig. 6a–f). However, the Arkocaps capsule extract influenced
the E1S and PregS transport in OATP2B1 transfected cells
(▶ Fig. 6c,e), whereas transport of DHEAS and PregS was inhib-
ited in MDCKII-OATP1A2 cells (▶ Fig. 6b, f). No effect was ob-
served on the accumulation of DHEAS in MDCKII‑OATP2B1 cells
(▶ Fig. 6a) or the E1S accumulation in MDCKII-OATP1A2 cells
(▶ Fig. 6d).ScSince apigenin, orientin, and vitexin showed interactions with
one or both OATPs and since orientin and vitexin are assumed to
be major constituents of P. incarnata, the formulations were ana-
lyzed for the presence of these molecules using HPLC‑UV‑MS
analysis to see whether the observed OATP interaction could be
attributed to the tested constituents. Arkocaps capsule extract
(▶ Fig. 7a) and Valverde tablets (▶ Fig. 7b) clearly showed a sim-
ilar chromatogram. However, based on the signal intensity (UV
254 nm), the content of the flavonoids in the Valverde tablets ap-häfer AM et al. Constituents of Passiflora… Planta Med | © 2021. Thieme. All rights reserved.
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▶ Fig. 3 Illustration of the principle and expected results of a transport inhibition assay and a CCF experiment. a Cellular, transporter-mediated
uptake of a substrate is assessed in the absence (left side, solvent control) and presence of a molecule (right side). If the molecule is an inhibitor of
the transporter, this would reduce the cellular accumulation, as depicted in the hypothetical figure in the middle. Importantly, the data do not
resolve the question whether inhibition is competitive or not. b CCF experiments were performed in the steady state (left side). If a test compound
added in the equilibrium decreases the equilibrium, and therefore the intracellular amount of the substrate, it interacts with the transporter and is
identified as substrate. No change of the substrate in the steady state is observed if the test compound is not a substrate of the transporter.
Sch
63 mmercial references and analysis of their mass spectra, we
re able to unambiguously confirm the presence of orientin (tR
.7min) and vitexin (tR 12.6min) in both preparations. In addi-
n, two major peaks eluting at tR 10.3 and tR 12.8min, respec-
ely, were assigned to isoorientin and isovitexin, respectively,
o further known flavonoids of P. incarnata (▶ Fig. 7d, e and
. 1S–5S, Supporting information). In contrast, apigenin was









fothis study, we report on the interaction of constituents of P. in-
rnata, an herbal remedy commonly used to treat sleep disorders
d anxiety, and the OATP2B1- or OATP1A2-mediated transport
the sulfated steroids E1S, DHEAS, and PregS. We not only con-
med uptake of E1S, DHEAS, and PregS by OATP2B1 [4,36], but
o uptake of E1S and DHEAS by OATP1A2 [35]. We also report
at PregS is a substrate of OATP1A2, which exhibits an affinity
m) of 10.98 µM and a maximum transport (Vmax) of 0.48 pmol/
protein/min, as determined in overexpressing cells.äfer AM et al. Constituents of Passiflora… Planta Med | © 2021. Thieme. All rights reserved.neral, it is assumed that the summary of their constituents is
e basis of their pharmacological activity. However, in our study,
not only tested the mixture, but also a group of flavonoids
pigenin, orientin, and vitexin) for interaction with the uptake
nsporters. The herein selected flavonoids are thought to take
rt in the neuroprotective, anxiolytic, and tranquilizing effect of
ssiflora species [26,37]. Notably, in order to reach their site of
tion, the constituents would have to cross cellular barriers. In
neral, transport proteins mediating cellular entry are assumed
be one of the mechanisms modulating the crossing of cellular
embranes. In this study, we assessed whether flavonoids and/or
e herbal remedies interact with OATP2B1 and OATP1A2 using
lfated steroids as substrates or victims since their transport
ross the cellular membrane via OATP2B1 and OATP1A2 would
impeded. Apigenin influenced the OATP2B1- and OATP1A2-
ediated uptake of DHEAS, E1S, and PregS, thereby confirming
dings by Mandery et al. [30].
Moreover, apigenin was identified as a substrate of OATP1A2,
t not of OATP2B1, applying CCF experiments. The glycosylated
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▶ Fig. 4 Estimation of potency of the OATP1A2 and OATP2B1 inhibitors. Inhibition of OATP2B1- or OATP1A2-mediated E1S uptake was assessed in
transporter overexpressing MDCKII cells. Concentration dependency was assessed for apigenin and vitexin with OATP2B1 (a, b), and for apigenin
and atorvastatin, with OATP1A2 (c, d). Results were a basis for the estimation of inhibitory potency (IC50 value) fitting the data to a sigmoidal log
(inhibitor)-normalized response curve (a,b,d) or to a log(inhibitor) vs. response curve (variable slope, four parameters, c) without weighing or

















































































▶ Fig. 5 CCF experiments with the herbal constituents. MDCKII-OATP2B1 (a) and MDCKII-OATP1A2 (b) cells were exposed to [3H]-labelled E1S until
steady state was reached. Subsequently, the supernatant was replaced by fresh [3H]-E1S supplemented with the test compounds (light grey =
constituents of P. incarnata; dark grey = constituents of V. officinalis) or solvent control. Atorvastatin served as a positive control. Statistical analysis
was conducted applying a one-way ANOVA with Dunnettʼs multiple comparisons test; *p ≤ 0.05. Data are presented as the mean ± SD of n = 3
experiments, each performed in biological triplicate.
Schäfer AM et al. Constituents of Passiflora… Planta Med | © 2021. Thieme. All rights reserved.
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▶ Fig. 6 Interaction of commercially available P. incarnata formulations with OATP2B1 or OATP1A2. The extract obtained from the Arkocaps cap-
sules or powdered Valverde tablets were solved in DMSO, and inhibition of OATP-mediated DHEAS (a,b), E1S (c,d), and PregS (e, f) accumulation
was determined in transporter overexpressing MDCKII cells. One-way ANOVA corrected for multiple comparisons (Dunnettʼs test) was used to test
for statistical significance, *p ≤ 0.05. Data are presented as the mean ± SD and experiments were performed 3 times in biological triplicate.
Sch
65 substrate of OATP2B1, but not of OATP1A2. Orientin, which is
o a glycosylated flavonoid, was identified as a substrate of both
TPs, although it did not inhibit the transporter function at a
ncentration of 50 µM. Notably, glycosylated flavonoids (orientin
d vitexin) were identified as OATP2B1 substrates while the non-
cosylated flavonoid apigenin was not. However, we did not find
ch an association for OATP1A2, since apigenin and orientin were
ntified as substrates but not vitexin.
In a next step, we tested the commercially available formula-
ns Arkocaps Passionsblume and Valverde Beruhigung and ob-
rved an interaction with both transporters. The inhibitory po-
ncy of Valverde tablets was higher for both transporters com-
red to that of the extract from the Arkocaps capsules. This
ay be explained by the higher flavonoid content as detected by
LC‑UV‑MS in the Valverde tablets. When analyzing the extracts
r the presence of orientin and vitexin, two further flavonoids
re observed, namely, isovitexin and isoorientin. Importantly,
igenin was not found in any of the herein tested formulations.
r findings are in line with those by Gadioli et al., who screened
species of Passiflora plants, reporting orientin and vitexin as the
ost abundant flavonoids [38]. In regard to the interaction of the
rmulations with OATP2B1 and OATP1A2, it may be speculated
at vitexin and orientin have contributed to the inhibition.äfer AM et al. Constituents of Passiflora… Planta Med | © 2021. Thieme. All rights reserved.rters is currently unknown.
Even if it is generally assumed that flavonoids show little bio-
ailability after oral application due to extensive metabolism in
e intestines and liver, there are data showing the presence of
vonoids in the circulation, and even in the brain [39,40].
hether the herein shown interaction of the flavonoids and the
TPs is of physiological relevance cannot be clarified. However,
can be speculated that if present at the blood-brain barrier, they
ay influence steroid homeostasis in the brain due to the localiza-
n of OATP2B1 and OATP1A2 at the blood-brain barrier. Indeed,
roid hormone homeostasis is pivotal for the CNS. An important
nction of both sulfated and desulfated steroid hormones is the
odulation of neuronal excitability [41]. It is assumed that ste-
ids are directly synthesized in neurons or glia cells [42]. How-
er, the origin of the sulfated precursors within the brain remains
be determined. One mechanism that may contribute to the
S entry of sulfated steroids is transporter-mediated uptake by
TP1A2 or OATP2B1, which both have been shown to be ex-
essed in endothelial cells, as also discussed by Grube et al. [17].
Interaction with OATP2B1may also be of relevance in the intes-
es, where the transporter functions as a facilitator of oral ab-
rption [43]. Consequently, the inhibition of OATP2B1 by con-
mitantly administered P. incarnata extracts might influence the

































0 5 10 15 20 25 min
▶ Fig. 7 HPLC‑UV chromatograms of commercially available P. incarnata formulations and reference compounds. Arkocaps capsule extract (a),
Valverde tablets (b), orientin, vitexin, and apigenin (c), isoorientin (d), and isovitexin (e) were analyzed by HPLC‑UV‑MS. Detection was performed at
254 nm. The corresponding HPLC‑MS traces are shown as Supporting Information (Figs. 1S–5S, Supporting Information). Peak numbers corre-
spond to isoorientin (1), orientin (2), vitexin (3), isovitexin (4), and apigenin (5).
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66substrate of OATP2B1, as also addressed in the work of Mandery
et al. [30]. Glaeser et al. found OATP1A2 to be localized at the api-
cal brush border membrane of human duodenal tissue sections
[44], however, in mass spectrometric-based screenings of mem-
brane transporters along the intestines, OATP1A2 was not de-
tected [45]. Accordingly, the presence and thereby contribution
of OATP1A2 to oral drug absorption is a matter of debate in the
field.
The other constituents that were assessed for interaction with
OATP2B1 and OATP1A2 were the sesquiterpenoid valerenic acid
and the structurally unrelated alkanoic acid valeric acid, two con-
stituents of V. officinalis. No interaction was observed for valeric
acid and the OATP2B1- or OATP1A2-mediated uptake of steroid
hormones. This might be explained by its simple chemical struc-Scture, a linear alkanoic acid which may passively diffuse through
membranes. For valerenic acid, Neuhaus et al. suggested that it
is not able to cross membranes passively but relies on active
mechanisms. The transport proteins involved in the process are
still unknown [46], however, the compound does not seem to in-
teract with the herein tested transporters.
Overall, our study showed that OATP2B1 and OATP1A2 might
mediate the uptake and influence the effect of the selected con-
stituents of the tranquilizing herbal remedy P. incarnata. Further-
more, the extracts of P. incarnata might influence the steroid
homeostasis or the pharmacokinetic of other substrates of the
transporters, which needs to be taken into account when thinking
about drug absorption in organs expressing OATP2B1 or












































































































igenin, vitexin, orientin, isoorientin, and atorvastatin were ob-
ined from Sigma-Aldrich. Isovitexin was purchased from Extra-
nthèse. The commercially available formulation Arkocaps Pas-
nsblume is made by Arkopharma, and Valverde Beruhigung
s manufactured by Sidroga. Both commercial preparations
lely consist of Passiflorae herba. The radioactively labelled [3H]-
trone 3-sulfate (E1S) and [3H]-pregnenolone sulfate (PregS)
re obtained from Hartmann Analytic. [3H]-dehydroepiandros-
rone sulfate (DHEAS) was purchased from Perkin Elmer.
ll culture
DCKII cells (p7-p20; ATCC no. CRL-2936) were obtained from
e ATCC and cultivated at 37 °C and 5% CO2 in DMEM (Sigma-Al-
ich) supplemented with 10% fetal calf serum (Bio Concept) and
glutamine 200mM (Bio Concept). MDCKII cells stably express-
g OATP2B1 (p3-p8) or OATP1A2 (p14-p20) were generated as
scribed elsewhere [47] and were cultured under constant selec-
n by the addition of hygromycin B (750 µg/mL; Carl Roth) or ge-
ticin (500 µg/mL; Carl Roth), respectively.
ansport experiments
DCKII, MDCKII-OATP2B1, or MDCKII-OATP1A2 cells were seeded
a density of 50000 cells/24 wells. One day after seeding, the
lls were treated with 2mM sodium butyrate for 24 h. After that,
lls were washed once with prewarmed PBS followed by incuba-
n with HBSS at 37 °C for 10min. Intracellular uptake was deter-
ined by incubating the cells with 1 nM E1S, 1 nM DHEAS, or 1 nM
egS, each supplemented with 100000 dpm/well of the respec-
e tritiated tracer. After 5min, the cells were washed twice with
-cold PBS before 200 µL lysis buffer (SDS 0.2% in 5mM EDTA)
re added. After cell lysis at 37 °C for 30min, the protein content
s measured using the Pierce BCA Protein Assay Kit (Themo
her Scientific) and the microplate reader Infinite M200 Pro
ecan) according to the manufacturerʼs instructions. The
ount of substrate was quantified, assessing the radiolabel by
uid scintillation counting using 2mL scintillation fluid (Rotiszint
o Plus, Carl Roth) and Tri-Carb 4910TR (Perkin Elmer).
The time-dependent uptake of PregS in OATP1A2 was deter-
ined at 2, 5, 10, 20, 30, and 60min using the same amount of
egS as mentioned above. Kinetic parameters of transport were
lculated testing the cellular accumulation of increasing
ounts of PregS (0.1, 1, 10, 50, 100 µM) in MDCKII‑OATP1A2
lls.
Apigenin, vitexin, and orientin from P. incarnata and valerenic
id and valeric acid from V. officinalis (50 µM each) were tested
r inhibition of OATP2B1- and OATP1A2-mediated transport of
e abovementioned substrates DHEAS, E1S, and PregS. Subse-
ently, increasing concentrations of the constituents were used
.01, 0.1, 1, 10, 100, and 200 µM) to estimate the inhibitory po-
ncy. Arkocaps capsules were extracted with 70% ethanol by
essurized liquid extraction in a Dionex ASE 200 Accelerated Sol-
nt Extractor. Three cycles of extraction were performed with
e temperature set at 70 °C and the pressure at 120 bar. Afteräfer AM et al. Constituents of Passiflora… Planta Med | © 2021. Thieme. All rights reserved.lverde tablets, which contain an ethanolic extract, were milled
fore dissolving in DMSO. To ensure complete dissolution, mix-
res were sonicated for 30 s. The final concentration used for
nsport experiments was 0.05mg/mL.
mpetitive counterflow
F experiments were performed following previously estab-
hed protocols [7, 14]. Briefly, MDCKII‑OATP2B1 and MDCKII-
TP1A2 cells were seeded and treated with sodium butyrate as
scribed above. After washing the cells with PBS and pre-
cubation with HBSS, the buffer was removed and 150 µL radio-
tively labelled estrone-3 sulfate ([3H]-E1S, 100000 dpm/well) in
SS were added followed by incubation at 37 °C for 30min to
ach steady state. Afterwards, the [3H]-E1S solution was removed
d 150 µL of test compound in HBSS containing [3H]-E1S
00000 dpm/well) were added followed by incubation at 37 °C
r 90 s and 7min for OATP2B1 and OATP1A2, respectively [7,
]. The cells were washed, lysed, and protein content was mea-
red as described above. The remaining samples were analyzed
scintillation counting. For CCF experiments, the applied con-
ntration of the test compounds corresponded to 10 × IC50 as
commended by Harper and Wright [34].
PLC‑UV‑MS analysis of commercially available
oducts containing Passiflora incarnata
st, 100mg of milled Valverde tablets and 10mg Arkocaps cap-
le extract were separately dissolved in 1mL DMSO. The mix-
res were filtrated through a syringe filter (Chromafil O-20/15
S, pore-size 0.2 µm; Macherey-Nagel). Subsequently, the
lverde solution was diluted to 10mg/mL. The reference com-
unds orientin, vitexin, apigenin, isoorientin, and isovitexin were
ssolved in DMSO (0.3mg/mL). HPLC‑UV‑MS analysis was per-
rmed on a chromatographic system consisting of a degasser, a
aternary pump (LC-20AD), a column oven (CTO-20AC), a PDA
tector (SPD-M20A), and a triple quadrupole mass spectrometer
CMS-8030; Shimadzu). The mobile phase consisted of water (A)
d acetonitrile (B), both containing 0.1% formic acid. Separa-
ns were achieved on a Poroshell120 EC‑C18 column (3.0 ×
0mm, 2.7 µm) with a gradient of 10–15% B in 10min, then
–70% B in 10min before reaching 90% B in 3min and going
ck to 10% in 8min. The flow rate was 0.5 mL/min. Then, 10 µL
rkocaps capsule extract), 2 µL (Valverde tablets), and 5 µL (ref-
ence compounds) were injected.
atistical analysis
e statistical analysis of the experimental data was performed
ing GraphPad Prism software 8.0 (Graphd Pad Software) and
icrosoft Excel. The herein reported concentrations, where half-
aximal inhibition was observed (IC50 values), were estimated
nonlinear curve fitting using normalized values. For calculation
the kinetic parameters of PregS with OATP1A2, the net trans-
rt normalized to the protein content and time was used. To
t the maximum enzyme velocity (Vmax) and the affinity (km),
nlinear regression was performed and analyzed with Michaelis-
enten enzyme kinetics. The resulting data are shown as the






68 statistically significant. The statistical test used to analyze the data
is described in the context of their reporting.
Supporting information
HPLC‑MS chromatographic traces of commercial formulations
and reference substances are available as Supporting Information
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ABSTRACT
The herbal remedy St. John’s wort (SJW) is used in the treatment
of mild depressive symptoms and is known for its drug-drug
interaction potential when enhanced expression of CYP3A4
modifies clearance of concomitantly applied substrate drugs.
Hyperforin is one constituent of SJW that alters CYP3A4
expression by activation of the nuclear receptor pregnane X
receptor (PXR). However, little is known about the transmem-
brane transport of hyperforin. One membrane protein that
modulates cellular entry of drugs is the organic anion-
transporting polypeptide (OATP) 2B1. It was the aim of this
study to test whether hyperforin interacts with this transport
protein. Transport inhibition studies and competitive counterflow
experiments suggested that hyperforin is a substrate of
OATP2B1. This notion was validated by showing that the
presence of OATP2B1 enhanced the hyperforin-induced PXR
activation in cell-based luciferase assays. Moreover, in Caco-2
cells transcellular transport of the known OATP2B1 substrate
atorvastatin was changed in the presence of hyperforin, resulting
in an increased efflux ratio. Eleven commercially available SJW
formulations were assessed for their influence on OATP2B1-
mediated transport of estrone 3-sulfate and for their impact on
CYP3A4 promoter transactivation. The correlation between
effect size and the hyperforin content as determined by high-
performance liquid chromatography with ultraviolet detection
suggested that hyperforin is the major determinant. Our results
indicate an interaction between hyperforin and OATP2B1, which
is not only known to contribute to hepatocellular uptake but also
to intestinal absorption of its substrates. These findings extend
the complexity of mechanisms that should be considered when
evaluating the interaction potential of SJW preparations.
Introduction
St. John’s wort is an herbal extract of Hypericum perforatum
and is commonly taken to treat depressive symptoms.The extract
is a complex mixture of structurally diverse constituents, includ-
ing flavonol glycosides, phloroglucinols, proanthocyanidins,
naphthodianthrones, and phenylpropanoids (Nahrstedt and
Butterweck, 1997). The naphthodianthrones pseudohypericin
and hypericin were originally assumed to be the active
components of Hypericum extracts (Suzuki et al., 1984).
Accordingly, hypericin became the constituent on which ther-
apeutically used extracts are standardized. However, even
though the antidepressive activity is still not fully understood,
more recent studies suggest that it is most probably linked to
the phloroglucinol hyperforin. (Mennini and Gobbi, 2004).
Beside its antidepressant activity, St. John’s wort is known
for its pronounced influence on expression and activity of
genes involved in drug metabolism (Soleymani et al., 2017).
Indeed, hyperforin enhances expression and activity of
CYP3A4, thereby modifying the first-pass metabolism and
clearance of concomitantly applied substrates (Wang et al.,
2013). Similar results were shown for the efflux transporter
P-glycoprotein (P-gp, ABCB1, MDR1), when treatment with St.
John’s wort extracts increased intestinal ABCB1 expression,
explaining the reduced bioavailability of ABCB1 substrates
(Dürr et al., 2000). The underlying mechanism is the activation
of the pregnane X receptor (PXR) (Kliewer et al., 2002). PXR is a
nuclear receptor functioning as ligand-activated transcription
factor of a genenetwork comprising various proteins involved in
drug metabolism, including CYP3A4 (Lehmann et al., 1998),
the efflux transporter P-gp (Geick et al., 2001), the multidrug-
resistance protein 3 (ABCC3, MRP3) (Aleksunes and Klaassen,
2012), the organic anion-transporting polypeptide (OATP)
1A2 (Meyer zu Schwabedissen et al., 2008), the UDP-
glucuronosyltransferase 1a5 (Ugt1a5), and the sulfotransferase
2a2 (Sult2a2) (Aleksunes and Klaassen, 2012). Accordingly,
PXR activation in general results in enhanced metabolic
activity and increased metabolic clearance. Hyperforin, even
if very potent, is not the only activator of PXR, since multiple
drugs in clinical use function as activating ligands (Meyer zu
Schwabedissen and Kim, 2009). Accordingly, PXR is also called
a xenosensor as it senses drug exposure and modulates
metabolic activity in response. There are multiple examples
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in the literature inwhichPXRactivation is the basis of observed
drug-drug interactions, e.g., simultaneous administration of
indinavir and St. John’s wort reduces exposure of the protease
inhibitor (Piscitelli et al., 2000). Additionally, Ruschitzka et al.
(2000) reported heart transplant rejections in patients concom-
itantly treated with cyclosporine and St. John’s wort. The
authors report reduced oral bioavailability and increased
hepatic clearance of the victim drug. Importantly, to interact
with PXR and to activate transcription of the targeted genes,
hyperforin has to enter the cell. So far, little is known about the
transmembrane transport and cellular uptake of this molecule.
Recent findings by our group suggest that hyperforin is a
substrate of OATP2B1, as was observed by testing whether
themethod of competitive counterflow (CCF) can be applied to
identify substrates of this uptake transporter (Schäfer et al.,
2018). OATP2B1 is amember of the organic anion-transporting
polypeptide family, and facilitates the sodium-independent
uptake of its substrates. Since its first description (Tamai
et al., 2000) multiple endogenous and exogenous substrates of
the transporter have been identified (Roth et al., 2012).
OATP2B1 exhibits two substrate binding sites that can be
distinguished in experimental setting by their contribution to
the cellular uptake of estrone 3-sulfate (E1S); one accepts E1S
at low concentration (binding site A), whereas the other
(binding site B) mainly drives uptake at high concentrations
of the sulfated steroid (Shirasaka et al., 2012). Another
characteristic of OATP2B1 is its ubiquitous expression, with
high amounts of the transporter in brain, heart, kidney, lung,
mammary gland, placenta, platelets, skeletal muscle and skin
(St-Pierre et al., 2002; Pizzagalli et al., 2003; Schiffer et al.,
2003; Bronger et al., 2005; Grube et al., 2006; Niessen et al.,
2009; Knauer et al., 2010; Sakamoto et al., 2013; Ferreira
et al., 2018). Considering the abovementioned impact of PXR
on hepatic clearance and oral bioavailability, it seems note-
worthy that OATP2B1 is expressed in the sinusoidal mem-
brane of hepatocytes (Kullak-Ublick et al., 2001) and in the
intestine (Kobayashi et al., 2003; Keiser et al., 2017), thereby
contributing to hepatic clearance and intestinal absorption,
respectively. Even if several drug transporters are part of the
PXR-regulated gene network, OATP2B1 is not (Knauer et al.,
2013; Meyer zu Schwabedissen et al., 2018). However, our
preliminary findings (Schäfer et al., 2018) suggest that drug-
drug interactions involving hyperforin may not be limited to
targets of PXR but may also involve OATP2B1-mediated
uptake. It was the aim of the present study to further evaluate
this notion.
Materials and Methods
Cell Culture. All cell lines were maintained at 37°C in a humidified
atmosphere with 5% CO2. The cell lines Madin-Darby canine kidney
epithelial cells (MDCKII; ATCC no. CRL-2936), HeLa (ATCC no. CCL2),
HepG2 (ATCC no. HB-8065), and Caco-2 (ATCC no. HTB37) were
originally obtained from the American Type Culture Collection (ATCC,
Wesel, Germany) and were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma-Aldrich, Buchs, Switzerland) supplemented
with 10% fetal calf serum (Sigma-Aldrich) and 1% stable glutamine
(BioConcept, Basel, Switzerland). For Caco-2 cells the medium was
supplemented with 1% penicillin/streptomycin (BioConcept, Basel,
Switzerland). MDCKII-OATP2B1 cells have been established and
characterized as described elsewhere (Grube et al., 2006) and were
kept under continuous selection with 750 mg/ml hygromycin B (Carl
Roth, Karlsruhe, Germany).
Transport Experiments. MDCKII-OATP2B1 cells were seeded
in 24-well plates at a density of 50,000 cells/well (Eppendorf,
Hamburg, Germany). After 1 day in culture, cells were treated with
sodium butyrate (2 mM) and cultured for an additional day. Uptake
experiments were started by washing the cells with prewarmed
phosphate-buffered saline (PBS) followed by a 10-minute equilibra-
tion with Hanks’ balanced salt solution (H8264, with sodium bi-
carbonate, without phenol red, pH 7.4; Sigma-Aldrich). To test the
inhibitory potency of hyperforin (as hyperforin dicyclohexylammonium
salt; Sigma-Aldrich) and hypericin (Tocris, Bio-Techne AG, Zug,
Switzerland) cells were exposed to either estrone 3-sulfate (0.005 or
50 mM; Sigma-Aldrich) or 0.1 mM bromosulfophthalein (BSP; Sigma-
Aldrich), supplemented with 50,000 dpm/well of [3H]-E1S (3 nM;
Hartmann Analytic, Braunschweig, Germany), or [3H]-BSP (9 nM;
Hartmann Analytic) in the presence of different concentrations of the
respective compound. After 5minutes of exposure the cellswerewashed
with ice-cold PBS, lysed in 200 ml of 0.2% SDS-5 mM EDTA, and the
cellular content of E1S or BSP was quantified determining the
amount of tracer by liquid scintillation counting using the Rotiszint
eco Plus (Carl Roth) and the Tri-Carb 2900TR counter (TopLab,
Basel, Switzerland). An aliquot was used to assess the amount of
protein in each well using the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific, Reinach, Switzerland) and the microplate reader
Infinite 200 Pro (Tecan, Männedorf, Switzerland). CCF experiments
were performed as previously described by our group (Schäfer et al.,
2018). MDCKII-OATP2B1 and MDCKII cells were seeded, treated,
and prepared for transport experiments as described above. Since
CCF experiments are conducted in the steady state, cells were
preincubated with [3H]-E1S (100,000 dpm/well) for 30 minutes. For a
time-dependent CCF experiment in MDCKII-OATP2B1 cells, the
supernatant was exchanged to either [3H]-E1S alone or supple-
mented with hyperforin (5 mM) or hypericin (100 mM). Cellular
accumulation of [3H]-E1S was measured as described above after 10,
20, 30, 45, 60, 90, 120, and 180 seconds. Since the system was
equilibrated again after 90 seconds, this was defined as the time
point when intracellular accumulation of [3H]-E1S was measured in
CCF experiments. MDCKII-OATP2B1 and MDCKII cells were
treated with [3H]-E1S until steady state before mediumwas changed
to the same concentration of [3H]-E1S supplemented with hyper-
forin, hypericin, atorvastatin (2.5 mM; Sigma-Aldrich) as positive,
and penicillin G (250 mM; Sigma-Aldrich) as negative control. For
inhibition studies, 2.5 mM atorvastatin supplemented with 50,000
dpm/well [3H]-atorvastatin (7.5 nM; PerkinElmer,Waltham,MA)was
used. Cellular accumulation after 5 minutes of exposure was assessed in
presence of different concentrations of hyperforin (0.1, 1, 5 mM) or
hypericin (10, 50, 100 mM).
Cell-Based Reporter Gene Assays. The previously reported
CYP3A4-XREM-pGL3 plasmid was used to test the influence of
OATP2B1 on PXR-mediated transactivation. Briefly, HepG2 and
HeLa cells were seeded in 24-well plates at a density of 50,000
cells/well. The cells were then transfected with 250 ng of CYP3A4-
XREM-pGL3 (Tirona et al., 2003), 25 ng of pRL-TK, 250 ng of PXR-
pEF6 (Meyer zu Schwabedissen et al., 2008), 250 ng of RXRa-pEF6),
250 ng of OATP2B1-pEF6, or 250 ng of pEF6-V5/HIS as control
(Thermo Fisher Scientific), using 2.25 ml/mg of DNA jetPRIME
(Polyplus distributed by Chemie Brunschwig, Basel, Switzerland).
After 4 hours, the medium was changed, and the cells were kept
in culture until treatment started 24 hours after transfection.
Hyperforin, hypericin, bromosulfophthalein, and rifampicin were
used at a final concentration of 0.1, 1, 10, and 10 mM, respectively.
The formulations were tested at a 1/100 dilution of one tablet or
capsule dissolved in 200 ml. To avoid phototoxicity the experiment
was performed in the dark. Finally, the cells were lysed after 24 hours
of exposure and luciferase activity was determined using the Dual-
Luciferase Assay System (Promega, Dübendorf, Switzerland) and the
plate reader Infinite M200 Pro (Tecan) as recommended by the
manufacturer. The observed activity of the firefly luciferase was
normalized to that of the Renilla.
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Transwell Transport of Hyperforin and Hypericin. Experi-
ments were performed as previously described (Meyer zu Schwabedissen
et al., 2018). Briefly, Caco-2 cells were seeded at a density of 3  105
cells/well onto polycarbonatemembraneswith 0.4-mmpore size inserted in
12-well plates (ChemieBrunschwig, Basel, Switzerland) and cultivated for
14 days with medium change every second day. Measuring the trans-
epithelial electrical resistance value of at least 200 V/cm 1 day before the
experiment confirmed the integrity of the monolayer. Furthermore,
integrity was tested after the experiment by addition of 1 mg/ml Lucifer
yellow (Sigma-Aldrich) to the apical side and measurement of absorbance
in the basolateral compartment after 1 hour by spectrofluorometry.On the
day of the experiment, cellswerewashed oncewith prewarmedPBSbefore
incubation with Krebs-Henseleit buffer (118 mMNaCl, 25 mMNaHCO3,
1.2 mMKH2PO4, 2.5 mMCaCl2, 1.2 mMMgSO4, 11 mM glucose, 4.7 mM
KCl) for 20 minutes at 37°C. The buffer was adjusted to a pH of 5.5 in the
apical compartment and to a pH of 7.4 in the basolateral compartment.
[3H]-Atorvastatin (100,000 dpm/well) was added either to the apical or to
the basolateral side to determine apical to basal (a–b) or basal to apical
(b–a) permeability. Hyperforin (0.1 mM) was added to either the apical or
the basal compartment. Amount of atorvastatin was assessed in 100-ml
aliquots by scintillation counting as described above. The amount of
transported [3H]-atorvastatin per time was calculated as permeability
coefficient (Papp) as previously described (Hubatsch et al., 2007). Papp of the
apical (a)-to-basal (b) or of the b-to-a direction was used to calculate the
uptake and efflux ratio, respectively, with the following equations:
uptake ratioPa2b 5
Pappða to bÞ
Pappðb to aÞ efflux ratio Pb2a 5
Pappðb to aÞ
Pappða to bÞ
Transport Studies with 11 Swiss Formulations Containing
St. John’s Wort. Before transport experiments, pills were milled
using the mixer mill MM 400 (Retsch GmbH, Haan, Germany) or
capsules were opened to release the content. The concentration for
inhibition experiments was estimated by calculating the expected
concentration in the intestine when the pill or capsule would be
ingestedwith 200mlwater. Two days before the experimentMDCKII-
OATP2B1 cells were seeded as described above. After washing the
cells with PBS and a 10-minute preincubation in Hanks’ balanced salt
solution buffer, influence was tested by treating the cells with 0.005
mM E1S supplemented with radiolabeled E1S (50,000 dpm/well) and
the respective formulation diluted 1:100 and 1:1000. After 5 minutes,
cells were washed with ice-cold PBS and lysed in 200 ml of 0.2%
SDS-5 mM EDTA. Protein amount and intracellular accumulation of
[3H]-E1S was measured as described in detail above.
Western Blot Analysis. HepG2 and HeLa cells were seeded at a
density of 1.8  106 cells/10-cm culture dish (Eppendorf). After reaching
confluence, cellswere harvested in 5mMTris-HCl (pH7.4) supplemented
with the protease inhibitor cocktail (Sigma-Aldrich). After several cycles
of freezing and thawing, protein content in the cell lysate was quantified
using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific).
Proteins were separated by SDS-PAGE (Mini-PROTEAN System)
followed by blotting onto a nitrocellulose membrane with the Mini
Trans-blot Cell (Bio-Rad Laboratories AG, Cressier, Switzerland). Fetal
calf serum (5%)–Tris-buffered saline–0.04% Tween 20 (TBS-T) was used
to block unspecific binding before the primary antibody anti-HNF4a
(ab41898; Abcam, Lucerna Chem AG, Luzern, Switzerland, diluted
1:1000) or anti-OATP2B1 [(Grube et al., 2005) diluted 1:5000] was added
and incubated at 4°C overnight. Actin (sc-1616, diluted 1:1000; Santa
Cruz Biotechnology, Heidelberg, Germany) served as control. HRP-
labeled secondary antibodies and the ECL Western blotting substrate
(Pierce/Thermo Fisher Scientific) were used to detect binding of the
primary antibody. TheChemidocXRSSystem (Bio-RadLaboratoriesAG)
was used for visualization and digitization of chemiluminescence.
Determination of Hyperforin and Hypericin Content in
11 Swiss Formulations with High-Performance Liquid Chro-
matography. One-hundredmilligrams of the powdered samples was
dissolved in 1ml of DMSOand centrifuged at 13,000 rpm for 5minutes
before filtration through a disposable syringe filter (Micropur PTFE,
pore-size: 0.45-mm, Altmann Analytik, Munich, Germany). Dissolu-
tion of the solid residue of Deprivita, Hyperiplant, Rebalance, Sandoz
Hypericum, and Vogel Hyperiforce using the same procedure
confirmed .80% and .90% dissolution of hypericin and hyperforin,
respectively. Hypericin was TOCRIS brand and had .98% purity
according to manufacturer. A calibration curve was prepared with a
hypericin dilution ranging from 1 to 0.002 mg/ml. The hypericin
calibration curve was also used for the simultaneous quantification of
pseudohypericin since both compounds have the same chromophore.
The identity of pseudohypericin was confirmed by chromatographic
comparison with a reference sample purchased from Sigma-Aldrich.
The content of hypericin was calculated as the sum of the content of
hypericin and pseudohypericin. Hyperforin was purchased fromSigma-
Aldrich as dicyclohexylammonium salt. According to themanufacturer,
purity was 98% as a mixture of hyperforin and adhyperforin. Consid-
ering that both compounds have the same chromophore and taking
into account their respective molecular weights, the commercial sample
was determined by high-performance liquid chromatography with UV
detection (HPLC-UV) to contain 83.6% hyperforin and 16.4%
adhyperforin. Two calibration curves were therefore prepared for
hyperforin (0.9–0.007 mg/ml) and adhyperforin (0.18–0.0014 mg/ml)
and the content of hyperforin was calculated as the sum of both
phloroglucinols. Since hyperforin is highly sensitive to light and
oxygen all preparatory steps for measuring hyperforin content were
performed under exclusion of light. Prior to grinding and solving of
the samples, the respective tubes were prefilled with nitrogen to
avoid oxidation. HPLC analyses were performed on an Alliance
2690 chromatographic system coupled to a PDA996 detector (Wa-
ters, Milford, MA). The mobile phase consisted of water (A) and
acetonitrile (B) both containing 0.1% trifluoroacetic acid (hyperforin
analysis) or 0.5% trifluoroacetic acid (hypericin analysis). Separa-
tion of hyperforin was achieved using a 115 Zorbax Eclipse XDB-C8
Narrow-Bore column (2.1  150 mm, 3.5 mm; Agilent, Santa Clara,
CA) with a gradient of 50%–100% B in 20 minutes, then 100% B for
15 minutes at a flow rate of 0.4 ml/minute. Hypericin was analyzed
on an Ascentis Express C18 column (3  100 mm, 2.7 mm; Supelco,
Bellefonte, PA) with a gradient of 45–100% in 15minutes, then 100%
B for 5 minutes at a flow rate of 0.6 ml/minute. The injection volume
was 10 ml for the calibrators and the formulation samples. Detection
was at 272 nm (hyperforin) or 588 nm (hypericin). Separations were
performed at 30°C. Data are reported as mean 6 S.D. of three
independent analyses.
Statistical Analysis. Microsoft Excel (Microsoft, Redmond, USA)
and GraphPad Prism software 6.0 (GraphPad Software, La Jolla, CA)
was used to analyze the data sets reported herein. Tests used for
statistical analysis are described in the context of data presentation.
A P-value below 0.05 was considered statistically significant.
Results
Interaction of Hyperforin and Hypericin with
OATP2B1-Mediated Uptake. To validate the interaction
of hyperforin and hypericin with OATP2B1, their impact on
the cellular accumulation of the known substrates estrone
3-sulfate (Pizzagalli et al., 2003) and bromosulfophthalein
(Kullak-Ublick et al., 2001) was determined in MDCKII-
OATP2B1 cells. As shown in Fig. 1 the estrone 3-sulfate
inhibition studies accounted for the previously reported two
binding sites (Shirasaka et al., 2012) testing the influence of
hyperforin and hypericin on estrone 3-sulfate accumulation at
low (Fig. 1, A and D; representing binding site A) and at high
concentrations (Fig. 1, B and E, representing binding site B).
For hyperforin, we observed concentration-dependent inhibi-
tion for both binding sites recognizing E1S. The inhibition data
were the basis for an estimation of the respective IC50
values, which revealed the highest potency for binding site
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A-mediated transport of E1S, with an IC50 value of 0.32mM(CI
0.24–0.42 mM, Fig. 1A), whereas for binding site B the IC50
value was 5.55 mM (CI 2.10–14.73 mM, Fig. 1B). Inhibition of
OATP2B1-mediated cellular accumulation of BSP resulted in
an estimated IC50 value for hyperforin of 0.82 mM (CI 0.53–
1.26 mM, Fig. 1C). Similar results were obtained for hypericin,
even if this compound exhibited much lower IC50 values for
binding site A (20.79 mM; CI 13.90–31.10 mM, Fig. 1D),
binding site B 256.2 mM (CI 119.4–550.0 mM, Fig. 1E), and
for BSP (108.7 mM (CI 76.39–154.8 mM, Fig. 1F). To test
whether hyperforin and hypericin are also substrates of
OATP2B1 we applied the method of competitive counterflow.
The basis of the experimental procedure used to identify
substrates competing for substrate recognition is depicted in
Fig. 1G. Briefly, interaction with the transporter is assessed in
the steady state. Reduction of the intracellular estrone
3-sulfate amount in the equilibrium would be attributable to
competitive inhibition, showing that the test compound is a
substrate of the facilitating mechanism, whereas inhibitors
would not influence the cellular equilibrium (Harper and
Wright, 2013). As shown in Fig. 1H, presence of the known
OATP2B1 substrate atorvastatin, as well as hyperforin (5mM)
or hypericin (100 mM), reduced the amount of E1S in the
steady state (P , 0.05), thereby suggesting that both constit-
uents of St. John’s wort are not only inhibitors but also
substrates of OATP2B1. Penicillin G served as nonsubstrate
control (Schäfer et al., 2018). In the CCF experiments in
MDCKII cells, no influence on the cellular amount of E1S was
observed for any of the compounds tested herein (Supplemen-
tal Fig. 1). Assessing the time-dependency of reaching the
second equilibrium for hyperforin (Supplemental Fig. 2A) and
hypericin (Supplemental Fig. 2B) revealed that it is reached
after 90 seconds of exposure, which is comparable to that
previously reported (Schäfer et al., 2018).
Influence of OATP2B1 on Hyperforin-Mediated
Transactivation of CYP3A4. Hyperforin is a well known
ligand and activator of the human pregnane X receptor, which
thereby influences transcription of CYP3A4 (Moore et al.,
2000). To verify that hyperforin is a substrate of OATP2B1,
we deployed cell-based reporter gene assays to assess the
transactivation of a synthetic CYP3A4-XREM-pGL3 reporter
gene construct. As shown in Fig. 2A, HepG2-cells transfected
with PXR- and OATP2B1-pEF6 exhibited higher luciferase
activation (P , 0.05) than cells not heterologously expressing
the transporter. Testing the influence of 10 mM BSP on
hyperforin-induced (0.1 mM) PXR-mediated transactivation
of CYP3A4 in OATP2B1-overexpressing cells showed that
presence of this competitive inhibitor of the transporter
reduced luciferase activity statistically significantly. Impor-
tantly, BSP did not influence the luciferase activity (Fig. 2B).
Impact of Hyperforin and Hypericin on Transcellu-
lar Fluxes in Caco-2 Cells. Expression of OATP2B1 is
assumed to contribute to intestinal absorption of orally
applied drugs. Transcellular flux experiments using the in-
testinal model cell line Caco-2 cells are often applied in the
preclinical phase to not only predict bioavailability but also to
determine whether there is an active transport component
influencing the transcellular path of a new molecular entity.
OATP2B1 is expressed in Caco-2 cells and is part of the
network of transporters influencing the transcellular flux
(Meyer zu Schwabedissen et al., 2018). To determine whether
hyperforin influences transcellular fluxes, and thereby oral
bioavailability, experiments were performed using the known
OATP2B1 substrate drug atorvastatin (Grube et al., 2006).
At first, interaction of hyperforin with OATP2B1-mediated
atorvastatin uptake was tested (Fig. 3A), revealing a decreased
amount of intracellular atorvastatin with increasing concen-
trations (P, 0.05). As controls, BSP and E1S were included in
the transport inhibition study. Estimation of the inhibitory
potency, even though a limited number of data points was
used as a basis, suggested an IC50 value for hyperforin of
0.23 mM (CI 0.11–0.48 mM). As shown in Fig. 3B, hyperforin
increased the efflux ratio observed for atorvastatin (mean
efflux ratio 6 S.D.; hyperforin vs. DMSO; 2.863 6 0.415 vs.
1.828 6 0.332; P 5 0.028). The observed effect can mainly be
attributed to changes in the flux from apical (a) to basal (b), as
there was a trend toward lower movement in this direction
[mean Papp (a–b) 6 S.D. (cm/s); hyperforin vs. DMSO; 1.33 
10266 3.161 1027 vs. 1.83 10266 2.621 1027;P5 0.103,
Fig. 3C)]. No trend for a change was observed for the
atorvastatin flux in b to a direction [mean Papp (b–a) 6 S.D.
(cm/s); hyperforin vs. DMSO 3.81  1026 6 1.153  1026 vs.
3.36x 10266 8.502 1027; P5 0.615, Fig. 3D]. Taken together
these data suggest that hyperforin interacts with intesti-
nal absorption of atorvastatin, which is in part mediated
by OATP2B1.
Effect of St. John’s Wort Formulations on OATP2B1-
Mediated Transport. St. John’s wort is widely used as
medication to treatmild tomoderate depression. In Switzerland
there are currently 11 solid formulations marketed. These
formulations contain different amounts of hypericin and
hyperforin as reported by the manufacturer and summarized
in Table 1. In a screening experiment, we tested for interaction
of the formulations with OATP2B1-mediated E1S uptake in
MDCKII-OATP2B1 cells. This screening was conducted using
two concentrations of the respective formulation, representing a
1/100 or 1/1000 dilution of one tablet or capsule dissolved in
200 ml of liquid. As shown in Fig. 4A, none of the 1/1000
dilutions lowered the cellular accumulation of E1S compared
with solvent control (P . 0.05). However, for the formulations
Arkocaps,Deprivita,HänselerMenopause,Hyperiplant, Jarsin,
Sandoz Hypericum, and Solevita, we observed reduced
OATP2B1-mediated uptake of estrone 3-sulfate for the 1/100
dilution (P, 0.05). Rebalance, Remotiv, Vogel Hyperimed, and
Vogel Hyperiforce did not affect OATP2B1-mediated E1S
uptake in our experiments.
Subsequently, we assessed the influence of the respective
formulation on the PXR-mediated transactivation of CYP3A4
either in HepG2 (Fig. 4B), or HeLa (Fig. 4C). Notably, in
accordance with our transport inhibition experiments,
Rebalance, Remotiv, Vogel Hyperimed, and Vogel Hyperiforce
did not affect luciferase activation in either cell-based reporter
gene assay (P. 0.05). Interestingly, treatment of HepG2 cells
resulted in an up to 125-fold induction in presence of a 1/100
dilution of the formulations, whereas a maximum of about
7-fold induction was observed in HeLa cells. This might be
explained by the endogenous expression of HNF4a, which is
permissive for the transactivation of CYP3A4 by PXR (Tirona
et al., 2003). The lack of HNF4a expression in HeLa cells was
verified by Western blot analysis (Fig. 4D; mean HNF4a
expression normalized to actin6 S.D.; HepG2 vs. HeLa; 17.88
6 3.43 vs. 0.26 6 0.02; P , 0.05, n 5 3, unpaired t test with
Welch’s correction), whereas no difference in expression of
OATP2B1 was observed (Fig. 4E; mean OATP2B1 expression
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normalized to actin 6 S.D.; HepG2 vs. HeLa; 1.52 6 1.28 vs.
1.41 6 0.72; P . 0.05, n 5 3, unpaired t test with Welch’s
correction).
Quantification of Hyperforin and Hypericin Content
in the St. John’s Wort Formulations. As mentioned
before, most manufacturers merely provide information on
the content of hypericin in their formulation owing to the
primal assumption that this component determines biologic
activity of the extract. We quantified the amount of hyperforin
(as the sum of hyperforin and adhyperforin) and hypericin (as
the sum of hypericin and pseudohypericin) in each formula-
tion by HPLC. As summarized in Table 1 and depicted
in Supplemental Figs. 3 and 4, all formulations contained
hypericin, but hyperforin was detected in all medications but
Vogel Hyperimed and Vogel Hyperiforce and to a low extent in
Rebalance and Remotiv. Importantly, these four medications
neither interacted with OATP2B1-mediated E1S accumula-
tion nor did they transactivate CYP3A4 in the cell-based
Fig. 1. Interaction of hyperforin and hypericin with OATP2B1. Inhibition of OATP2B1-mediated transport by hyperforin and hypericin was tested in
MDCKII-OATP2B1 cells. The influence on cellular accumulation of estrone 3-sulfate was determined at low (0.005 mM;A andD) or high (50mM; B and E)
concentration to account for binding site A or B, respectively, or of bromosulfophthalein (C and F). The IC50 values were calculated fitting the data to a
sigmoidal log(inhibitor)-normalized response curve, without constraining of top or bottom, or weighting. (G) Schematic of the molecular basis of
competitive-counterflow experiments, in which substrates are reduced by the amount of another substrate in the steady state. Tested was the influence of
hyperforin or hypericin on the cellular equilibrium of E1S in MDCKII-OATP2B1 cells compared with DMSO control (H). Atorvastatin and penicillin G
were used as positive and negative controls, respectively. Data are presented asmean6S.D. of n = 3 independent experiments, each performed in biologic
triplicates. *P # 0.05, one-way analysis of variance with Dunnett’s multiple comparisons test.
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reporter gene assays reported herein, suggesting that hyperforin
is the key determinant of the observed effects. To test this notion,
we analyzed whether the relationship between hyperforin
content and the observed luciferase activation assessed in
transfected HepG2 (Fig. 5A) or HeLa cells (Fig. 5B) revealed a
direct correlation. The association as determined by Pearson
correlation was most pronounced when Hyperiplant, the
formulation containing the highest amount of hyperforin,
was excluded. An indirect and statistically significant corre-
lation was observed for the percentage of E1S uptake and
hyperforin content in MDCKII-OATP2B1 cells (Fig. 5C).
Importantly, no correlation was observed for hypericin and
the experimental results (Fig. 5, D–F).
Discussion
In this study we report that the constituents of St. John’s
wort—hyperforin and to a lower extent hypericin—are inhib-
itors of the ubiquitously expressed membrane transporter
OATP2B1. Furthermore, CCF experiments suggested that the
compounds are not only inhibitors but also substrates of
OATP2B1. This was further supported by findings in reporter
gene assays, in whichOATP2B1 enhanced hyperforin-induced
transactivation of CYP3A4, whichwas reduced in the presence
of the competitive inhibitor bromosulfophthalein.
Hyperforin is known especially as a major determinant of
drug-drug interactions observed during coadministration of
St. John’s wort, with the expected result of a pronounced
increase in CYP3A4 activity (Willson and Kliewer, 2002).
However, the influence of concomitant use of St. John’s wort is
not limited to CYP3A4-substrates as the underlying mecha-
nism; it is the binding and activation of PXR that finally
Fig. 2. Influence of OATP2B1 on hyperforin-induced PXR-mediated
transactivation of CYP3A4. Luciferase activation was determined in
HepG2 cells transfected with PXR-pEF6 in presence or absence of
heterologously expressed OATP2B1 and treated with 0.1 mM hyperforin
or DMSO (striped bars) (A). The influence of bromosulfophthalein on
hyperforin-induced PXR activation was assessed in HepG2 cells tran-
siently transfected with PXR-pEF6 and OATP2B1-pEF6 (B). Firefly
luciferase activity was normalized to that of Renilla. Data are presented
as mean 6 S.D. of n = 3 independent experiments each performed in
biologic triplicates. *P-value # 0.05, two-way analysis of variance with
Tukey’s multiple comparisons test.
Fig. 3. Interaction of hyperforin with OATP2B1-mediated transport of atorvastatin. The inhibitory effect of hyperforin on atorvastatin transport was
determined in MDCKII-OATP2B1 cells, bromosulfophthalein, and estrone 3-sulfate served as control (A). The influence on transcellular fluxes was
assessed on permeable supports using cultured Caco-2 cells. The unidirectional Papp-coefficients in (C) apical (a)-to-basal (b), or (D) b-to-a directions for
atorvastatin were used to calculate (B) the efflux ratio [Papp (b–a)/Papp (a–b)]. Data are presented as mean6 S.D. of n = 3 independent experiments each
performed in biologic triplicates, *P # 0.05 one-way analysis of variance with Dunnett’s multiple comparisons test (A) or Student’s t test (B, C, D).
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results in induced expression of multiple target genes, most of
them with functions in drug elimination (Tolson and Wang,
2010). Indeed, one compound exemplifying this is the cardiac
glycoside digoxin (Johne et al., 1999). This drug is commonly
used in clinics and is not a CYP3A4 substrate (Lacarelle et al.,
1991), but findings by Greiner et al. (1999) clearly showed
that concomitant oral intake of digoxin and rifampin de-
creased drug disposition and exposure owing to induction of
P-glycoprotein (P-gp, ABCB1, MDR1) expression. Impor-
tantly, rifampin is another well known activating ligand of
PXR and can be applied to analyze the influence of PXR
activation on drug metabolism (Chen and Raymond, 2006).
Accordingly, the reduction in oral bioavailability of digoxin
can be explained by enhanced expression of ABCB1 (Greiner
et al., 1999). This transporter is responsible for active
extrusion of substrates from enterocytes back into the intes-
tinal lumen (Shapiro and Ling, 1995). Considering our
findings on inhibition of OATP2B1-mediated transport by
hyperforin and hypericin, the interaction of St. John’s wort is
extended to a further class of compounds, namely OATP2B1
substrates, whose mechanism of interaction would most
probably be the competitive inhibition of cellular uptake.
OATP2B1 is assumed to play a role in intestinal absorption
of orally administered drugs (Shitara et al., 2013). Testing
the influence of hyperforin on transcellular transport of
atorvastatin revealed an enhanced efflux ratio for atorvastatin.
The experimental setup of Caco-2 cells cultured on permeable
supports is commonly utilized for predictions of bioavailability
and the contribution of transporters to intestinal absorption
(Hubatsch et al., 2007). Indeed, when an efflux ratio, which is
calculated relating the net flux in b-to-a direction with that in
a-to-b direction, is above 1.5, it is assumed to indicate that
active transporter-mediated processes are involved in the
transcellular transport of a compound (Hubatsch et al.,
2007). From the results of our study, one is certainly tempted
to attribute the observed effect of an enhanced efflux ratio to
the inhibition of OATP2B1 only. However, what was assessed
were net fluxes, and even though it has been reported as an
OATP2B1 substrate (Grube et al., 2006), atorvastatin is not a
specific substrate of this transporter. Indeed, atorvastatin
is also a substrate of the efflux transporters multidrug
resistance-associated protein (MRP)1 (ABCC1), MRP4
(ABCC4), MRP5 (ABCC5) (Knauer et al., 2010), and ABCB1
(Wu et al., 2000). Especially for ABCB1, some data suggest
that hyperforin may influence transport activity directly
(Hennessy et al., 2002). Our data suggest that, when present,
hyperforin acutely interacts with oral absorption of OATP2B1
substrates, enhancing the complexity of drug-hyperforin
interactions that should be considered when evaluating the
interaction potential of St. John’s wort preparations.
In addition to its involvement in intestinal drug absorption,
OATP2B1 is assumed to contribute to the hepatocellular
uptake. Recent findings by Lutz et al. (2018) suggest that
there is at least some induction of OATP-mediated transport,
as observed for concomitant treatment with rosuvastatin and
pravastatin and increasing doses of rifampin. Even if
OATP2B1 (OATP-B) may contribute to the hepatocellular
uptake of these statins (Knauer et al., 2010; Shirasaka et al.,
2010), OATP2B1 is not regulated in primary human hepato-
cytes treated with the PXR-inducer (Jigorel et al., 2006).
Although there was no direct regulation by PXR, we recently
reported interaction of the transporter with PDZ domain
containing 1 (PDZK1), which influences OATP2B1 membrane
localization (Ferreira et al., 2018). PDZK1 is transcriptionally
controlled by multiple nuclear receptors (Ferreira et al., 2018;
Prestin et al., 2017). Accordingly, whether long-term exposure
to hyperforin influences localization of OATP2B1 remains
to be determined, as we only tested the acute influence.
Our findings suggest that the intracellular abundance of
hyperforin, and thereby PXR-mediated transactivation of
CYP3A4, is influenced by OATP2B1. Considering this finding,
one might speculate that changes in OATP2B1 activity could
influence the extent of PXR activation. Multiple mechanisms
affect the activity of a transporter, and one possibility is the
TABLE 1
Content of hypericin and hyperforin determined by HPLC-UV
Percentage of hypericin or hyperforin content given in the compendium was converted to content per 100 mg extract. For quantification by HPLC,






(Quantified by HPLC) Hyperforin
b (Declared Content) Hyperforin
b
(Quantified by HPLC)
mg/100 mg mg/100 mg 6 S.D. mg/100 mg mg/100 mg 6 S.D.
ARKOCAPSc 0.3 0.09 6 0.04 — 0.24 6 0.01
DEPRIVITAd 0.1–0.3 0.18 6 0.01 — 1.04 6 0.05
HAENSELER MENOPAUSEe 0.1–0.3 0.10 6 0.01 — 0.34 6 0.01
HYPERIPLANTf 0.1–0.3 0.15 6 0.02 36 1.62 6 0.03
JARSINg 0.1–0.3 0.20 6 0.02 — 0.70 6 0.02
REBALANCEh 0.1–0.3 0.08 6 0.01 ,0.2 0.02 6 0.01
REMOTIVh 0.1–0.3 0.09 6 0.01 ,0.2 0.02 6 0.01
SANDOZ HYPERICUMi 0.1–0.3 0.21 6 0.02 — 0.85 6 0.04
SOLEVITAd 0.1–0.3 0.16 6 0.03 — 1.02 6 0.07
VOGEL HYPERIMED j 0.5–0.8 0.08 6 0.01 — — —
VOGEL HYPERIFORCE j 0.2–2.1 0.08 6 0.01 — — —
aThe content of hypericin corresponds to the sum of the content of hypericin and pseudohypericin.
bThe content of hyperforin corresponds to the sum of the content of hyperforin and adhyperforin.
cArko Diffusion SA, Les Avacias, Switzerland.
dPermamed AG, Therwil, Switzerland.
eHänseler AG, Herisau, Switzerland.
fSchwabe Pharma AG, Küssnacht, Switzerland.
gVifor SA, Bern, Switzerland.
hZeller AG, Romanshorn, Switzerland.
iSandoz Pharmaceuticals AG, Holzkirchen, Germany.
jBioforce AG, Roggwil, Switzerland.
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change in expression by transcriptional modifiers. Another
would be modifications in genetic information with influence
on transport activity. We recently reported that OATP2B1 is
transcriptionally modulated by thyroid hormones (Meyer zu
Schwabedissen et al., 2018), thereby associating thyroid
hormone status to OATP2B1 transport function, and Nozawa
et al. (2002) identified genetic polymorphisms that changed the
maximal transport velocity (Vmax) of OATP2B1.
Testing extracts from all oral formulations of St. John’s
wort currently marketed in Switzerland for their influence on
OATP2B1 transport activity, and the influence of OATP2B1
on their transactivating activity, revealed a clear association
Fig. 4. Influence of commercially available St. John’s wort preparations on OATP2B1 function and transactivation of CYP3A4. Transport inhibition
studies assessing binding site A were conducted in MDCKII-OATP2B1 cells. Formulations were tested in two concentrations representing a 1/100 or
1/1000 dilution of the respective formulation dissolved in 200 ml liquid (A). The influence of each formulation (1/100 dilution) on CYP3A4 activation was
determined in cell-based reporter gene assays using (B) HepG2 or (C) HeLa cells as cellular models. Firefly luciferase was normalized to that ofRenilla in
each sample. Expression of HNF4a andOATP2B1 inHepG2 andHeLa cells was detected byWestern blot analysis; actin served as control (D, E). Data are
presented as mean 6 S.D. of n = 3 independent experiments. *P-value # 0.05 one-way analysis of variance followed by Dunnett’s multiple comparisons
test; Vogel 1, Hyperimed; Vogel 2, Hyperiforce.
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between hyperforin content and the observed effect for most
formulations. Importantly, no such association was observed for
hypericin content and PXR-mediated transactivation, thus con-
firming that hypericin is no activator of PXR (Moore et al., 2000;
Wentworth et al., 2000). Furthermore, there is no clear associ-
ation of hypericin content and OATP2B1 inhibition, which is in
line with the much lower inhibitory potency observed for hyper-
icin compared with hyperforin. This indicates that hyperforin is
the component of St. John’s wort extracts involved in interaction
with OATP2B1-mediated uptake.
The formulations were tested in cell-based reporter gene
assays using HepG2 or HeLa cells as cellular models. In the
liver cell model we observed a huge induction of luciferase
activity of about 50- to 100-fold, whereas the increase in
activity was only about 5- to 7-fold in HeLa cells, with some
formulations not affecting transactivation. On the one hand,
the difference in extent of activation might certainly be
explained by endogenous expression of HNF4a in HepG2
cells, which is not present in HeLa cells as confirmed by
Western blot analysis in this study and previously reported by
Knauer et al. (2013). Importantly, HNF4a is permissive for
the transcriptional regulation by PXR (Ma et al., 2008). On the
other hand, the fact that we observed induction in HeLa cells
and a clear association of the extent of activation with the
hyperforin content suggests that hyperforin is the driving
component, but also that there is at least some HNF4a-
independent PXR activation.
As mentioned before, the hyperforin content was directly
correlated with the observed luciferase activation. However,
this association was most pronounced when Hyperiplant was
excluded from the correlation. In other words, the observed
effect of Hyperiplant on OATP2B1-mediated transport or
CYP3A4 activation was lower than expected considering the
hyperforin content. In this context, it seems noteworthy that
hyperforin is phototoxic (Onoue et al., 2011), inducing acute
cell lysis. Even though our experiments were conducted under
light protection, we cannot exclude the presence of some
toxicity that could have modified the experimental outcome.
Taken togetherwe report that hyperforin is a potent inhibitor
of OATP2B1-mediated cellular uptake and we suggest that it is
also a substrate. Inhibition of the transportermay influence the
contribution of OATP2B1 to pharmacokinetics of its substrate
drugs. Moreover, OATP2B1 activity influences intracellular
accumulation of hyperforin and thereby its binding to the
xenosensor. With this study, we added to the complexity of
potentialmechanisms that should be included in the evaluation
of potential drug-drug interactions associatedwith the dispensing
of St. John’s wort.
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Conclusion and Outlook 
With the results of the underlying work, I conclude that the indirect method of competitive 
counterflow (CCF) is applicable to identify substrates of OATP2B1 and OATP1A2. The 
applicability of the CCF was validated with known substrates and the conducted screening 
revealed new substrates either of synthetic or natural origin. The method was established for 
both transporters using estrone 3-sulfate (E1S) as model substrate. However, the experimental 
procedure had to be adapted. Although both transporters reached the steady state after 30 
minutes, the time to reach the equilibrium in presence of a test compound was much longer for 
OATP1A2. Indeed, after addition of the test compound OATP2B1 transport was equilibrated 
after 90 seconds, while cells overexpressing OATP1A2 reached this state only after 7 minutes. 
Whether this discrepancy reflects the known differences in affinity and capacity of the tested 
transporters to E1S remains to be further validated. However, the currently available data 
suggest that this phenomenon is linked to the affinity Km OATP2B1 vs. OATP1A2, 1.56 μM 
vs. 16.1 μM and transport capacity Vmax OATP2B1 vs. OATP1A2, 1.15 nmol/mg protein/min 
vs. 0.156 nmol/mg protein/min [25, 117]. Nevertheless, this assumption is rather speculative 
and has to be validated comparing the time to reach equilibrium for other OATPs. Notably, 
many OATPs recognize E1S as substrate including the kidney-specific OATP4C1 [118] or 
OATP3A1 and OATP4A1 [49]. For these OATPs, there is little information on their substrate 
spectrum, especially from the chemical space of drugs. It remains to be tested whether the CCF 
method could be applied to search for substrates of these transporters. For such an approach the 
CCF appears to be a cost and time saving alternative. As mentioned before, the strength of the 
CCF experiments is the possibility to screen for substrates. However, obtaining transport 
kinetics requires subsequent characterization using the methods described earlier [85], 
especially as the results of CCF experiments do not capture these parameters. Specifically, 
results of a CCF experiment provide the percentage of the intracellular amount of the primary 
substrate in the equilibrium of cells treated with the solvent control. Furthermore, the data are 
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obtained in presence of 10 x the estimated IC50 of the competitive substrate as this concentration 
is expected to occupy around 90% of the available binding sites [88]. Neither the IC50 nor the 
Km or Vmax are predictive for the observed percentage change in cellular probe substrate 
accumulation. For illustration, I provide the examples for the drugs glibenclamide, atorvastatin, 
and fexofenadine. For glibenclamide the IC50 was 0.57 μM, the reported Km and Vmax are 
6.26 ± 3.15 μM and 112 ± 52.2 pmol/mg protein/min, respectively [119] while there was an 
about 51% change in equilibrium in the CCF experiment. For atorvastatin the estimated IC50 
was 0.26 μM, with reported Km and Vmax values of 0.2 ± 0.1 μM and 
30.5 ± 2.9 pmol/mg protein/min [51] and in CCF we observed a reduction of around 70%. 
Finally, the estimated IC50 for fexofenadine was 524.50 μM and its Km and Vmax were reported 
to be 0.140 ± 0.062 µM and 0.183 ± 0.060 fmol/min/oocyte, respectively [120]. The change in 
equilibrium in CCF was 55%. For OATP1A2 a larger compound screen needs to be performed 
in order to find whether there is a similar disconnection between percent reduction in 
equilibrium and Km or Vmax. 
Even if there are multiple substrates identified for OATP2B1, there is still a limited 
understanding of its contribution to pharmacokinetics in vivo. One factor that may underlie this 
limitation is that most of the currently identified and clinically tested molecules (glibenclamide, 
montelukast, rosuvastatin) are also substrates of the hepatically expressed OATP1B 
transporters [35, 121, 122]. The colocalization of OATP2B1 and OATP1B-transporters in the 
sinusoidal membrane of hepatocytes and the substrate overlap with OATP1B transporters may 
confound the ability to show the influence of OATP2B1 on the process of hepatic clearance. 
Interestingly, using data from proteomic analyses by LC-MS/MS, McFeely et al. determined 
the relative abundance of the transporter in comparison to other transporters in the liver and 
intestine. Due to the high expression, they conclude that OATP2B1 could play an important 
role in those organs [123]. However, when Drozdzik and coworkers compared the absolute 
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protein contents in the liver, they observed a lower amount of OATP2B1 compared to the 
OATP1B transporters [124].  
For the role in intestinal absorption, the data on coadministration with fruit juices are 
convincing but have been subject of debates in the field, which was fueled by their 
inconsistency. While Mougey et al. observed an influence of OATP2B1 genetic variants on the 
plasma concentration of montelukast, Tapaninen et al. were unable to confirm these findings 
[125, 126]. Furthermore, Vaidyanathan et al. identified aliskiren as a substrate of OATP2B1 
which served as explanation for observed changes in aliskiren pharmacokinetics after co-
ingestion with citrus juices [63, 127]. However, a more recent study couldn’t confirm aliskiren 
as a substrate of OATP2B1 [128]. Lastly, the debate was stimulated by the finding that 
OATP2B1 is localized in the basolateral membrane of enterocytes [62]. Notably, in contrast to 
the well studied and better understood OATP1B transporters, OATP2B1 is ubiquitously 
expressed. Changes in OATP2B1 function may therefore impact not only intestinal absorption 
and hepatic/renal elimination, but also the distribution of the test compound. In this scenario, 
where OATP2B1 influences uptake in other compartments, one may speculate that inhibition 
could influence the apparent volume of distribution (Vd). One extravascular compartment 
where OATP2B1 has been shown to be expressed is the skeletal muscle [57]. It remains to be 
determined, whether changes in OATP2B1 activity (due to genetic variants or drug-drug 
interaction) influences substrate distribution and therefore the Vd. In clinical studies this would 
be the pharmacokinetic parameter that could be monitored as a surrogate for altered 
extravascular drug distribution. At this point it seems noteworthy, that the functional 
consequences of the genetic variants of OATP2B1 (in contrast to those reported for OATP1B1 
[19]) are rather limited and that the minor allele frequency of genetic variants with functional 
consequences is extremely low in most populations [123]. Even if currently available data 
suggest a contribution of OATP2B1 in the ADME processes of distribution, elimination, and 
absorption, it may not be sensitive to quantify its relevance through inference from 
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pharmacokinetic parameters. One possibility to tackle this issue could eventually be to 
determine changes in the pharmacodynamic effect of a selected substrate drug.  
One region where proper function of uptake and efflux transporters is assumed to play a pivotal 
role is the blood-brain barrier (BBB). Here, there is data reporting the expression of OATP2B1 
and OATP1A2 suggesting their contribution to compound permeation into the brain [22-24]. 
Furthermore, OATP1A2 is suggested to contribute to neuronal processes since expression was 
found in neuronal cells [24]. Using mass spectrometric analysis I was able to confirm the 
presence of both transporters in cellular structures of the BBB. Importantly, OATP2B1 was 
shown to be expressed in the vascular endothelium and OATP1A2 was also found in glial cells. 
Quantification of the transporter confirmed the restricted and broad central nervous system 
expression of OATP2B1 and OATP1A2, respectively.  
Currently available data suggest that OATP2B1 and OATP1A2 transport sulfated steroid 
hormones such as dehydroepiandrosterone sulfate (DHEAS) and pregnenolone sulfate (PregS). 
In the context of the central nervous system, it seems noteworthy that both DHEAS and PregS 
are considered to be neurosteroids and important regulators of processes in the brain [80]. 
However, whether they are synthesized within the brain or depend on the supply from the 
systemic circulation involving the permeation of the BBB is currently not fully understood [31]. 
Despite that, it may be hypothesized that OATP1A2 and/or OATP2B1 are involved if they are 
taken up from the circulation. It may further be speculated that administration of substances 
functioning as (competitive) inhibitors of these transporters influences their homeostasis and 
potentially their function. Besides the neurosteroids, there are substrates of OATP2B1 and 
OATP1A2 that have to penetrate the BBB to exert their pharmacological effect. Applying CCF 
we identified the dopamine receptor agonists bromocriptine and cabergoline as substrates of 
both transporters. Furthermore, dopamine receptor antagonists were screened identifying 
domperidone as a substrate of OATP1A2 and OATP2B1, and metoclopramide as a substrate of 
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OATP1A2. It remains to be determined whether changes in activity of the transporters influence 
their brain entry, and therefore the outcome of patients treated with them.  
In the context of the central nervous system and the potential involvement of transporter 
mediated entry, I have investigated constituents of Passiflora incarnata and Valeriana 
officinalis for interaction with OATP2B1 and OATP1A2. Therapeutically, both extracts find 
their indication in pathologies of the brain as anxiolytic or sedative agents. Constituents of 
Valeriana officinalis only weakly interacted with the transporters. However, constituents of 
Passiflora incarnata act as substrates of OATP2B1 and/or OATP1A2. It remains to be 
determined whether and to what extent these constituents are available in the systemic 
circulation and therefore are reaching the BBB. In general, it is assumed that the investigated 
flavonoids exhibit only limited bioavailability [114, 115]. Nevertheless, considering the 
contribution of OATP2B1 to intestinal drug absorption, interaction with the transporter needs 
to be considered especially when the herbal remedy is given orally with another OATP2B1 
substrate drug or inhibitor. 
Another herbal constituent I identified in CCF experiments as substrate of OATP2B1 is 
hyperforin. For this component of St. John's wort, I was able to compile a data set supporting 
the idea that OATP2B1 not only acts as a cellular entry mechanism, but also influences its effect 
as a modulator of drug metabolism. Briefly, in a cell based reporter gene assay assessing the 
transactivation of a synthetic CYP3A4-reporter gene construct presence of OATP2B1 
significantly increased the transactivation. Moreover, using the Caco-2 transwell system, 
hyperforin was shown to influence the transcellular flux of the known OATP2B1 substrate 
atorvastatin. Taken together, our in vitro data suggest that St. John’s wort formulations 
containing hyperforin could influence the pharmacokinetics of OATP2B1 substrates. 
Furthermore, the activity of OATP2B1 could influence the intracellular amount of hyperforin 
and therefore its impact on the PXR-regulated genes in drug metabolism. This finding would 
89
add another class of compounds that must be considered when assessing the interaction 
potential of St. John’s wort - namely OATP2B1 substrates. I think this should be further studied 
in in vivo experiments. In this regard, animal studies using the currently available knockout 
mouse models could be the first step [73, 129]. The study design would be similar to that 
reported by Medwid et al. investigating the influence of OATP2B1 on intestinal drug absorption 
[73]. Briefly, the known OATP2B1 substrate fexofenadine was orally administered to knockout 
and wildtype mice and the influence of the transporter on fexofenadine AUC(0-last) and Cmax was 
compared. Importantly, a decrease of fexofenadine AUC(0-last) and Cmax was seen in animals 
lacking the transporter. Subsequently, fexofenadine was co-administered with grapefruit juice 
which revealed a decreased AUC(0-last) and Cmax in wildtype animals whereas no effect was 
observed in knockout mice [73]. Adapting this experimental strategy for my purposes would 
include the co-administration of a known OATP2B1 substrate and a St. John’s wort formulation 
containing hyperforin. However, it may also be possible to test for OATP2B1-mediated 
differences in hyperforin “efficacy” by comparing knockout and wildtype animals. In order to 
test for the influence of OATP2B1 on the activation of the drug metabolism, long term studies 
would be needed [130]. The induction of PXR target genes including the rodent orthologues of 
ABCB1 and CYP3A4 in wildtype animals could be compared to animals in which the 
transporter was knocked-out.  
A prerequisite for these studies would be to validate that hyperforin is also a substrate of the 
mouse OATP2B1 transporter orthologue, and that hyperforin is also an activating ligand of 
mouse PXR. Notably, this nuclear receptor is known to exhibit species-specific differences in 
terms of activating ligands [131]. Pronounced differences were found for the probe-ligand 
rifampicin, which is recommended as clinical inducer by most agencies5. While rifampicin is 
5 US Food and Drug Administration. Guidance for industry: drug interaction studies—study design, data analysis, 
implications for dosing, and labeling recommendations. 2012; European Medicines Agency. Guideline on the Investigation 
of Drug Interactions, 2012, last access on February 18, 2021; last access on February 18, 2021 
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known to greatly induce the human PXR target genes there is minimal induction of genes in 
rodents due to species-selected ligand transactivation [132]. On the contrary, pregnenolone-
16α-carbonitrile activates rodent PXR and greatly induces the rodent CYP3A enzymes but 
shows only little activation of human PXR [132]. So far, there is only little data available 
investigating the interaction between the mouse PXR and hyperforin [133]. In this regard, Bray 
et al. report an increased catalytic activity of CYP3A in mice treated with St. John’s wort 
compared to control. Whether this observation is based on mouse PXR transactivation was not 
addressed by the authors [134]. In a comparative study published by the Nuclear Receptor 
Resource, the effect of hyperforin on human and mouse PXR was investigated performing 
Luciferase reporter assays. Dose response relationships obtained from the luciferase activity 
revealed activation of the mouse PXR, albeit less active compared to the human [135]. 
In terms of hyperforin as substrate of the rodent PXR, one has to consider that there may also 
be species specificity. Unfortunately, there is only limited and contradictory data available 
reporting on the rodent variants. Medwid et al. identified the exogenous compounds 
bromosulfophthalein, fexofenadine and rosuvastatin as well as the endogenous DHEAS and 
E1S as substrates of the mouse OATP2B1. However, no significant difference between control 
cells and cells transfected with the mouse OATP2B1 were found by Sugiura et al. when 
performing in vitro uptake studies with E1S [136]. Consequently, further studies investigating 
characteristics of the rodent transporter and the rodent nuclear receptor are needed to determine 
to what extent the data obtained herein can be translated from in vitro to in vivo experiments. 
In summary, the competitive counterflow experiment can be used as a cost and time saving 
screening tool to identify substrates of OATP2B1 and OATP1A2 and might be a useful method 
in the challenging goal of finding transporter specific substrates. Using this method, I was able 
to identify centrally active drugs of synthetic and herbal origin as substrates. With the 
confirmation of OATP2B1 and OATP1A2 in the blood-brain barrier, the possibility is raised 
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that these uptake transporters enable brain entry of their substrates. Furthermore, OATP2B1 
might also play a role in the intestinal absorption of the drugs. In this context, another herbal 
constituent was identified as OATP2B1 substrate namely hyperforin, a constituent of St. John’s 
wort. Hyperforin is widely known to intracellularly activate PXR to induce target genes and 
therefore to cause drug-herb interactions. With the identification of hyperforin as OATP2B1 
substrate the list of possible candidates that are influenced by hyperforin might be extended to 
OATP2B1 substrates. Furthermore, the activity of OATP2B1 could influence the intracellular 
amount of hyperforin and therefore its induction of PXR target genes. Importantly, these 
conclusions are based on in vitro experiments and whether these investigations are of clinical 
relevance remains to be determined. Nevertheless, my findings unraveled novel determinants 
contributing to cellular compound uptake, which might influence ADME processes and effects 
of drugs.  
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Supporting information to the manuscript “Establishment and validation 
of competitive counterflow as a method to detect substrates of the 
organic anion transporting polypeptide 2B1” 
Anima M. Schäfer, Thomas Bock, Henriette E. Meyer zu Schwabedissen 
This supporting information is providing data about the establishment of experimental conditions 
for competitive counterflow, the time dependent uptake of estrone 3-sulfate at pH 5.5 and pH 7.4, 
a summary of the data underlying Figure 2 of the manuscript, and transport experiments 








Supporting Information Figure 1. Time-dependent cellular accumulation of estrone 3-
sulfate applying different systems for cellular overexpression. For experiments MDCKII-
OATP2B1 (A, D) a vTF-7 based (B, E) and an adenoviral (C, F) expression system in HeLa cells 
were used to determine time dependent uptake of 6 nM radiolabeled estrone 3-sulfate (A, B, C). 
After the steady state was reached the equilibrium of competitive counterflow was determined by 
removing the supernatant and then adding the same amount of radiolabeled E1S plus 50 µM 
unlabeled E1S (D, E, F). Data are presented as mean ± SD, n=3 independent experiments 
followed by nonlinear curve fitting with Savistsky-Golay smoothing. *p ≤ 0.05, two-way 
ANOVA with Sidak’s multiple comparisons test. 
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Supporting Information Figure 2. Time of reaching equilibrium in CCF experiments using 
BSP and atorvastatin. MDCKII-OATP2B1 cells were exposed to 6 nM [3H]-E1S for 30 min to 
reach steady state. Then the supernatant was replaced by 6 nM [3H]-E1S plus 50 µM BSP (A) or 
50 µM atorvastatin (B). Data are presented as mean ± SD, n=3 independent experiments followed 




































Supporting Information Figure 3. Time dependent uptake of estrone 3-sulfate at pH 5.5 (A) 
and pH 7.4 (B) determined in MDCKII-wt and MDCKII-OATP2B1 cells. Data are presented 
as mean ± SD, n=3 in biological triplicates, *p ≤ 0.05 two-way ANOVA with Sidak’s multiple 
comparisons test. 
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Supporting Information Table 1: Summary of data obtained assessing various molecules 
for their influence on the cellular amount of estrone-3 sulfate applying competitive 
counterflow experiments in MDCKII-OATP2B1 cells. Each compound was tested against its 
solvent (DMSO, ethanol, or H2O). n=3 independent experiments each performed in biological 
triplicates. *p ≤ 0.05, one-way ANOVA with Dunnett’s multiple comparisons test. 
E1S-content 
[% of solvent control] 
E1S-content 
[% of solvent control] 
mean  ± SD mean ± SD 
Astemizole 48.01 ± 7.26 * Loxiglumide 44.87 ± 6.93 * 
Atorvastatin 32.93 ± 7.03 * Metoprolol 92.60 ± 11.85
Bromosulfophthalein h 37.67 ± 4.71 * Naringin 38.00 ± 8.36 * 
Cerivastatin† 50.45 ± 9.02 * Paclitaxel 87.10 ± 15.74
Cyclosporine A e 57.36 ± 11.34 * Penicillin G h 92.78 ± 11.94
Domperidone 72.72 ± 8.95 * Probenecid 77.75 ± 8.79
Dronedarone† 79.15 ± 7.77 Proglumide h 89.96 ± 10.12
Enalapril 127.7 ± 17.85 * Sunitinib† 73.96 ± 9.62 * 
Erythromycin e 95.05 ± 8.90 Talinolol† 70.90 ± 10.92 *
Etoposide† 44.10 ± 5.38 * Teniposide 61.13 ± 6.67 * 
Fenofibrate† 80.10 ± 12.09 Thyroxine 66.75 ± 9.99 * 
Fexofenadine† 54.98 ± 11.81 * Tolbutamide 104.2 ± 13.04
Fluoxetine 128.1 ± 23.06 * Triiodthyronine 23.64 ± 3.52 * 
Fumitremorgin C 147.6 ± 14.64 * Troglitazone 87.26 ± 17.08
Gemfibrozil† 85.59 ± 12.09 Valproate 103.9 ± 18.77
Glibenclamide 49.51 ± 8.37 * Valsartan 93.91 ± 13.47
Hyperforin 67.61 ± 15.22 * Venlafaxin h 113.0 ± 9.12
Indomethacin 80.74 ± 9.76 Verapamil 110.0 ± 18.34
Irbesartan 44.38 ± 12.61 * Solvent controls 
Itraconazole† 74.94 ± 14.93 * DMSO control 102.1 ± 5.76 
Ketoconazole 52.67 ± 9.31 * ethanol control 100.0 ± 3.34 
Lorglumide 48.41 ± 7.35 * H2O control 100.0 ± 5.33 

























































































































































Supporting Information Figure 4. Cellular accumulation of estrone 3-sulfate (E1S) was 
determined in MDCKII-wt cells. (A) In a transport inhibition study MDCKII cells were 
incubated with E1S in presence of compounds identified as inhibitors and substrates (astemizole, 
atorvastatin, hyperforin) of OATP2B1, molecules that did not interact with OATP2B1 in the 
competitive counterflow but were identified as inhibitors in the primary assessment 
(dronedarone, fenofibrate, gemfibrozil, indomethacin, troglitazone) and a selection of compounds 
which were significantly increasing E1S accumulation in CCF experiments (fluoxetine, 
fumitremorgin C). (B) Competitive counterflow experiments were performed in MDCKII-wt 
cells using the same compounds. None of the molecules significantly influences the cellular 
accumulation of E1S in native MDCKII cells. DMSO served as solvent control. Data are 
presented as mean ± SD; n = 3, performed in biological duplicates and for statistical analysis one-
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Fig. 1S HPLC-UV-MS analysis of Arkocaps capsule extract. Numbers refer to 
isoorientin (1), orientin (2), vitexin (3), and isovitexin (4). 
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Fig. 2S HPLC-UV-MS analysis of Valverde tablets. Numbers refer to isoorientin (1), 
orientin (2), vitexin (3), and isovitexin (4).
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Fig. 4S HPLC-UV-MS analysis of the reference isoorientin (1).
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Fig. 5S HPLC-UV-MS analysis of the reference isovitexin (4).
104
Molecular Pharmacology - MOL # 114066 - Supplemental Data 
SD-1 
Hyperforin induced activation of the Pregnane X Receptor is influenced by the Organic Anion 
Transporting Polypeptide 2B1 (OATP2B1) 
Anima M. Schäfer, Olivier Potterat, Isabell Seibert, Orlando Fertig, Henriette E. Meyer zu 
Schwabedissen 
- Supplemental Data -
105







Supplemental Figure 1. Counterflow experiments performed in MDCKII cells. Cells were exposed 
to [3H]-E1S for 30 min. After reaching the steady state the supernatant was replaced by [3H]-E1S 
supplemented with DMSO or the respective test compound. Atorvastatin was used as positive control, 
penicillin G served as negative control, DMSO was the solvent control. Data are presented as mean ± SD 
of n=3 independent experiments each performed in biological triplicates. For statistical analysis one-
way ANOVA was used corrected for multiple comparisons (Dunnett’s test). 
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A B
Supplemental Figure 2. Competitive counterflow experiment with hyperforin (A) or hypericin (B). 
MDCKII-OATP2B1 cells were treated with [3H]-E1S for 30 min to reach steady state. Then the 
supernatant was removed and cells were exposed to either the same amount of [3H]-E1S (control) or the 
same amount of [3H]-E1S supplemented with either hyperforin (0.5 μM, A) or hypericin (100 μM, B). 
Cellular accumulation of the radiolabel was quantified at the respective time points by liquid scintillation 
counting. Data are presented as mean ± SD, of n=3 independent experiments performed in biological 
duplicates followed by nonlinear curve fitting with Savistsky-Golay smoothing. *p ≤ 0.05, two-way 
ANOVA with Sidak’s multiple comparisons test.  
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SD-5 
Supplemental Figure 3. Chromatograms of a mixture of the references hypericin (TOCRIS) and 
pseudohypericin (Sigma-Aldrich), and of the 11 in Switzerland marketed St. John’s wort 
formulations. Detection was at 588 nm. Experiments were performed n=3 with three independent 
experiments, one representative chromatogram is shown.  
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SD-7 
Supplemental Figure 4. Chromatograms of the reference hyperforin (Sigma-Aldrich) and of the 
11 in Switzerland marketed St. John’s wort formulations. Detection was at 272 nm. Experiments 




Table 1. Summary of clinical studies to investigate drug-drug or drug-food interactions with 




study approach/ type 
Outcome of the study Ref 
Fexofenadine (2x60mg) 
and 
Grapefruit juice (2 
concentrations) or 
orange juice or apple juice 




Grapefruit (high concentration), 
orange, apple juices decreased 
fexofenadine AUC(0-8h) to 30% 
and Cmax to 40% 
Grapefruit juice (low 
concentration) to 80% 
No difference of fexofenadine 
tmax and t1/2 between treatments 
Grapefruit (high conc), orange, 
apple juices reduced urinary 
fexofenadine excretion to 30% 





Grapefruit juice  
(300mL vs. 1200mL) 
12 healthy volunteers 
single-dose, randomized 4-
way crossover study 
300mL: decrease of 
fexofenadine AUC(0-8h) to 58%, 
Cmax to 53% 
1200mL: decrease of 
fexofenadine AUC(0-8h) to 36% 
and Cmax to 33% 
[42] 
Fexofenadine (120mg) and 
Grapefruit juice (300mL) 
(-4h vs. -2h vs. 
simultaneous (0h) 
administration) 




-2h: decrease of fexofenadine
AUC(0-8h) to 38%





Grapefruit juice (300ml) 
or naringin solution 
12 healthy subjects 
single-dose, randomized, 
open, crossover 
Grapefruit juice decreased 
fexofenadine AUC(0-8h) to 55% 
and Cmax to 58%; naringin 
solution decreased 
fexofenadine AUC(0-8h) to 75% 
No difference of fexofenadine 




Grapefruit juice (300ml) or 
mediate/low concentrated 
naringin solutions 
12 healthy subjects 
single-dose, randomized, 
open, crossover 
Grapefruit juice decreased 
fexofenadine AUC(0-8h) to 57% 
and Cmax to 61%;  
No effect on fexofenadine 






green tea consumption 
(700ml/day) for 14 days 
10 healthy volunteers 
single-dose, randomized, 
crossover, 2-phases 
Green tea decreased nadolol 
AUC(0-48) to 85% and Cmax to 
85.3% 
Reduction of urine nadolol 
[34]
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excretion by 81.6%  
Reduced nadolol-induced effect 
on systolic blood pressure  
Aliskiren (300mg) 
and  
Grapefruit juice (300mL) 
28 healthy subjects 
single-dose, open-label, 
2-way crossover
Grapefruit juice decreased 





low dose (LD) of green tea 
extract or high dose (HD) of 
green tea extract (both 
300mL) 
30 healthy volunteers 
three-phase, randomized, 
crossover 
Green tea (LD) decreased 
nadolol AUC(0-8h) to 69%, HD 
to 53% and Cmax to 59% (LD) 
and 50% (HD) 
No changes for blood pressure 




folic acid (5mg) and D3 
(0.5μg) 
10 healthy volunteers 
prospective single arm, 
single center 
No change in fexofenadine or 
folic acid absorption due to 
vitamin D3 
[48] 
Table 2. Summary of OATP1A2 polymorphisms and their in vitro or in vivo observations. 
rs number Nucleotide/ 
amino acid 
exchange 
















reduced capacity for uptake 
of E1S and delta-opioid 
receptor agonists  
substrate dependent change 
in transport activity 
1.9 EA, 2.0 ME 
1.3 AA 














induced uptake of E1S and 
MTX 
reduced transport capacity 
of E1S and MTX 
hypofunctional 
non-functional 
2.5 AA, 16.3 EA, 
5.0 ME 







significantly lower imatinib 
clearance than patients with 
GA or AA, but no clinical 
response 




slightly higher CSF 
darunavir penetration 
compared to AA 









highly association with risk 
of life-threatening febrile 
neutropenia in breast 
cancer patients treated with 
docetaxel and doxorubicin 
NA 
88 EA, 70 AA, 
100 Asian 
[47] 





NA E184K, D185N, 
T259P, D288N 
impaired E1S, imatinib and 
MTX transport 
NA [140] 
AA, African American; CSF, cerebrospinal fluid; EA, European American; E1S, estrone 3-sulfate; ME, 
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